

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Treatment delay after non-small cell lung cancer diagnosis impacts patient survival rate: A National Cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034351
Article Type:	Original research
Date Submitted by the Author:	16-Sep-2019
Complete List of Authors:	Tsai, Chang-Hung; China Medical University, Department of Public Health; Miaoli General Hospital Ministry of Health and Welfare Kung, Pei-Tseng ; Asia University, Department of Healthcare Administration; China Medical University, Department of Medical Research, China Medical University Hospital Kuo, Wei-Yin; China Medical University, Department of Health Services Administration Tsai, Wen-Chen; China Medical University, Department of Health Services Administration
Keywords:	lung cancer, non-small cell lung cancer, delay treatment, timeliness of treatment, survival

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Treatment delay after non-small cell lung cancer diagnosis impacts patient**

5  
6  
7 **survival rate: A National Cohort study**

8  
9  
10 **Running head:** Treatment delay and survival for non-small cell lung cancer

11  
12  
13  
14 Chang-Hung Tsai<sup>a,b,c</sup>, Pei-Tseng Kung<sup>d,e,#</sup>, Wei-Yin Kuo<sup>b</sup>, Wen-Chen Tsai<sup>b,#,\*</sup>

15  
16  
17  
18 <sup>a</sup> Miao-Li General Hospital, Ministry of Health and Welfare, Taiwan, R.O.C

19  
20  
21  
22  
23 <sup>b</sup> Department of Health Services Administration, China Medical University, Taichung,  
24  
25  
26 Taiwan, R.O.C.

27  
28  
29  
30 <sup>c</sup> Department of Public Health, China Medical University, Taichung, Taiwan, R.O.C.

31  
32  
33  
34 <sup>d</sup> Department of Healthcare Administration, Asia University, Taichung, Taiwan,  
35  
36  
37 R.O.C

38  
39  
40  
41 <sup>e</sup> Department of Medical Research, China Medical University Hospital, China  
42  
43  
44 Medical University, Taichung, Taiwan, R.O.C.

45  
46  
47  
48 **\*Corresponding Author:** Professor Wen-Chen Tsai, Dr.PH. Department of Health  
49  
50  
51 Services

52  
53  
54  
55 Address: No. 91 Hsueh-Shih Road, Taichung, Taiwan 40402, R.O.C.

56  
57  
58  
59 Tel: +886-422073070; Fax: +886-422028895

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

E-mail: [wtsai@mail.cmu.edu.tw](mailto:wtsai@mail.cmu.edu.tw)

# Authors had equal contributions to this work.

**Words:** 3346

For peer review only

## Abstract

**OBJECTIVES.** This study aimed to determine if treatment delay after non-small cell lung cancer (NSCLC) diagnosis impacts patient survival rate.

**STUDY DESIGN.** This study is a natural experiment in Taiwan. A retrospective cohort investigation was conducted from 2004 to 2010, which included 42,962 patients with newly diagnosed NSCLC.

**METHODS.** We identified 42,962 patients with newly diagnosed NSCLC in the Taiwan Cancer Registry from 2004 to 2010. We calculated the time interval between diagnosis and treatment initiation. All patients were followed from the index date to death, or the end of 2012. Cox proportional hazard models were used to examine the relationship between mortality and time interval.

**RESULTS.** We included 42,962 patients (15,799 men and 27,163 women) with newly diagnosed NSCLC. The mortality rate exhibited a significantly positive correlation to time interval from cancer diagnosis to treatment initiation. The adjusted hazard ratios ranged from 1.04 to 1.08 in all subgroups time interval more than 7 days compared with the counterpart subgroup of the interval from cancer diagnosis to treatment  $\leq 7$  days. The trend was also noted regardless of the patients with lung cancer in stage I, stage II, and stage III-IV.

1  
2  
3  
4 **CONCLUSIONS.** Timeliness of treatment for NSCLC was crucial to improve the  
5  
6  
7 survival rate of patients with NSCLC, especially in stage I and II. We suggest patients  
8  
9  
10 with NSCLC should receive treatment as early as possible since the diagnosis was  
11  
12  
13 confirmed.  
14

#### 15 16 17 18 19 **Strengths and limitations of this study**

- 20  
21  
22 ● We collected nationwide data from 42,962 non-small cell lung cancer patients,  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
● which, to the best of our knowledge, is the largest nationwide study to date.
- We investigated the correlation between lung cancer treatment delay and survival  
rate in different cancer stages (stages I, II, III& IV) with pathological  
confirmation.
- The information on individual lifestyle, health behaviors, which may also affect  
the results, is not available.

● **Keywords:** lung cancer; non-small cell lung cancer; delay treatment; timeliness of  
treatment; survival

## INTRODUCTION

Lung cancer is among the most common causes of cancer death, particularly in industrialized countries.<sup>1</sup> In addition, the incidence of lung cancer has been gradually increasing over the last 50 years,<sup>2</sup> becoming a worldwide public health issue.<sup>3</sup> Lung cancer can be classified into small cell lung cancer and non-small cell lung cancer, of which the latter accounts for 80% of all lung cancer cases.<sup>4</sup> Despite recent improvements in treatment, the prognosis for lung cancer patients is still poor. Regardless of whether a patient has non-small cell lung cancer or small cell lung cancer, the 5-year survival rate is only 17.4%.<sup>2 5-7</sup> Most lung cancers are in the late stage (stages IIIB or IV) when diagnosed, which is likely to be a result of the long interval between the onset of symptoms and diagnosis.<sup>8</sup> There are often large differences in the length of the interval from the first appearance of symptoms to confirmation of diagnosis and treatment initiation in these patients.<sup>4</sup> Although there were many relevant studies on whether differences in the time delay between diagnosis to treatment initiation affects the prognosis of lung cancer patients, no definitive conclusion has been reached.<sup>4</sup> An increasing number of relevant studies have also highlighted the importance of this topic.

In Taiwan, 99.68% of the populace is covered by National Healthcare Insurance (NHI) program, which is a national insurance scheme that provides convenient



1  
2  
3  
4 medical consultations and highly accessible treatment.<sup>9</sup> Under this system, lung  
5  
6  
7 cancer is classified as a catastrophic illness and is exempt from treatment-related fees,  
8  
9  
10 thereby that patients are not affected by economic factor. According to 2016 statistics  
11  
12  
13 from the Taiwan Ministry of Health and Welfare, cancer has consistently been the top  
14  
15  
16 cause of death. Among various types of cancer, lung cancer ranks first in the cause of  
17  
18  
19 death, with a mortality rate of 39.9 per 100,000 people. Therefore, it is important for  
20  
21  
22 public health providers to improve lung cancer prognoses and increase survival rates.  
23  
24  
25 This study aims to utilize national large-scale statistical data to investigate whether  
26  
27  
28 the interval between lung cancer diagnosis and treatment affects survival rate;  
29  
30  
31 concurrently, we also aim to examine the impact of other relevant factors on survival.  
32  
33  
34 This will provide a reference for future treatment for lung cancer patients of  
35  
36  
37 improving their survival.

## 40 **METHODS**

### 43 **Data sources and participants**

46 We included 55,014 newly diagnosed non-small cell lung cancer patients from  
47  
48  
49 2004 to 2010. The newly diagnosed non-small cell lung cancer patients were defined  
50  
51  
52 as ICD-O-3 with C339 to C349 without any cancers before. Then we excluded those  
53  
54  
55 lung cancer patients with unknown stage for 3,993 patients. We also excluded lung  
56  
57  
58 cancer patients in situ (70 patients), with multiple cancer (1,298 patients), palliative  
59  
60

1  
2  
3  
4 treatment in first year (1,934 patients), mortality before lung cancer diagnosed (64  
5  
6  
7 patients), personal characteristics data missing (109 patients), and hospital data  
8  
9  
10 missing (4,584 patients). Finally, we had 42,962 people.  
11  
12

13 The data for this study was obtained from the Taiwan Cancer Registry, which  
14  
15  
16 was used to acquire study participants. We also linked this data to the National Health  
17  
18  
19 Insurance Database and the Cause of Death File from 2002 to 2012 that was provided  
20  
21  
22 by the Ministry of Health and Welfare.  
23  
24

### 25 **Patient and public involvement**

26  
27  
28 No patients were involved in this study, as it was based on the National Health  
29  
30  
31 Insurance Research Database, published by the Ministry of Health and Welfare,  
32  
33  
34 Taiwan.  
35  
36

### 37 **Variable descriptions**

38  
39  
40 In this study, with regards to the variables used, the general characteristics of  
41  
42  
43 lung cancer patients included sex and age. Age was defined as the age at which the  
44  
45  
46 patient had a confirmatory diagnosis by pathology. The financial status of the patient  
47  
48  
49 was based on their monthly salary. The degree of urbanization at the patient's place of  
50  
51  
52 residence was used to represent environmental factors. The level of urbanization was  
53  
54  
55 based on 7 levels of classification from highly urbanized developed cities (level 1) to  
56  
57  
58 remote areas (level 7). The health status of the patient included data on whether the  
59  
60

1  
2  
3  
4 patient had other catastrophic illnesses besides cancer, their Charlson Comorbidity  
5  
6  
7 Index (CCI), and the stage of non-small cell lung cancer. The definition of  
8  
9  
10 catastrophic illness was based on the 30 types of catastrophic illnesses or injuries as  
11  
12  
13 defined by the National Health Insurance Administration, which include stroke,  
14  
15  
16 chronic kidney failure, systemic lupus erythematosus, type I diabetes and severe  
17  
18  
19 mental illness. The degree of comorbidity was classified into three levels based on the  
20  
21  
22 CCI <sup>10</sup>. Tumor staging was based on the guidelines of the American Joint Committee  
23  
24  
25 on Cancer (6<sup>th</sup> edition for tumors diagnosed from 2004-2009, 7<sup>th</sup> edition for tumors  
26  
27  
28 diagnosed in 2010), which includes stages I, II, III, and IV. Hospital attributes include  
29  
30  
31 the level of hospital (medical centers, regional hospitals, district hospitals, and  
32  
33  
34 others), hospital ownership (public or private institutions), and the volume of hospital  
35  
36  
37 services (low, medium, high) in treatment of non-small cell lung cancer patients. The  
38  
39  
40 volume of hospital services was divided into low, medium, and high on the basis of  
41  
42  
43 quartiles: service volumes of <25%, 25-75% and >75% were defined as low, medium  
44  
45  
46 and high, respectively. Patients were considered to be enrolled in multidisciplinary  
47  
48  
49 team (MDT) care if they received MDT treatment after pathological diagnosis of  
50  
51  
52 non-small cell lung cancer; the definition of MDT is based on patients who were  
53  
54  
55 declared MDT treatment fees in the NHI database (47079B). The interval between  
56  
57  
58 diagnosis of non-small cell lung cancer and treatment initiation was defined as the  
59  
60

1  
2  
3  
4 period between pathological sectioning and diagnosis of non-small cell lung cancer  
5  
6  
7 after biopsy to the time when the patient underwent their first treatment (including  
8  
9  
10 surgery, radiotherapy, or chemotherapy). The operating definition of relevant  
11  
12  
13 treatments is based on the relevant treatment code that was declared in the NHI  
14  
15  
16 database, which was checked against the treatment registration information in the  
17  
18  
19 Taiwan Cancer Information Database.

### 22 **Main outcome measurements**

25 The main outcome examined in this study was the survival rate of lung cancer  
26  
27  
28 patients. Confirmation of death was based on patient data from the NHI database and  
29  
30  
31 this was compared with the Taiwan Cause of Death archives for confirmation.

### 34 **Statistical analysis**

37 We employed descriptive statistics to show general characteristics (gender and  
38  
39  
40 age of cancer onset), financial status (monthly salary), environmental factors (level of  
41  
42  
43 urbanization of place of residence), health status of patients (catastrophic illnesses  
44  
45  
46 other than cancer, CCI, cancer stage), hospital attributes (level and ownership of  
47  
48  
49 hospital, annual service volume of the hospital), enrolment in MDT and the  
50  
51  
52 distribution status of the interval from diagnosis confirmation to treatment initiation in  
53  
54  
55 lung cancer patients who had a confirmatory diagnosis by pathology from 2004 to  
56  
57  
58 2010. Following this, bivariate analysis was performed using the log-rank test to  
59  
60

1  
2  
3  
4 investigate whether there were significant differences between survival status by the  
5  
6  
7 end of 2012 and the interval from diagnosis to treatment initiation. We then used  
8  
9  
10 univariate Cox proportional hazards regression to analyze relevant prognostic factors  
11  
12  
13 that affect the survival of lung cancer patients. The adjusted Cox proportional hazards  
14  
15  
16 model was used to investigate the relative risk of survival of lung cancer patients with  
17  
18  
19 different cancer stages with different intervals from diagnosis confirmation to  
20  
21  
22 treatment initiation, after controlling for related variables. Independent variables  
23  
24  
25 included patient characteristics, financial status, environmental factors, health status,  
26  
27  
28 hospital attributes, enrolment in MDT, and grouping of time to treatment initiation.  
29  
30  
31 The dependent variable was survival. Lastly, after controlling for relevant variables,  
32  
33  
34 the adjusted Cox proportional hazards model was used to generate survival curves for  
35  
36  
37 lung cancer patients of various stages and with different interval periods.

38  
39  
40 All statistical analyses were performed using SAS software, version 9.2 (SAS  
41  
42  
43 Institute Inc., Cary, NC). A P value <0.05 was regarded as statistically significant and  
44  
45  
46 all tests were two-sided. This study was approved by the Institutional Review Board  
47  
48  
49 of Cheng Ching Hospital Chung Kang Branch (IRB number: HP150003).

## 51 RESULTS

### 52 Descriptive statistics of lung cancer patient characteristics for different 53 54 55 56 57 58 59 60 treatment intervals

This study consisted of 46,962 non-small cell lung cancer patients. Out of all

non-small cell lung cancer patients, 36.70% patients had an initial treatment within seven days, while 12.54% patients received their initial treatments more than 61 days after cancer diagnosed. In all non-small cell lung cancer patients, the mean 5-year survival rate was 17.61%. As the interval from diagnosis to treatment initiation increased, the 5-year survival rate decreased from 26.12% to 6.02% (Table 1).

**Table 1. Bivariate analysis of non-small cell lung cancer patient characteristics for different treatment intervals**

Variables	Total		Interval from cancer diagnosis to treatment								P value <sup>a</sup>
			≤ 7 days		8~14 days		15~60 days		≥ 61 days		
	N	%	N	%	N	%	N	%	N	%	
<b>Total number</b>	42,962	100.00	15,769	36.70	9,296	21.64	12,510	29.12	5,387	12.54	-
<b>Five-year survival rate</b>	42,962	17.61	15,769	26.12	9,296	15.96	12,510	12.99	5,387	6.02	<0.001
<b>Gender</b>											<0.001
Female	15,799	36.77	6,154	38.95	3,235	20.48	4,419	27.97	1,991	12.60	
Male	27,163	63.23	9,615	35.40	6,061	22.31	8,091	29.79	3,396	12.50	
<b>Age</b>											<0.001
≤ 44	2,106	4.90	889	42.21	455	21.60	568	26.97	194	9.21	
45~54	5,686	13.23	2,375	41.77	1,263	22.21	1,549	27.24	499	8.78	
55~64	9,155	21.31	3,634	39.69	2,033	22.21	2,658	29.03	830	9.07	
65~74	12,659	29.47	4,548	35.93	2,801	22.13	3,819	30.17	1,491	11.78	
≥ 75	13,356	31.09	4,323	32.37	2,744	20.55	3,916	29.32	2,373	17.77	
<b>Mean age (m, sd)</b>	66.76	12.44	65.52	12.55	66.45	12.22	67.04	12.15	70.25	12.46	<0.001
<b>Monthly salary</b>											<0.001

Variables	Total		Interval from cancer diagnosis to treatment								P value <sup>a</sup>
			≤ 7 days		8~14 days		15~60 days		≥ 61 days		
	N	%	N	%	N	%	N	%	N	%	
Low-income	461	1.07	137	29.72	101	21.91	154	33.41	69	14.97	
≤ 17280	1,475	3.43	542	36.75	311	21.08	447	30.31	175	11.86	
17281~22800	22,935	53.38	8,074	35.20	5,079	22.15	6,751	29.44	3,031	13.22	
22801~28800	8,069	18.78	2,961	36.70	1,690	20.94	2,376	29.45	1,042	12.91	
28801~36300	2,676	6.23	1,011	37.78	588	21.97	782	29.22	295	11.02	
36301~45800	3,280	7.63	1,333	40.64	689	21.01	923	28.14	335	10.21	
≥ 45801	4,066	9.46	1,711	42.08	838	20.61	1,077	26.49	440	10.82	
<b>Urbanization</b>											0.186
Level 1	11,759	27.37	4,335	36.87	2,494	21.21	3,404	28.95	1,526	12.98	
Level 2	12,117	28.20	4,506	37.19	2,615	21.58	3,527	29.11	1,469	12.12	
Level 3	6,523	15.18	2,334	35.78	1,424	21.83	1,946	29.83	819	12.56	
Level 4	6,795	15.82	2,518	37.06	1,506	22.16	1,974	29.05	797	11.73	
Level 5	1,524	3.55	523	34.32	338	22.18	439	28.81	224	14.70	
Level 6	2,217	5.16	807	36.40	490	22.10	627	28.28	293	13.22	
Level 7	2,027	4.72	746	36.80	429	21.16	593	29.26	259	12.78	
<b>CCI score</b>											<0.001
≤ 3	20,388	47.46	7,475	36.66	4,576	22.44	6,186	30.34	2,151	10.55	
4~6	7,587	17.66	2,761	36.39	1,646	21.70	2,218	29.23	962	12.68	
≥ 7	14,987	34.88	5,533	36.92	3,074	20.51	4,106	27.40	2,274	15.17	
<b>Other catastrophic illness</b>											<0.001
No	41,474	96.54	15,300	36.89	8,984	21.66	12,076	29.12	5,114	12.33	

Variables	Total		Interval from cancer diagnosis to treatment								P value <sup>a</sup>
			≤ 7 days		8~14 days		15~60 days		≥ 61 days		
	N	%	N	%	N	%	N	%	N	%	
Yes	1,488	3.46	469	31.52	312	20.97	434	29.17	273	18.35	
<b>Cancer stage</b>											<0.001
Stage I	5,681	13.22	3,226	56.79	910	16.02	1,269	22.34	276	4.86	
Stage II	1,526	3.55	589	38.60	338	22.15	462	30.28	137	8.98	
Stage III	11,696	27.22	4,030	34.46	2,843	24.31	3,500	29.92	1,323	11.31	
Stage IV	24,059	56.00	7,924	32.94	5,205	21.63	7,279	30.25	3,651	15.18	
<b>MDT care</b>											<0.001
No	37,716	87.79	13,669	36.24	8,012	21.24	10,974	29.10	5,061	13.42	
Yes	5,246	12.21	2,100	40.03	1,284	24.48	1,536	29.28	326	6.21	
<b>Hospital level</b>											<0.001
Medical centers	29,228	68.03	11,075	37.89	6,452	22.07	8,427	28.83	3,274	11.20	
Regional hospitals	12,601	29.33	4,395	34.88	2,655	21.07	3,787	30.05	1,764	14.00	
District hospitals	1,014	2.36	261	25.74	178	17.55	279	27.51	296	29.19	
Others	119	0.28	38	31.93	11	9.24	17	14.29	53	44.54	
<b>Hospital ownership</b>											<0.001
Public	16,770	39.03	6,619	39.47	3,776	22.52	4,558	27.18	1,817	10.83	
Private	26,192	60.97	9,150	34.93	5,520	21.08	7,952	30.36	3,570	13.63	
<b>Hospital services volume</b>											<0.001
Low	10,807	25.15	3,905	36.13	2,177	20.14	2,935	27.16	1,790	16.56	
Middle	21,043	48.98	7,519	35.73	4,652	22.11	6,486	30.82	2,386	11.34	
High	11,112	25.86	4,345	39.10	2,467	22.20	3,089	27.80	1,211	10.90	



<sup>a</sup> Log-rank test

### Five-year survival rate of patients for different treatment intervals

At the same time, we found that in stage I patients, the 5-year survival rate decreased by 10.34% due to delayed treatment (patients with intervals >7 days). In stage II patients, if patients started treatment earlier (interval  $\leq 7$  days), their 5-year survival rate increased by 10.28%. Early treatment (interval  $\leq 7$  days) was found to have a smaller effect on 5-year survival rate in stage III and IV patients, with an increase in 5-year survival rate of 2.63% (Table 2).

**Table 2. Five-year survival rate of patients for different treatment intervals**

Variables	Stage I		Stage II		Stage III and IV		P value <sup>a</sup>
	N	%	N	%	N	%	
<b>Total number</b>	5,681	64.66	1,526	34.72	35,755	9.37	-
<b>Interval from cancer diagnosis to treatment</b>							<0.001
$\leq 7$ days	3,226	75	589	45	11,954	12	
8~14 days	910	62	338	34	8,048	10	
15~60 days	1,269	50	462	28	10,779	8	
$\geq 61$ days	276	20	137	15	4,974	5	

<sup>a</sup> Log-rank test

## The effect of different treatment intervals on mortality risk in patients with lung cancer

Table 3 shows that when the group with interval from cancer diagnosis to treatment  $\leq 7$  days was used as a reference, the adjusted HR for mortality in other groups (8-14 days, 15-60 days, and  $\geq 61$  days) was significantly increased with increasing interval time (HR: 1.04-1.08). Among patients at various cancer stages, using stage I patients as a control group, the adjusted HRs for mortality for cancer patients at various stages was significantly higher (HR: 2.06-5.89) and the more advanced the cancer stages, the higher the adjusted HR for mortality. Patients who underwent MDT care had a significantly lower adjusted HR for mortality compared with patients who did not (HR: 0.91, 95% CI: 0.88-0.94).

**Table 3. Relative risk of death in patients for different treatment intervals**

Variables	Unadjusted		Adjusted		
	HR	P value	HR	95% CI	P value
<b>Interval from cancer diagnosis to treatment</b>					
$\leq 7$ days (ref.)					
8~14 days	<b>1.26</b>	<0.001	<b>1.04</b>	1.01 1.07	0.004
15~60 days	<b>1.30</b>	<0.001	<b>1.06</b>	1.04 1.09	<0.001
$\geq 61$ days	<b>1.66</b>	<0.001	<b>1.08</b>	1.04 1.11	<0.001

Variables	Unadjusted		Adjusted			
	HR	P value	HR	95% CI	P value	
<b>Gender</b>						
Female (ref.)						
Male	<b>1.54</b>	<0.001	<b>1.50</b>	1.47	1.53	<0.001
<b>Age</b>						
≤ 44 (ref.)						
45~54	<b>0.97</b>	0.357	<b>0.97</b>	0.92	1.03	0.351
55~64	<b>1.02</b>	0.478	<b>1.03</b>	0.97	1.09	0.331
65~74	<b>1.63</b>	<0.001	<b>1.27</b>	1.21	1.34	<0.001
≥ 75	<b>1.93</b>	<0.001	<b>1.79</b>	1.69	1.88	<0.001
<b>Monthly salary</b>						
Low-income (ref.)						
≤ 17280	<b>0.72</b>	<0.001	<b>0.89</b>	0.80	1.00	0.049
17281~22800	<b>0.81</b>	<0.001	<b>0.86</b>	0.78	0.95	0.002
22801~28800	<b>0.74</b>	<0.001	<b>0.83</b>	0.75	0.91	<0.001
28801~36300	<b>0.60</b>	<0.001	<b>0.79</b>	0.71	0.87	<0.001
36301~45800	<b>0.59</b>	<0.001	<b>0.78</b>	0.70	0.87	<0.001
≥ 45801	<b>0.56</b>	<0.001	<b>0.73</b>	0.66	0.81	<0.001
<b>Urbanization level</b>						
Level 1 (ref.)						
Level 2	<b>1.07</b>	<0.001	<b>0.99</b>	0.96	1.02	0.523
Level 3	<b>1.20</b>	<0.001	<b>1.04</b>	1.00	1.07	0.036
Level 4	<b>1.21</b>	<0.001	<b>1.01</b>	0.98	1.05	0.596
Level 5	<b>1.33</b>	<0.001	<b>1.01</b>	0.95	1.08	0.671

Variables	Unadjusted		Adjusted			
	HR	P value	HR	95% CI	P value	
Level 6	<b>1.39</b>	<0.001	<b>1.09</b>	1.04	1.15	0.001
Level 7	<b>1.25</b>	<0.001	<b>1.02</b>	0.96	1.07	0.570
<b>CCI score</b>						
≤ 3 (ref.)						
4~6	<b>1.35</b>	<0.001	<b>1.18</b>	1.14	1.21	<0.001
≥ 7	<b>1.80</b>	<0.001	<b>1.28</b>	1.25	1.31	<0.001
<b>Other catastrophic illness</b>						
No (ref.)						
Yes	<b>1.25</b>	<0.001	<b>1.26</b>	1.19	1.33	<0.001
<b>Cancer stage</b>						
Stage I (ref.)						
Stage II	<b>2.29</b>	<0.001	<b>2.06</b>	1.91	2.23	<0.001
Stage III	<b>4.48</b>	<0.001	<b>3.94</b>	3.75	4.13	<0.001
Stage IV	<b>6.51</b>	<0.001	<b>5.89</b>	5.62	6.17	<0.001
<b>MDT care</b>						
No (ref.)						
Yes	<b>0.95</b>	0.001	<b>0.91</b>	0.88	0.94	<0.001
<b>Hospital level</b>						
Medical centers (ref.)						
Regional hospitals	<b>1.28</b>	<0.001	<b>0.99</b>	0.96	1.02	0.347
District hospitals	<b>2.06</b>	<0.001	<b>1.25</b>	1.17	1.34	<0.001
Others	<b>1.17</b>	0.137	<b>0.90</b>	0.73	1.10	0.286
<b>Hospital ownership</b>						

Variables	Unadjusted		Adjusted			
	HR	P value	HR	95% CI	P value	
Public (ref.)						
Private	<b>1.27</b>	<0.001	<b>1.13</b>	1.10	1.16	<0.001
<b>Hospital services volume</b>						
Low (ref.)						
Middle	<b>0.72</b>	<0.001	<b>0.83</b>	0.81	0.85	<0.001
High	<b>0.59</b>	<0.001	<b>0.71</b>	0.68	0.74	<0.001

### The effect of different treatment intervals on mortality risk in patients with lung cancer at different cancer stages

Table 4 shows that in stage I lung cancer patients, with patients with intervals of  $\leq 7$  days as the reference group, as the interval increased, the relative risk of death also significantly increased (HR: 1.45-2.41). This was also true for stage II (HR: 1.21-1.58) and the intervals between 15 days and 60 days of stage III and IV patients (HR: 1.03, 95% CI: 1.00-1.06). In stage III and IV patients, using patients with an interval  $\leq 7$  days as a reference group, the relative risk of death in patients with intervals  $\geq 61$  days was significantly increased (HR: 1.06, 95% CI: 1.02-1.09).

**Table 4. Relative risk of death in patients for different treatment intervals and at different cancer stages**

Variables	Stage I <sup>a</sup>			Stage II <sup>a</sup>			Stage III and IV <sup>a</sup>					
	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value			
<b>Interval from cancer diagnosis to treatment</b>												
≤ 7 days (ref.)												
8~14 days	<b>1.45</b>	1.28 1.64	<0.001	<b>1.21</b>	1.01 1.45	0.039	<b>1.01</b>	0.98 1.04	0.526			
15~60 days	<b>1.66</b>	1.49 1.84	<0.001	<b>1.44</b>	1.22 1.69	<0.001	<b>1.03</b>	1.00 1.06	0.045			
≥ 61 days	<b>2.41</b>	2.06 2.83	<0.001	<b>1.58</b>	1.26 1.97	<0.001	<b>1.06</b>	1.02 1.09	0.002			

- a. Patient age, gender, monthly salary, level of urbanization of residence area, CCI score, other catastrophic illnesses, MDT care, hospital level, hospital ownership, and hospital services volume were controlled in all adjusted Cox proportional hazard models.

## DISCUSSION

We found that the mortality rate exhibited significantly positive correlation to time interval from cancer diagnosis to treatment initiation in all stage NSCLC patients. The ratio of male to female in our study is similar to that in previous studies.<sup>11 12</sup> The delays between diagnosis and treatment can be categorized into three stages: namely, patient delay, diagnosis delay, and treatment delay.<sup>2</sup> Of all studies which investigated treatment delays in lung cancer patients, the study with the largest number of patients included 54,338 patients,<sup>11</sup> but was limited to non-metastatic lung cancer patients. In addition, the study only focused on patients who underwent surgical excision and did not analyze the treatment delay status and associated factors for all lung cancer patients. Another study collected data from 28,732 patients<sup>13</sup> to investigate whether treatment delay affects survival rate. The researchers found that if the interval from diagnosis to treatment was within 35 days, then there is improved survival for patients with localized disease, reduced survival for those with distant disease, but didn't have significant effect on patients with regional disease. However, in that study, the diagnosis to treatment interval was divided into just two groups (<35 days and >35 days), which makes it more difficult to show the correlation between different treatment delay groups and patient survival rates. In addition, in that study, the authors did not investigate whether different treatment delay periods affect

1  
2  
3  
4 survival rate for different cancer stages as they only classified cancers as localized,  
5  
6  
7 regional, or distant. Another study included 20,561 patients<sup>14</sup>; however, this was only  
8  
9  
10 a descriptive statistical study and did not distinguish between the different cancer  
11  
12  
13 stages or examine relevant factors. The authors also did not carry out a correlation  
14  
15  
16 analysis between treatment delay and survival rate. To the best of our knowledge, the  
17  
18  
19 current study is the first large-scale nationwide study that examines whether treatment  
20  
21  
22 delay in non-small cell lung cancer affects patient survival rate. In addition, we also  
23  
24  
25 investigated the correlation between lung cancer treatment delay and survival rate for  
26  
27  
28 different cancer stages (stages I, II, III and IV).  
29

30  
31 Previous studies have observed that if patients are older, have more  
32  
33  
34 comorbidities, or have stage I cancer, they are more likely to delay treatment (interval  
35  
36  
37 from diagnosis to treatment >30 days).<sup>11</sup> Similar findings were observed in our study:  
38  
39  
40 for patients aged  $\geq 55$  years, the greater the age the greater the proportion with  
41  
42  
43 treatment delay (interval  $\geq 61$  days) (Table 1). Patients with high CCI scores also  
44  
45  
46 demonstrated significantly increased proportions in treatment delay (interval  $\geq 61$   
47  
48  
49 days) (Table 1). However, during analysis of the correlation between treatment delay  
50  
51  
52 and lung cancer stage, we found that the proportion of stage I patients with treatment  
53  
54  
55 delay was significantly lower than patients with other stages of lung cancer. A  
56  
57  
58 previous study has observed that in non-small cell lung cancer patients, treatment  
59  
60



1  
2  
3  
4 delay is not associated with cancer stage.<sup>15, 16-20</sup> In contrast, treatment delay had more  
5  
6  
7 serious effects in stage III and IV patients.<sup>21</sup> However, in our study, we found that the  
8  
9  
10 proportion of stage I patients with treatment delay (interval from diagnosis to  
11  
12  
13 treatment  $\geq 61$  days) was significantly lower (4.86%,  $p < 0.001$ ), when compared with  
14  
15  
16 patients at other stages.

17  
18  
19 Previous studies have mentioned that in non-small cell lung cancer patients, our  
20  
21  
22 understanding of the effects of diagnosis and treatment delay on the prognosis of  
23  
24  
25 patients is limited, although an increasing number of recent studies are emphasizing  
26  
27  
28 the importance of this topic.<sup>4</sup> Some studies have found that in patients with a  
29  
30  
31 symptom-to-treatment interval (STI) of  $> 60$  days, the survival rate was significantly  
32  
33  
34 higher than that of patients with a STI of  $< 60$  days. However, if patients were further  
35  
36  
37 divided on the basis of the type of lung cancer, this difference was only significant in  
38  
39  
40 NSCLC patients. However, the number of patients included in this study was only  
41  
42  
43 103 (96 men).<sup>22</sup> Two other studies, with 378 and 410 patients each, found that  
44  
45  
46 delaying diagnosis and treatment did not affect patient survival rates.<sup>16 17</sup> Another  
47  
48  
49 study of 466 non-small cell lung cancer patients found that patients with shorter STIs  
50  
51  
52 had lower survival rates.<sup>23</sup> One study with 189 lung cancer patients found that  
53  
54  
55 treatment delay resulted in poorer prognosis for patients,<sup>24</sup> whilst another study with  
56  
57  
58 132 patients found that longer specialist treatment delay does not result in poorer  
59  
60

1  
2  
3  
4 prognosis.<sup>25</sup> An aforementioned article also observed that most previous studies in  
5  
6  
7 different countries were monocentric studies and that it is difficult to decide which  
8  
9  
10 study is most reliable with regards to whether treatment delay affects patient survival  
11  
12  
13 rates.<sup>4</sup>

14  
15  
16 Most studies show no relationship between time-to-chemotherapy (TTC) and  
17  
18  
19 their survival rate.<sup>26</sup> However, it should be noted that in these review articles, the  
20  
21  
22 number of cases collected is generally very low, with the highest number of patients  
23  
24  
25 only 10,583. In summary, the majority of previous studies into whether treatment  
26  
27  
28 delay affects survival rate in non-small cell lung cancer patients lack large-scale  
29  
30  
31 nationwide statistical data. This can easily lead to bias and produce divergent  
32  
33  
34 conclusions. In this study, we collected nationwide data from 42,962 non-small cell  
35  
36  
37 lung cancer patients, which, to the best of our knowledge, is the largest nationwide  
38  
39  
40 study to date. In addition, we also investigated the correlation between lung cancer  
41  
42  
43 treatment delay and survival rate in different cancer stages (stages I, II, III and IV).

44  
45  
46 In addition, detailed examination of the literature found that a decreased  
47  
48  
49 treatment delay increases the risk of death in patients; the explanation provided for  
50  
51  
52 this is that a shorter treatment delay may mean that the patients have more obvious or  
53  
54  
55 more severe symptoms. Therefore, there is a need to correct the result with cancer  
56  
57  
58 stage and severity.<sup>23</sup> A previous study has also suggested that a shorter treatment  
59  
60

1  
2  
3  
4 delay may reflect a requirement for more urgent treatment due to severity of  
5  
6  
7 symptoms, resulting in a poor prognosis.<sup>27</sup> Therefore, in this paper, we also  
8  
9  
10 considered the effects of cancer stage on treatment delay and patient prognosis. In  
11  
12  
13 another paper, it was also mentioned that the definition of treatment delay should be  
14  
15  
16 more standardized and accurate.<sup>4</sup> Another paper mentioned that it is not easy to  
17  
18  
19 accurately calculate the time of treatment initiation.<sup>23</sup> In addition, the calculation of  
20  
21  
22 patient delay (from symptom to doctor) is also prone to errors. Therefore, in this  
23  
24  
25 study, our definition of treatment delay was made according to the cancer registration  
26  
27  
28 archives and NHI database, from pathological diagnosis confirmation until treatment  
29  
30  
31 initiation.

32  
33  
34 For cancer patients in general, current medical guidelines all recommend early  
35  
36  
37 diagnosis and treatment to improve patient prognosis. However, early diagnosis is  
38  
39  
40 difficult due to multiple factors, such as non-apparent symptoms and patient delay.  
41  
42  
43 However, in this study, we found that if the interval from confirmation of pathological  
44  
45  
46 diagnosis to treatment initiation in non-small cell lung cancer patients is shortened to  
47  
48  
49 7 days, this can effectively improve their 5-year survival rate (improvements of  
50  
51  
52 2.63-10.34% were observed, according to the different stages of lung cancer). We also  
53  
54  
55 found that this improvement in 5-year survival rate was particularly marked for  
56  
57  
58 non-small cell lung cancer patients at early stages (stage I and II), at 10.28-10.34%.

1  
2  
3  
4 However, in late stage (stage III and IV) patients, the 5-year survival rate was only  
5  
6  
7 increased by 2.63%. Therefore, we recommended that in future policies, treatment  
8  
9  
10 recommendations should be formulated so that patients can start treatment within 7  
11  
12  
13 days after pathological diagnosis confirmation of non-small cell lung cancer to  
14  
15  
16 increase their 5-year survival rate. This is particularly important for early stage (stage  
17  
18  
19 I and II) non-small cell lung cancer patients, where improvement effects are more  
20  
21  
22 significant.  
23

24  
25 In this study, we also found that the effect of the interval from diagnosis to  
26  
27  
28 treatment initiation and patient survival rate decreased with more advanced cancer  
29  
30  
31 stages. Therefore, in patients who have stage I (HR: 1.45-2.41) or stage II (HR:  
32  
33  
34 1.21-1.58) cancer, the longer the interval from diagnosis to treatment initiation, the  
35  
36  
37 higher the risk of death in patients. However, in stage III patients, compared with  
38  
39  
40 patients with an interval from diagnosis to treatment initiation  $\leq 7$  days, only when the  
41  
42  
43 interval from diagnosis to treatment initiation was  $>15$  days was the risk of death  
44  
45  
46 increased. However, the magnitude of the increased risk of death is lower than in  
47  
48  
49 stage I and II patients (HR: 1.03-1.06). Therefore, this study found that timely  
50  
51  
52 treatment of stage I and II lung cancer patients has greater benefits. Therefore, we  
53  
54  
55 recommend that we should shorten the interval from diagnosis to treatment initiation  
56  
57  
58 especially in stage I and II lung cancer patients, thus decreasing the risk of death and  
59  
60

1  
2  
3  
4 improving prognosis.  
5  
6

7 In recent studies, it was found that patients with oral cancers who underwent  
8  
9  
10 MDT treatment had significantly higher survival rates, and that the proportion of  
11  
12  
13 patients who underwent treatment was higher than those who did not joining MDT.<sup>9</sup>  
14  
15  
16 Previous studies have shown that the use of MDT care in cancer treatment can  
17  
18  
19 improve patient prognosis.<sup>28</sup> This is particularly the case in head and neck cancers,  
20  
21  
22 where MDT care is not only cost-effective but can also improve survival rates.<sup>29</sup>  
23  
24  
25 Previous studies have shown that in lung cancer patients MDT care can significantly  
26  
27  
28 improve the patient's acceptance of treatment, but does not significantly improve  
29  
30  
31 patient survival rates.<sup>28</sup> In this study, we found that patients who underwent MDT  
32  
33  
34 care had a significantly lower adjusted HR for mortality compared with patients who  
35  
36  
37 did not (HR: 0.91, 95% CI: 0.88-0.94).  
38  
39

40 In summary, this study recommends that the interval from diagnosis to treatment  
41  
42  
43 initiation should be minimized during treatment of lung cancer patients at various  
44  
45  
46 cancer stages, particularly in stage I and II patients. In addition, in stage III and IV  
47  
48  
49 patients, we recommend the addition of MDT care to decrease the risk of death and  
50  
51  
52 improve prognosis.  
53

#### 54 **Limitations**

55  
56  
57 A secondary random database derived from the National Health Insurance  
58  
59  
60

1  
2  
3  
4 Research Database was employed for this study. The information on individual  
5  
6  
7 lifestyle, health behaviors, which may also affect the result, is not available.  
8  
9

## 10 **Conclusions**

11  
12  
13  
14 In this study, we collected nationwide data from 42,962 non-small cell lung  
15  
16 cancer patients, which, to the best of our knowledge, is the largest nationwide study to  
17  
18 date. In addition, we also investigated the correlation between lung cancer treatment  
19  
20 delay and survival rate in different cancer stages (stages I, II, III& IV) with  
21  
22 pathological confirmation. Timeliness of treatment for NSCLC was crucial to  
23  
24 improve the survival rate especially in stage I and II.  
25  
26  
27  
28  
29  
30  
31  
32

## 33 **Acknowledgements**

34  
35  
36 This study was supported by the grants (CMU106-ASIA-13; MOST 104-2410-H-039  
37  
38 -002) from China Medical University, Asia University, and the Ministry of Science  
39  
40 and Technology, Taiwan. We are grateful to the Science Center of the Ministry of  
41  
42 Health and Welfare for providing us with access to the National Health Insurance  
43  
44 Research Database, Cancer Registry Files, and Cause of Death File.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure Legend**

Figure 1. Adjusted survival curve in lung cancer patients with different cancer stages

For peer review only

## References

1. Ferlay J. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10. <http://globocan.iarc.fr> 2010
2. Jensen AR, Mainz J, Overgaard J. Impact of delay on diagnosis and treatment of primary lung cancer. *Acta Oncologica* 2002;41(2):147-52.
3. Valdés S, García E, Pérez H, et al. Length of diagnostic delay in patients with non-small-cell lung cancer. *MEDICC review* 2010;12(1)
4. Vinas F, Ben Hassen I, Jabot L, et al. Delays for diagnosis and treatment of lung cancers: a systematic review. *The clinical respiratory journal* 2016;10(3):267-71.
5. Storm H, Dickman P, Engeland A, et al. Do morphology and stage explain the inferior lung cancer survival in Denmark? *European Respiratory Journal* 1999;13(2):430-35.
6. Teppo L, Dickman PW, Hakulinen T, et al. Cancer patient survival-patterns, comparisons, trends: A population-based cancer registry study in Finland. *Acta oncologica* 1999;38(3):283-94.
7. Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. *Journal of the National Comprehensive Cancer Network* 2016;14(3):255-64.
8. Chandra S, Mohan A, Guleria R, et al. Delays during the diagnostic evaluation and treatment of lung cancer. *Asian Pac J Cancer Prev* 2009;10(3):453-6.
9. Tsai W-C, Kung P-T, Wang S-T, et al. Beneficial impact of multidisciplinary team management on the survival in different stages of oral cavity cancer patients: results of a nationwide cohort study in Taiwan. *Oral oncology* 2015;51(2):105-11.
10. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *Journal of clinical epidemiology* 1992;45(6):613-19.
11. Bilimoria KY, Ko CY, Tomlinson JS, et al. Wait times for cancer surgery in the United States: trends and predictors of delays. *Annals of surgery* 2011;253(4):779-85.
12. Australian M. Timeliness of lung cancer care in Victoria: a retrospective cohort study. 2016
13. Gomez DR, Liao K-P, Swisher SG, et al. Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. *Radiotherapy and Oncology* 2015;115(2):257-63.
14. Radzikowska E, Roszkowski K, Głaz P. Lung cancer--diagnosis and therapy delay. *Pneumonologia i alergologia polska* 2001;69(11-12):600-10.
15. Liberman M, Liberman D, Sampalis JS, et al. Delays to surgery in non-small-cell lung cancer. *Canadian journal of surgery* 2006;49(1):31.
16. Pita-Fernández S, Montero-Martinez C, Pértega-Díaz S, et al. Relationship between



- 1  
2  
3 delayed diagnosis and the degree of invasion and survival in lung cancer. *Journal of*  
4 *clinical epidemiology* 2003;56(9):820-25.
- 5  
6 17. Porta M, Gallen M, Malats N, et al. Influence of " diagnostic delay" upon cancer survival:  
7 an analysis of five tumour sites. *Journal of Epidemiology & Community Health*  
8 1991;45(3):225-30.
- 9  
10 18. Koyi H, Hillerdal G, Brandén E. Patient's and doctors' delays in the diagnosis of chest  
11 tumours. *Lung cancer* 2002;35(1):53-57.
- 12  
13 19. Billing J, Wells F. Delays in the diagnosis and surgical treatment of lung cancer. *Thorax*  
14 1996;51(9):903-06.
- 15  
16 20. Mor V, Masterson-Allen S, Goldberg R, et al. Pre-diagnostic symptom recognition and  
17 help seeking among cancer patients. *Journal of community health*  
18 1990;15(4):253-66.
- 19  
20 21. Christensen E, Harvald T, Jendresen M, et al. The impact of delayed diagnosis of lung  
21 cancer on the stage at the time of operation. *European Journal of Cardio-Thoracic*  
22 *Surgery* 1997;12(6):880-84.
- 23  
24 22. Annakkaya AN, Arbak P, Balbay O, et al. Effect of symptom-to-treatment interval on  
25 prognosis in lung cancer. *Tumori* 2007;93(1):61.
- 26  
27 23. Myrdal G, Lambe M, Hillerdal G, et al. Effect of delays on prognosis in patients with  
28 non-small cell lung cancer. *Thorax* 2004;59(1):45-49.
- 29  
30 24. Robinson E, Mohilever J, Zidan J, et al. Delay in diagnosis of cancer. Possible effects on  
31 the stage of disease and survival. *Cancer* 1984;54(7):1454-60.
- 32  
33 25. Salomaa E-R, Sallinen S, Hiekkanen H, et al. Delays in the diagnosis and treatment of lung  
34 cancer. *Chest Journal* 2005;128(4):2282-88.
- 35  
36 26. Alexander M, Blum R, Burbury K, et al. Timely initiation of chemotherapy: a systematic  
37 literature review of six priority cancers—results and recommendations for clinical  
38 practice. *Internal medicine journal* 2017;47(1):16-34.
- 39  
40 27. Diaconescu R, Lafond C, Whittom R. Treatment delays in non-small cell lung cancer and  
41 their prognostic implications. *Journal of Thoracic Oncology* 2011;6(7):1254-59.
- 42  
43 28. Boxer MM, Vinod SK, Shafiq J, et al. Do multidisciplinary team meetings make a  
44 difference in the management of lung cancer? *Cancer* 2011;117(22):5112-20.
- 45  
46 29. Birchall M, Bailey D, King P. South West Cancer Intelligence Service Head and Neck  
47 Tumour Panel. Effect of process standards on survival of patients with head and neck  
48 cancer in the south and west of England. *Br J Cancer* 2004;91(8):1477-81.
- 49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1

244x254mm (96 x 96 DPI)

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
<b>Introduction</b>			<b>5-6</b>
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any pre-specified hypotheses	6
<b>Methods</b>			<b>6-10</b>
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7,9
Bias	9	Describe any efforts to address potential sources of bias	6-7
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	10
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10-19
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10-19
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			20-26
Key results	18	Summarise key results with reference to study objectives	20
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	23
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	26
Generalisability	21	Discuss the generalisability (external validity) of the study results	26-27
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	27

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Effect of time interval from diagnosis to treatment for non-small cell lung cancer on survival: A national cohort study in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034351.R1
Article Type:	Original research
Date Submitted by the Author:	17-Dec-2019
Complete List of Authors:	Tsai, Chang-Hung; China Medical University, Department of Public Health; Miaoli General Hospital Ministry of Health and Welfare Kung, Pei-Tseng ; Asia University, Department of Healthcare Administration; China Medical University, Department of Medical Research, China Medical University Hospital Kuo, Wei-Yin; China Medical University, Department of Health Services Administration Tsai, Wen-Chen; China Medical University, Department of Health Services Administration
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Epidemiology, Health services research, Public health, Evidence based practice
Keywords:	lung cancer, non-small cell lung cancer, delay treatment, timeliness of treatment, survival

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Effect of time interval from diagnosis to treatment for non-small cell lung cancer on**  
5  
6  
7 **survival: A national cohort study in Taiwan**  
8  
9

10 **Running head:** Treatment delay and survival for non-small cell lung cancer  
11  
12

13  
14 Chang-Hung Tsai<sup>a,b,c</sup>, Pei-Tseng Kung<sup>d,e,#</sup>, Wei-Yin Kuo<sup>b</sup>, Wen-Chen Tsai<sup>b,#,\*</sup>  
15  
16

17  
18 <sup>a</sup> Miao-Li General Hospital, Ministry of Health and Welfare, Taiwan, R.O.C  
19  
20

21  
22 <sup>b</sup> Department of Health Services Administration, China Medical University, Taichung,  
23  
24 Taiwan, R.O.C.  
25  
26

27  
28 <sup>c</sup> Department of Public Health, China Medical University, Taichung, Taiwan, R.O.C.  
29  
30

31  
32 <sup>d</sup> Department of Healthcare Administration, Asia University, Taichung, Taiwan, R.O.C  
33  
34

35  
36 <sup>e</sup> Department of Medical Research, China Medical University Hospital, China Medical  
37  
38 University, Taichung, Taiwan, R.O.C.  
39  
40  
41  
42

43  
44  
45 **\*Corresponding Author:** Professor Wen-Chen Tsai, Dr.PH. Department of Health Services  
46  
47

48  
49 Address: No. 91 Hsueh-Shih Road, Taichung, Taiwan 40402, R.O.C.  
50  
51

52  
53 Tel: +886-422073070; Fax: +886-422028895  
54  
55

56  
57 E-mail: wtsai@mail.cmu.edu.tw  
58  
59  
60

1  
2  
3 # Authors had equal contributions to this work.  
4  
5

6 **Words:** 3346  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## Abstract

**OBJECTIVES.** This study aimed to determine if treatment delay after non-small cell lung cancer (NSCLC) diagnosis impacts patient survival rate.

**STUDY DESIGN.** This study is a natural experiment in Taiwan. A retrospective cohort investigation was conducted from 2004 to 2010, which included 42,962 patients with newly diagnosed NSCLC.

**METHODS.** We identified 42,962 patients with newly diagnosed NSCLC in the Taiwan Cancer Registry from 2004 to 2010. We calculated the time interval between diagnosis and treatment initiation. All patients were followed from the index date to death, or the end of 2012. Cox proportional hazard models were used to examine the relationship between mortality and time interval.

**RESULTS.** We included 42,962 patients (15,799 men and 27,163 women) with newly diagnosed NSCLC. The mortality rate exhibited significantly positive correlation to time interval from cancer diagnosis to treatment initiation. The adjusted hazard ratios ranged from 1.04 to 1.08 in all subgroups time interval more than 7 days compared with the counterpart subgroup of interval from cancer diagnosis to treatment  $\leq 7$  days. The trend was also noted regardless of the patients with lung cancer in stage I, stage II, and stage III.

1  
2  
3  
4 **CONCLUSIONS.** Timeliness of treatment for NSCLC was crucial to improve the survival  
5  
6  
7 rate of patients with NSCLC especially in stages I and II. We suggest patients with NSCLC  
8  
9  
10 should receive treatment as early as possibility since the diagnosis was confirmed.  
11  
12  
13  
14  
15

### 16 **Strengths and limitations of this study**

- 17
- 18
- 19 ● It consisted of nationwide patients with non-small cell lung cancer.
- 20
- 21
- 22 ● We collected nationwide data from 42,962 non-small cell lung cancer patients, which is the  
23  
24 largest nationwide study to date.
- 25
- 26
- 27
- 28 ● There were very few studies investigating treatment delay effects on the reduction of  
29  
30 survival rate of lung cancer patients.
- 31
- 32
- 33 ● Our lung cancer stages (stages I, II, III, and IV) were based on pathological confirmation.
- 34
- 35
- 36 ● The information on individual lifestyle and health behaviors is not available.
- 37
- 38
- 39

40 **Keywords:** lung cancer; non-small cell lung cancer; delay treatment; timeliness of treatment;  
41  
42  
43 survival  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Lung cancer is among the most common causes of cancer death, particularly in industrialized countries.<sup>1</sup> In addition, the incidence of lung cancer has been gradually increasing over the last 50 years,<sup>2</sup> becoming a worldwide public health issue.<sup>3</sup> Lung cancer can be classified into small cell lung cancer and non-small cell lung cancer, of which the latter accounts for 80% of all lung cancer cases.<sup>4</sup> Despite recent improvements in treatment, the prognosis for lung cancer patients is still poor. Regardless of whether a patient has non-small cell lung cancer or small cell lung cancer, the 5-year survival rate is only 17.4%.<sup>2 5-7</sup> Most lung cancers are in the late stage (stages IIIB or IV) when diagnosed, which is likely to be a result of the long interval between the onset of symptoms and diagnosis.<sup>8</sup> There are often large differences in the length of the interval from the first appearance of symptoms to confirmation of diagnosis and treatment initiation in these patients.<sup>4</sup> Although there were many relevant studies on whether differences in the time delay between diagnosis to treatment initiation affects the prognosis of lung cancer patients, no definitive conclusion has been reached.<sup>4</sup> An increasing number of relevant studies have also highlighted the importance of this topic.

In Taiwan, 99.68% of the populace is covered by National Healthcare Insurance (NHI) program. Under this system, lung cancer is classified as a catastrophic illness and is exempt from treatment-related fees, thereby that patients are not affected by economic factor. According to 2016 statistics from the Taiwan Ministry of Health and Welfare, cancer has

1  
2  
3  
4 consistently been the top cause of death. Among various types of cancer, lung cancer ranks  
5  
6  
7 first in the cause of death, with a mortality rate of 39.9 per 100,000 people. Therefore, it is  
8  
9  
10 important for public health providers to improve lung cancer prognoses and increase survival  
11  
12  
13 rates. The Taiwan Cancer Registry (TCR), a population-based cancer registry, was founded in  
14  
15  
16 1979. The registry is organized by the Ministry of Health and Welfare. The Taiwan Cancer  
17  
18  
19 Registry Database (TCRD) records data of all types of cancer diagnosed and treatments in  
20  
21  
22 patients in Taiwan. The completeness (97%) and data quality of the Cancer Registry Database  
23  
24  
25 has achieved at an excellent level.<sup>9</sup> The accuracy of NHIRD has been validated in previous  
26  
27  
28 studies.<sup>10</sup> This study aims to utilize national large-scale statistical data to investigate whether  
29  
30  
31 the interval between lung cancer diagnosis and treatment affects survival rate; concurrently,  
32  
33  
34 we also aim to examine the impact of other relevant factors on survival. This will provide a  
35  
36  
37 reference for future treatment for lung cancer patients of improving their survival.  
38  
39

## 40 **METHODS**

### 41 42 43 **Data sources and participants**

44  
45  
46 We included 55,014 newly diagnosed non-small cell lung cancer patients from 2004 to  
47  
48  
49 2010. The newly diagnosed non-small cell lung cancer patients were defined as ICD-O-3 with  
50  
51  
52 C339 to C349 without any cancers before. Then we excluded those lung cancer patients with  
53  
54  
55 unknown stage for 3,993 patients. We also excluded lung cancer patients in situ (70 patients),  
56  
57  
58 with multiple cancer (1,298 patients), palliative treatment at the beginning (1,934 patients),  
59  
60

1  
2  
3  
4 mortality before lung cancer diagnosed (64 patients), personal characteristics data missing (109  
5  
6  
7 patients), and hospital data missing (4,584 patients). In our study, patients with multiple cancers  
8  
9  
10 may affect survival due to other cancer effect. In Taiwan, palliative treatment is coded as  
11  
12 special code in NHIRD. Non-small cell lung cancer patients with palliative treatment at  
13  
14 beginning may be due to patients refusing further treatment or not receiving aggressive  
15  
16 treatment. We excluded them for informal treatment. Otherwise, we also excluded those  
17  
18 patients with data missing for accuracy. Finally, we had 42,962 people.  
19  
20  
21  
22  
23  
24

25 The data for this study was obtained from the Taiwan Cancer Registry, which was used  
26  
27 to acquire study participants. We also linked this data to the National Health Insurance  
28  
29 Database and the Cause of Death File from 2002 to 2012 that was provided by the Ministry of  
30  
31 Health and Welfare. The accuracy of Taiwan Cancer Registry and NHIRD has achieved at an  
32  
33 excellent level.  
34  
35  
36  
37  
38  
39

#### 40 **Patient and public involvement**

41  
42  
43 No patients were involved in the planning, conception and design of this study, as this  
44  
45 study was based on the National Health Insurance Research Database, published by the  
46  
47 Ministry of Health and Welfare, Taiwan.  
48  
49  
50  
51

#### 52 **Variable descriptions**

53  
54  
55 In this study, with regards to the variables used, the general characteristics of lung cancer  
56  
57 patients included sex and age. Age was defined as the age at which the patient had a  
58  
59  
60

1  
2  
3  
4 confirmatory diagnosis by pathology. The financial status of the patient was based on their  
5  
6  
7 monthly salary. The degree of urbanization at the patient's place of residence was used to  
8  
9  
10 represent environmental factors. The level of urbanization was based on 7 levels of  
11  
12  
13 classification from highly urbanized developed cities (level 1) to remote areas (level 7). The  
14  
15  
16 health status of the patient included data on whether the patient had other catastrophic illnesses  
17  
18  
19 besides cancer, their Charlson Comorbidity Index (CCI), and the stage of non-small cell lung  
20  
21  
22 cancer. The definition of catastrophic illness was based on the 30 types of catastrophic illnesses  
23  
24  
25 or injuries as defined by the National Health Insurance Administration, which include stroke,  
26  
27  
28 chronic kidney failure, systemic lupus erythematosus, type I diabetes and severe mental illness.  
29  
30  
31 The degree of comorbidity was classified into three levels based on the CCI<sup>11</sup>. Tumor staging  
32  
33  
34 was based on the guidelines of the American Joint Committee on Cancer (6<sup>th</sup> edition for tumors  
35  
36  
37 diagnosed from 2004-2009, 7<sup>th</sup> edition for tumors diagnosed in 2010), which includes stages I,  
38  
39  
40 II, III, and IV. Hospital attributes include the level of hospital (medical centers, regional  
41  
42  
43 hospitals, district hospitals, and others), hospital ownership (public or private institutions), and  
44  
45  
46 the volume of hospital services (low, medium, high) in treatment of non-small cell lung cancer  
47  
48  
49 patients. The volume of hospital services was divided into low, medium, and high on the basis  
50  
51  
52 of quartiles: service volumes of <25%, 25-75% and >75% were defined as low, medium and  
53  
54  
55 high, respectively. Patients were considered to be enrolled in multidisciplinary team (MDT)  
56  
57  
58 care if they received MDT treatment after pathological diagnosis of non-small cell lung cancer;  
59  
60

1  
2  
3  
4 the definition of MDT is based on patients who were declared MDT treatment fees in the NHI  
5  
6  
7 database (47079B). The interval between diagnosis of non-small cell lung cancer and treatment  
8  
9  
10 initiation was defined as the period between pathological sectioning and diagnosis of non-small  
11  
12  
13 cell lung cancer after biopsy to the time when the patient underwent their first treatment  
14  
15  
16 (including surgery, radiotherapy, or chemotherapy). The operating definition of relevant  
17  
18  
19 treatments is based on the relevant treatment code that was declared in the NHI database, which  
20  
21  
22 was checked against the treatment registration information in the Taiwan Cancer Information  
23  
24  
25 Database.

### 26 27 28 **Main outcome measurements**

29  
30  
31 The main outcome examined in this study was the survival rate of lung cancer patients.  
32  
33  
34 Confirmation of death was based on patient data from the NHI database and this was compared  
35  
36  
37 with the Taiwan Cause of Death archives for confirmation.  
38  
39

### 40 **Statistical analysis**

41  
42  
43 We employed descriptive statistics to show general characteristics, financial status,  
44  
45  
46 environmental factors, health status of patients, hospital attributes, enrolment in MDT and the  
47  
48  
49 distribution status of the interval from diagnosis confirmation to treatment initiation in lung  
50  
51  
52 cancer patients who had a confirmatory diagnosis by pathology from 2004 to 2010. Following  
53  
54  
55 this, bivariate analysis was performed using the log-rank test to investigate whether there were  
56  
57  
58 significant differences between survival status by the end of 2012 and the interval from  
59  
60

1  
2  
3  
4 diagnosis to treatment initiation. We then used univariate Cox proportional hazards regression  
5  
6  
7 to analyze relevant prognostic factors that affect the survival of lung cancer patients. The  
8  
9  
10 adjusted Cox proportional hazards model was used to investigate the relative risk of survival  
11  
12  
13 of lung cancer patients with different cancer stages with different intervals from diagnosis  
14  
15  
16 confirmation to treatment initiation, after controlling for related variables. Independent  
17  
18  
19 variables included patient characteristics, financial status, environmental factors, health status,  
20  
21  
22 hospital attributes, enrolment in MDT, and grouping of time to treatment initiation. The  
23  
24  
25 dependent variable was survival. Lastly, after controlling for relevant variables, the adjusted  
26  
27  
28 Cox proportional hazards model was used to generate survival curves for lung cancer patients  
29  
30  
31 of various stages and with different interval periods.

32  
33  
34 All statistical analyses were performed using SAS software, version 9.2 (SAS Institute  
35  
36  
37 Inc., Cary, NC). A P value  $<0.05$  was regarded as statistically significant and all tests were  
38  
39  
40 two-sided.

## 41 42 43 **RESULTS**

### 44 45 **Descriptive statistics of lung cancer patient characteristics for different treatment** 46 47 **intervals**

48  
49  
50 In all lung cancer patients, the mean 5-year survival rate was 17.61%. As the interval from  
51  
52  
53 diagnosis to treatment initiation increased, the 5-year survival rate decreased from 26.12% to  
54  
55  
56 6.02% (Table 1). We also included time to treatment with 0 day (TTT=0) cases in the  $<7$  days  
57  
58  
59 group in our study. There were 7,363 cases with TTT=0 accounting for 17.14% of all patients  
60



1  
2  
3  
4 in our study. We had 3,258 females accounting for 44.25% in this subgroup. The age of  
5  
6  
7 diagnosed in most patients was from 65-74 years old accounting for 28.28% with mean age of  
8  
9  
10 64.67 years old. The treatment of most patients with TTT=0 was surgery combining with  
11  
12  
13 radiotherapy and chemotherapy.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1. Bivariate analysis of lung cancer patient characteristics for different treatment intervals

Variables	Total		Interval from cancer diagnosis to treatment								P value <sup>a</sup>
			≤ 7 days		8~14 days		15~60 days		≥ 61 days		
	N	%	N	%	N	%	N	%	N	%	
<b>Total number</b>	42,962	100.00	15,769	36.70	9,296	21.64	12,510	29.12	5,387	12.54	-
<b>Five-year survival rate</b>	42,962	17.61	15,769	26.12	9,296	15.96	12,510	12.99	5,387	6.02	<0.001
<b>Gender</b>											<0.001
Female	15,799	36.77	6,154	38.95	3,235	20.48	4,419	27.97	1,991	12.60	
Male	27,163	63.23	9,615	35.40	6,061	22.31	8,091	29.79	3,396	12.50	
<b>Age</b>											<0.001
≤ 44	2,106	4.90	889	42.21	455	21.60	568	26.97	194	9.21	
45~54	5,686	13.23	2,375	41.77	1,263	22.21	1,549	27.24	499	8.78	
55~64	9,155	21.31	3,634	39.69	2,033	22.21	2,658	29.03	830	9.07	
65~74	12,659	29.47	4,548	35.93	2,801	22.13	3,819	30.17	1,491	11.78	
≥ 75	13,356	31.09	4,323	32.37	2,744	20.55	3,916	29.32	2,373	17.77	
<b>Mean age (m, sd)</b>	66.76	12.44	65.52	12.55	66.45	12.22	67.04	12.15	70.25	12.46	<0.001
<b>Monthly salary</b>											<0.001
Low-income	461	1.07	137	29.72	101	21.91	154	33.41	69	14.97	
≤ 17280	1,475	3.43	542	36.75	311	21.08	447	30.31	175	11.86	
17281~22800	22,935	53.38	8,074	35.20	5,079	22.15	6,751	29.44	3,031	13.22	
22801~28800	8,069	18.78	2,961	36.70	1,690	20.94	2,376	29.45	1,042	12.91	
28801~36300	2,676	6.23	1,011	37.78	588	21.97	782	29.22	295	11.02	
36301~45800	3,280	7.63	1,333	40.64	689	21.01	923	28.14	335	10.21	
≥ 45801	4,066	9.46	1,711	42.08	838	20.61	1,077	26.49	440	10.82	

Table 1. Bivariate analysis of lung cancer patient characteristics for different treatment intervals (continued)

Variables	Total		Interval from cancer diagnosis to treatment								P value <sup>a</sup>
			≤ 7 days		8~14 days		15~60 days		≥ 61 days		
	N	%	N	%	N	%	N	%	N	%	
<b>Urbanization</b>											0.186
Level 1	11,759	27.37	4,335	36.87	2,494	21.21	3,404	28.95	1,526	12.98	
Level 2	12,117	28.20	4,506	37.19	2,615	21.58	3,527	29.11	1,469	12.12	
Level 3	6,523	15.18	2,334	35.78	1,424	21.83	1,946	29.83	819	12.56	
Level 4	6,795	15.82	2,518	37.06	1,506	22.16	1,974	29.05	797	11.73	
Level 5	1,524	3.55	523	34.32	338	22.18	439	28.81	224	14.70	
Level 6	2,217	5.16	807	36.40	490	22.10	627	28.28	293	13.22	
Level 7	2,027	4.72	746	36.80	429	21.16	593	29.26	259	12.78	
<b>CCI score</b>											<0.001
≤ 3	20,388	47.46	7,475	36.66	4,576	22.44	6,186	30.34	2,151	10.55	
4~6	7,587	17.66	2,761	36.39	1,646	21.70	2,218	29.23	962	12.68	
≥ 7	14,987	34.88	5,533	36.92	3,074	20.51	4,106	27.40	2,274	15.17	
<b>Other catastrophic illness</b>											<0.001
No	41,474	96.54	15,300	36.89	8,984	21.66	12,076	29.12	5,114	12.33	
Yes	1,488	3.46	469	31.52	312	20.97	434	29.17	273	18.35	
<b>Cancer stage</b>											<0.001
Stage I	5,681	13.22	3,226	56.79	910	16.02	1,269	22.34	276	4.86	
Stage II	1,526	3.55	589	38.60	338	22.15	462	30.28	137	8.98	
Stage III	11,696	27.22	4,030	34.46	2,843	24.31	3,500	29.92	1,323	11.31	
Stage IV	24,059	56.00	7,924	32.94	5,205	21.63	7,279	30.25	3,651	15.18	

Table 1. Bivariate analysis of lung cancer patient characteristics for different treatment intervals (continued)

Variables	Total		Interval from cancer diagnosis to treatment								P value <sup>a</sup>
			≤ 7 days		8~14 days		15~60 days		≥ 61 days		
	N	%	N	%	N	%	N	%	N	%	
<b>MDT care</b>											<0.001
No	37,716	87.79	13,669	36.24	8,012	21.24	10,974	29.10	5,061	13.42	
Yes	5,246	12.21	2,100	40.03	1,284	24.48	1,536	29.28	326	6.21	
<b>Hospital level</b>											<0.001
Medical centers	29,228	68.03	11,075	37.89	6,452	22.07	8,427	28.83	3,274	11.20	
Regional hospitals	12,601	29.33	4,395	34.88	2,655	21.07	3,787	30.05	1,764	14.00	
District hospitals	1,014	2.36	261	25.74	178	17.55	279	27.51	296	29.19	
Others	119	0.28	38	31.93	11	9.24	17	14.29	53	44.54	
<b>Hospital ownership</b>											<0.001
Public	16,770	39.03	6,619	39.47	3,776	22.52	4,558	27.18	1,817	10.83	
Private	26,192	60.97	9,150	34.93	5,520	21.08	7,952	30.36	3,570	13.63	
<b>Hospital services volume</b>											<0.001
Low	10,807	25.15	3,905	36.13	2,177	20.14	2,935	27.16	1,790	16.56	
Middle	21,043	48.98	7,519	35.73	4,652	22.11	6,486	30.82	2,386	11.34	
High	11,112	25.86	4,345	39.10	2,467	22.20	3,089	27.80	1,211	10.90	

<sup>a</sup> Log-rank test

### Five-year survival rate of patients for different treatment intervals

At the same time, we found that in stage I patients, the 5-year survival rate decreased by 9.07% due to delayed treatment (patients with intervals >7 days). In stage

II patients, if patients started treatment earlier (interval  $\leq 7$  days), their 5-year survival rate increased by 9.01%. Early treatment (interval  $\leq 7$  days) was found to have a smaller effect on 5-year survival rate in stage III and stage IV patients, with an increase in 5-year survival rate of 1.91% and 0.49% (Table 2).

Table 2. Five-year survival rate of patients for different treatment intervals

Variables	Stage I		Stage II		Stage III		Stage IV		P value <sup>a</sup>
	N	%	N	%	N	%	N	%	
<b>Total number</b>	5,681	61.61	1,526	34.41	11,696	12.95	24,059	5.11	
<b>Interval from cancer diagnosis to treatment</b>									<0.001
$\leq 7$ days	3,226	70.68	589	43.42	4,030	14.86	7,924	5.60	
8~14 days	910	60.58	338	33.74	2,843	12.11	5,205	4.58	
15~60 days	1,269	49.07	462	29.81	3,500	13.81	7,279	5.43	
$\geq 61$ days	276	21.10	137	14.56	1,323	6.83	3,651	4.12	

<sup>a</sup> Log-rank test

## **The effect of different treatment intervals on mortality risk in patients with lung cancer**

Table 3 shows that when the group with interval from cancer diagnosis to treatment  $\leq 7$  days was used as a reference, the adjusted HR for mortality in other groups (8-14 days, 15-60 days, and  $\geq 61$  days) was significantly increased with increasing interval time (HR: 1.04-1.08). Among patients at various cancer stages, using stage I patients as a control group, the adjusted HRs for mortality for cancer patients at various stages was significantly higher (HR: 2.06-5.89) and the more advanced the cancer stages, the higher the adjusted HR for mortality. Patients who underwent MDT care had a significantly lower adjusted HR for mortality compared with patients who did not (HR: 0.91, 95% CI: 0.88-0.94).

Table 3. Relative risk of death in patients for different treatment intervals

Variables	Unadjusted		Adjusted			
	HR	P value	HR	95% CI	P value <sup>a</sup>	
<b>Interval from cancer diagnosis to treatment</b>						
≤ 7 days (ref.)						
8~14 days	<b>1.26</b>	<0.001	<b>1.04</b>	1.01	1.07	0.004
15~60 days	<b>1.30</b>	<0.001	<b>1.06</b>	1.04	1.09	<0.001
≥ 61 days	<b>1.66</b>	<0.001	<b>1.08</b>	1.04	1.11	<0.001
<b>Gender</b>						
Female (ref.)						
Male	<b>1.54</b>	<0.001	<b>1.50</b>	1.47	1.53	<0.001
<b>Age</b>						
≤ 44 (ref.)						
45~54	<b>0.97</b>	0.357	<b>0.97</b>	0.92	1.03	0.351
55~64	<b>1.02</b>	0.478	<b>1.03</b>	0.97	1.09	0.331
65~74	<b>1.63</b>	<0.001	<b>1.27</b>	1.21	1.34	<0.001
≥ 75	<b>1.93</b>	<0.001	<b>1.79</b>	1.69	1.88	<0.001
<b>Monthly salary</b>						
Low-income (ref.)						
≤ 17280	<b>0.72</b>	<0.001	<b>0.89</b>	0.80	1.00	0.049
17281~22800	<b>0.81</b>	<0.001	<b>0.86</b>	0.78	0.95	0.002
22801~28800	<b>0.74</b>	<0.001	<b>0.83</b>	0.75	0.91	<0.001
28801~36300	<b>0.60</b>	<0.001	<b>0.79</b>	0.71	0.87	<0.001
36301~45800	<b>0.59</b>	<0.001	<b>0.78</b>	0.70	0.87	<0.001

Variables	Unadjusted		Adjusted			
	HR	P value	HR	95% CI	P value <sup>a</sup>	
≥ 45801	<b>0.56</b>	<0.001	<b>0.73</b>	0.66	0.81	<0.001
<b>Urbanization level</b>						
Level 1 (ref.)						
Level 2	<b>1.07</b>	<0.001	<b>0.99</b>	0.96	1.02	0.523
Level 3	<b>1.20</b>	<0.001	<b>1.04</b>	1.00	1.07	0.036
Level 4	<b>1.21</b>	<0.001	<b>1.01</b>	0.98	1.05	0.596
Level 5	<b>1.33</b>	<0.001	<b>1.01</b>	0.95	1.08	0.671
Level 6	<b>1.39</b>	<0.001	<b>1.09</b>	1.04	1.15	0.001
Level 7	<b>1.25</b>	<0.001	<b>1.02</b>	0.96	1.07	0.570
<b>CCI score</b>						
≤ 3 (ref.)						
4~6	<b>1.35</b>	<0.001	<b>1.18</b>	1.14	1.21	<0.001
≥ 7	<b>1.80</b>	<0.001	<b>1.28</b>	1.25	1.31	<0.001
<b>Other catastrophic illness</b>						
No (ref.)						
Yes	<b>1.25</b>	<0.001	<b>1.26</b>	1.19	1.33	<0.001
<b>Cancer stage</b>						
Stage I (ref.)						
Stage II	<b>2.29</b>	<0.001	<b>2.06</b>	1.91	2.23	<0.001
Stage III	<b>4.48</b>	<0.001	<b>3.94</b>	3.75	4.13	<0.001
Stage IV	<b>6.51</b>	<0.001	<b>5.89</b>	5.62	6.17	<0.001
<b>MDT care</b>						
No (ref.)						



Variables	Unadjusted		Adjusted			
	HR	P value	HR	95% CI	P value <sup>a</sup>	
Yes	<b>0.95</b>	0.001	<b>0.91</b>	0.88	0.94	<0.001
<b>Hospital level</b>						
Medical centers (ref.)						
Regional hospitals	<b>1.28</b>	<0.001	<b>0.99</b>	0.96	1.02	0.347
District hospitals	<b>2.06</b>	<0.001	<b>1.25</b>	1.17	1.34	<0.001
Others	<b>1.17</b>	0.137	<b>0.90</b>	0.73	1.10	0.286
<b>Hospital ownership</b>						
Public (ref.)						
Private	<b>1.27</b>	<0.001	<b>1.13</b>	1.10	1.16	<0.001
<b>Hospital services volume</b>						
Low (ref.)						
Middle	<b>0.72</b>	<0.001	<b>0.83</b>	0.81	0.85	<0.001
High	<b>0.59</b>	<0.001	<b>0.71</b>	0.68	0.74	<0.001

<sup>a</sup> Cox proportional hazards regression

### The effect of different treatment intervals on mortality risk in patients with lung cancer at different cancer stages

Table 4 shows that in stage I lung cancer patients, with patients with intervals of  $\leq 7$  days as the reference group, as the interval increased, the relative risk of death also significantly increased (HR: 1.45-2.41). This was also true for stage II (HR: 1.21-1.58) and the intervals more than 60 days of stage III lung cancer patients (HR: 1.13, 95% CI: 1.06-1.21). In stage IV patients, using patients with an interval  $\leq 7$  days as a

1  
2  
3  
4 reference group, the relative risk of death was without significantly difference. Figure

5  
6  
7 1 shows adjusted survival curve in lung cancer patients with different cancer stages.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 4. Relative risk of death in patients for different treatment intervals and at different cancer stages

Variables	Stage I <sup>a</sup>			Stage II <sup>a</sup>			Stage III <sup>a</sup>			Stage IV <sup>a</sup>		
	HR	95% CI	P value <sup>b</sup>	HR	95% CI	P value <sup>b</sup>	HR	95% CI	P value <sup>b</sup>	HR	95% CI	P value <sup>b</sup>
<b>Interval from cancer diagnosis to treatment</b>												
≤ 7 days (ref.)												
8~14 days	<b>1.45</b>	1.28 1.64	<0.001	<b>1.21</b>	1.01 1.45	0.039	<b>1.04</b>	0.98 1.09	0.177	<b>0.99</b>	0.95 1.03	0.561
15~60 days	<b>1.66</b>	1.49 1.84	<0.001	<b>1.44</b>	1.22 1.69	<0.001	<b>1.02</b>	0.97 1.07	0.560	<b>1.01</b>	0.98 1.04	0.572
≥ 61 days	<b>2.41</b>	2.06 2.83	<0.001	<b>1.58</b>	1.26 1.97	<0.001	<b>1.13</b>	1.06 1.21	<0.001	<b>0.98</b>	0.94 1.02	0.249

a. Patient age, gender, monthly salary, level of urbanization of place of residence, CCI score, other illness, MDT care, hospital level, hospital ownership, and hospital services volume were all controlled for using various models.

<sup>b</sup> adjusted Cox proportional hazards model

## DISCUSSION

We found that the mortality rate exhibited significantly positive correlation to time interval from cancer diagnosis to treatment initiation in all stage NSCLC patients. The ratio of male to female in our study is similar to that in previous studies.<sup>12 13</sup> The delays between diagnosis and treatment can be categorized into three stages: namely, patient delay, diagnosis delay, and treatment delay.<sup>2</sup> Of all studies which investigated treatment delays in lung cancer patients, the study with the largest number of patients included 54,338 patients, but was limited to non-metastatic lung cancer patients.<sup>12</sup> In addition, the study only focused on patients who underwent surgical excision and did not analyze the treatment delay status and associated factors for all lung cancer patients. Another study collected data from 28,732 patients to investigate whether treatment delay affects survival rate.<sup>14</sup> The researchers found that if the interval from diagnosis to treatment was within 35 days, then there is improved survival for patients with localized disease, reduced survival for those with distant disease, but didn't have significant effect on patients with regional disease.<sup>14</sup> However, in that study, the diagnosis to treatment interval was divided into just two groups (<35 days and >35 days), which makes it more difficult to show the correlation between different treatment delay groups and patient survival rates. In addition, in that study, the authors did not investigate whether different treatment delay periods affect survival rate for different cancer stages as they only

1  
2  
3  
4 classified cancers as localized, regional, or distant. To the best of our knowledge, the  
5  
6  
7 current study is the first large-scale nationwide study that examines whether treatment  
8  
9  
10 delay in non-small cell lung cancer affects patient survival rate. In addition, we also  
11  
12  
13 investigated the correlation between lung cancer treatment delay and survival rate for  
14  
15  
16 different cancer stages (stages I, II, III and IV).  
17

18  
19 Previous studies have observed that if patients are older, have more comorbidities,  
20  
21  
22 or have stage I cancer, they are more likely to delay treatment (interval from diagnosis  
23  
24  
25 to treatment >30 days).<sup>12</sup> Similar findings were observed in our study: for patients aged  
26  
27  
28  $\geq 55$  years, the greater the age the greater the proportion with treatment delay (interval  
29  
30  
31  $\geq 61$  days) (Table 1). Patients with high CCI scores also demonstrated significantly  
32  
33  
34 increased proportions in treatment delay (interval  $\geq 61$  days) (Table 1). However, during  
35  
36  
37 analysis of the correlation between treatment delay and lung cancer stage, we found  
38  
39  
40 that the proportion of stage I patients with treatment delay was significantly lower than  
41  
42  
43 patients with other stages of lung cancer. A previous study has observed that in non-  
44  
45  
46 small cell lung cancer patients, treatment delay is not associated with cancer stage.<sup>15, 16-</sup>  
47  
48  
49 <sup>20</sup> In contrast, treatment delay had more serious effects in stage III and IV patients.<sup>21</sup>  
50  
51  
52 However, in our study, we found that the proportion of stage I patients with treatment  
53  
54  
55 delay (interval from diagnosis to treatment  $\geq 61$  days) was significantly lower (4.86%,  
56  
57  
58  $p < 0.001$ ), when compared with patients at other stages.  
59  
60

1  
2  
3  
4 Previous studies have mentioned that in non-small cell lung cancer patients, our  
5  
6  
7 understanding of the effects of diagnosis and treatment delay on the prognosis of  
8  
9  
10 patients is limited, although an increasing number of recent studies are emphasizing the  
11  
12  
13 importance of this topic.<sup>4</sup> Some studies have found that in patients with a symptom-to-  
14  
15  
16 treatment interval (STI) of >60 days, the survival rate was significantly higher than that  
17  
18  
19 of patients with a STI of <60 days.<sup>22</sup> However, if patients were further divided on the  
20  
21  
22 basis of the type of lung cancer, this difference was only significant in NSCLC  
23  
24  
25 patients.<sup>22</sup> However, the number of patients included in this study was only 103 (96  
26  
27  
28 men).<sup>23</sup> Two other studies, with 378 and 410 patients each, found that delaying  
29  
30  
31 diagnosis and treatment did not affect patient survival rates.<sup>16 17</sup> Another study of 466  
32  
33  
34 non-small cell lung cancer patients found that patients with shorter STIs had lower  
35  
36  
37 survival rates.<sup>24</sup> One study with 189 lung cancer patients found that treatment delay  
38  
39  
40 resulted in poorer prognosis for patients,<sup>25</sup> whilst another study with 132 patients found  
41  
42  
43 that longer specialist treatment delay does not result in poorer prognosis.<sup>26</sup> An  
44  
45  
46 aforementioned article also observed that most previous studies in different countries  
47  
48  
49 were monocentric studies and that it is difficult to decide which study is most reliable  
50  
51  
52 with regards to whether treatment delay affects patient survival rates.<sup>4</sup>

53  
54  
55 Most studies show no relationship between time-to-chemotherapy (TTC) and their  
56  
57  
58 survival rate.<sup>27</sup> However, it should be noted that in these review articles, the number of  
59  
60

1  
2  
3  
4 cases collected is generally very low, with the highest number of patients only 10,583.<sup>27</sup>  
5  
6

7 Another study showed time intervals from diagnosis to treatment were not associated  
8  
9  
10 with survival outcomes in NSCLC.<sup>28</sup> In this previous study, they discussed NSCLC  
11  
12  
13 patients with different treatment such as surgery, radiotherapy, systemic therapy and  
14  
15  
16 palliative care which were not discussed in our study. They also suggested that delays  
17  
18  
19 to treatment might impact on other outcomes other than survival. However, there were  
20  
21  
22 only 1,729 patients in this previous study.<sup>28</sup> In summary, the majority of previous  
23  
24  
25 studies into whether treatment delay affects survival rate in non-small cell lung cancer  
26  
27  
28 patients lack large-scale nationwide statistical data. This can easily lead to bias and  
29  
30  
31 produce divergent conclusions. In this study, we collected nationwide data from 42,962  
32  
33  
34 non-small cell lung cancer patients, which, to the best of our knowledge, is the largest  
35  
36  
37 nationwide study to date. In addition, we also investigated the correlation between lung  
38  
39  
40 cancer treatment delay and survival rate in different cancer stages (stages I, II, III and  
41  
42  
43 IV).  
44  
45

46 In addition, detailed examination of the literature found that a decreased treatment  
47  
48  
49 delay increases the risk of death in patients; the explanation provided for this is that a  
50  
51  
52 shorter treatment delay may mean that the patients have more obvious or more severe  
53  
54  
55 symptoms.<sup>24</sup> Therefore, there is a need to correct the result with cancer stage and  
56  
57  
58 severity.<sup>24</sup> A previous study has also suggested that a shorter treatment delay may  
59  
60

1  
2  
3  
4 reflect a requirement for more urgent treatment due to severity of symptoms, resulting  
5  
6  
7 in a poor prognosis.<sup>29</sup> Therefore, in this paper, we also considered the effects of cancer  
8  
9  
10 stage on treatment delay and patient prognosis. In another paper, it was also mentioned  
11  
12  
13 that the definition of treatment delay should be more standardized and accurate.<sup>4</sup>  
14  
15  
16 Another paper mentioned that it is not easy to accurately calculate the time of treatment  
17  
18  
19 initiation.<sup>24</sup> In addition, the calculation of patient delay (from symptom to doctor) is  
20  
21  
22 also prone to errors. Therefore, in this study, our definition of treatment delay was made  
23  
24  
25 according to the cancer registration archives and NHI database, from pathological  
26  
27  
28 diagnosis confirmation until treatment initiation.

31 For cancer patients in general, current medical guidelines all recommend early  
32  
33  
34 diagnosis and treatment to improve patient prognosis. However, early diagnosis is  
35  
36  
37 difficult due to multiple factors, such as non-apparent symptoms and patient delay.  
38  
39  
40 However, in this study, we found that if the interval from confirmation of pathological  
41  
42  
43 diagnosis to treatment initiation in non-small cell lung cancer patients is shortened to 7  
44  
45  
46 days, this can effectively improve their 5-year survival rate (improvements of 0.49-  
47  
48  
49 9.07% were observed, according to the different stages of lung cancer). We also found  
50  
51  
52 that this improvement in 5-year survival rate was particularly marked for non-small cell  
53  
54  
55 lung cancer patients at early stages (stage I and II), at 10.28-10.34%. However, in late  
56  
57  
58 stage (stage III and stage IV) patients, the 5-year survival rate was only increased by  
59  
60



1  
2  
3  
4 1.91% and 0.49%. A previous study showed that NSCLC growth rate appeared to be  
5  
6  
7 highly variable and related to histological subtype which was not discussed in our  
8  
9  
10 study.<sup>30</sup> Doubling times can be quite variable in different stages of NSCLC. Another  
11  
12  
13 study showed that rapid tumor progression was noted in patients with untreated,  
14  
15  
16 predominantly stage III NSCLC.<sup>31</sup> In our study, table 4 shows stage III non-small cell  
17  
18  
19 lung cancer patients with the interval from diagnosis to treatment initiation more than  
20  
21  
22 60 days had significantly higher relative risk of death than patients with an interval  $\leq 7$   
23  
24  
25 days (HR: 1.13, 95% CI: 1.06-1.21). This may be due to rapid tumor progression  
26  
27  
28 characteristics of stage III NSCLC. However, the delay treatment effect is not  
29  
30  
31 significant in stage IV NSCLC patients, which may be associated with poor outcome  
32  
33  
34 and low survival rate in late stage of NSCLC. Therefore, we recommended that in future  
35  
36  
37 policies, treatment recommendations should be formulated so that patients can start  
38  
39  
40 treatment within 7 days after pathological diagnosis confirmation of non-small cell lung  
41  
42  
43 cancer to increase their 5-year survival rate. This is particularly important for early  
44  
45  
46 stage (stage I and II) non-small cell lung cancer patients, where improvement effects  
47  
48  
49 are more significant.

50  
51  
52 In this study, we also found that the effect of the interval from diagnosis to  
53  
54  
55 treatment initiation and patient survival rate decreased with more advanced cancer  
56  
57  
58 stages. Therefore, in patients who have stage I (HR: 1.45-2.41) or stage II (HR: 1.21-

1  
2  
3  
4 1.58) cancer, the longer the interval from diagnosis to treatment initiation, the higher  
5  
6  
7 the risk of death in patients. However, in stage III patients, compared with patients with  
8  
9  
10 an interval from diagnosis to treatment initiation  $\leq 7$  days, only when the interval from  
11  
12  
13 diagnosis to treatment initiation was  $\geq 61$  days was the risk of death increased. However,  
14  
15  
16 the magnitude of the increased risk of death is lower than in stage I and II patients (HR:  
17  
18  
19 1.03-1.06). Therefore, this study found that timely treatment of stage I and II lung  
20  
21  
22 cancer patients has greater benefits. Therefore, we recommend that we should shorten  
23  
24  
25 the interval from diagnosis to treatment initiation especially in stage I and II lung cancer  
26  
27  
28 patients, thus decreasing the risk of death and improving prognosis. However, due to  
29  
30  
31 data limitation, we used crude survival instead of disease free survival.

32  
33  
34 In recent studies, it was found that patients with oral cancers who underwent MDT  
35  
36  
37 treatment had significantly higher survival rates, and that the proportion of patients who  
38  
39  
40 underwent treatment was higher than those who did not joining MDT.<sup>32</sup> Previous  
41  
42  
43 studies have shown that the use of MDT care in cancer treatment can improve patient  
44  
45  
46 prognosis.<sup>33</sup> This is particularly the case in head and neck cancers, where MDT care is  
47  
48  
49 not only cost-effective but can also improve survival rates.<sup>34</sup> Previous studies have  
50  
51  
52 shown that in lung cancer patients MDT care can significantly improve the patient's  
53  
54  
55 acceptance of treatment, but does not significantly improve patient survival rates.<sup>33</sup> In  
56  
57  
58 this study, we found that patients who underwent MDT care had a significantly lower  
59  
60

1  
2  
3  
4 adjusted HR for mortality compared with patients who did not (HR: 0.91, 95% CI: 0.88-  
5  
6  
7 0.94).  
8  
9

10 In summary, this study recommends that the interval from diagnosis to treatment  
11  
12 initiation should be minimized during treatment of lung cancer patients at various  
13  
14 cancer stages, particularly in stage I and II patients. In addition, in stage III and stage  
15  
16 IV patients, we recommend the addition of MDT care to decrease the risk of death and  
17  
18 improve prognosis.  
19  
20  
21  
22  
23  
24

### 25 **Limitations**

26  
27  
28 A secondary random database derived from the National Health Insurance  
29  
30 Research Database was employed for this study. The information on individual lifestyle,  
31  
32 health behaviors, which may also affect the result, is not available. The lung function  
33  
34 testing such as forced expiratory volume in one second (FEV1) and diffusing capacity  
35  
36 of the lung for carbon monoxide (DLCO) is not available in our database, and disease  
37  
38 free survival is also not available in our database.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **Conclusions**

50  
51  
52 In this study, we collected nationwide data from 42,962 non-small cell lung cancer  
53  
54 patients, which, to the best of our knowledge, is the largest nationwide study to date. In  
55  
56 addition, we also investigated the correlation between lung cancer treatment delay and  
57  
58  
59  
60

1  
2  
3  
4 survival rate in different cancer stages (stages I, II, III and stage IV) with pathological  
5  
6  
7 confirmation. NSCLC patients with timeliness treatment in stage I and II have better  
8  
9  
10 survival rate than others.  
11  
12  
13

### 14 **Acknowledgements**

15  
16  
17 We are grateful to the Science Center of the Ministry of Health and Welfare for  
18  
19  
20 providing us with access to the National Health Insurance Research Database, Cancer  
21  
22  
23 Registry Files, and Cause of Death File. We are also grateful to Health Data Science  
24  
25  
26 Center, China Medical University Hospital for providing administrative, technical and  
27  
28  
29 funding support.  
30  
31

### 32 **Funding source**

33  
34  
35 This study was supported by the grants (CMU107-ASIA-18; MOST 104-2410-H-039  
36  
37  
38 -002) from China Medical University, Asia University, and the Ministry of Science  
39  
40  
41 and Technology, Taiwan.  
42  
43

### 44 **Competing interests**

45  
46  
47 The authors declare that they have no competing interests.  
48  
49

### 50 **Author's contribution**

51  
52  
53 Conceptualization: Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai

54  
55  
56 Methodology: Chang-Hung Tsai, Pei-Tseng Kung, Wei-Yin Kuo, Wen-Chen Tsai

57  
58  
59 Software: Wen-Chen Tsai  
60

1  
2  
3  
4 Validation: Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai  
5  
6

7 Formal analysis: Chang-Hung Tsai, Wei-Yin Kuo  
8  
9

10 Data curation: Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai  
11  
12

13 Resources: Pei-Tseng Kung, Wen-Chen Tsai  
14  
15

16 Writing (original draft preparation): Chang-Hung Tsai, Wen-Chen Tsai  
17  
18

19 Writing (review and editing): Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai  
20  
21

22 Supervision: Wen-Chen Tsai  
23  
24

25 Project administration: Chang-Hung Tsai, Wei-Yin Kuo, Pei-Tseng Kung  
26  
27

28 Funding acquisition: Pei-Tseng Kung, Wen-Chen Tsai  
29  
30

### 31 **Patient consent form** 32

33  
34 As this study used anonymized secondary data retrieved from the Taiwan's National  
35  
36  
37 Health Insurance Research Database, the requirement for informed consent was  
38  
39  
40 waived by the ethics committee.  
41  
42

### 43 **Data sharing** 44

45  
46  
47 This study used the National Health Insurance Research Database published by the  
48  
49  
50 Ministry of Health, Taiwan. Due to legal restrictions imposed by the Taiwan  
51  
52  
53 government related to the Personal Information Protection Act, the database cannot be  
54  
55  
56 made publicly available. All researchers can apply for using the databases for  
57  
58  
59 conducting their studies. Requests for data can be sent as a formal proposal to the  
60

1  
2  
3  
4 Science Center of the Ministry of Health and Welfare

5  
6  
7 (<http://www.mohw.gov.tw/EN/Ministry/Index.aspx>). Any raw data are not allowed to

8  
9  
10 be brought out from the Science Center. Only the analytic outputs in format of table

11  
12  
13 or figure can be printed out. The restrictions prohibited the authors from making the

14  
15  
16 minimal data set publicly available.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 **Figure Legend**  
4

5  
6 Figure 1. Adjusted survival curve in lung cancer patients with different cancer stages  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## References

1. Ferlay J. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10. <http://globocan.iarc.fr> 2010
2. Jensen AR, Mainz J, Overgaard J. Impact of delay on diagnosis and treatment of primary lung cancer. *Acta Oncologica* 2002;41(2):147-52.
3. Valdés S, García E, Pérez H, et al. Length of diagnostic delay in patients with non-small-cell lung cancer. *MEDICC review* 2010;12(1)
4. Vinas F, Ben Hassen I, Jabot L, et al. Delays for diagnosis and treatment of lung cancers: a systematic review. *The clinical respiratory journal* 2016;10(3):267-71.
5. Storm H, Dickman P, Engeland A, et al. Do morphology and stage explain the inferior lung cancer survival in Denmark? *European Respiratory Journal* 1999;13(2):430-35.
6. Teppo L, Dickman PW, Hakulinen T, et al. Cancer patient survival-patterns, comparisons, trends: A population-based cancer registry study in Finland. *Acta oncologica* 1999;38(3):283-94.
7. Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. *Journal of the National Comprehensive Cancer Network* 2016;14(3):255-64.
8. Chandra S, Mohan A, Guleria R, et al. Delays during the diagnostic evaluation and treatment of lung cancer. *Asian Pac J Cancer Prev* 2009;10(3):453-6.
9. Chiang C-J, You S-L, Chen C-J, et al. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. *Japanese journal of clinical oncology* 2015;45(3):291-96.
10. Cheng CL, Kao YHY, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. *Pharmacoepidemiology and drug safety* 2011;20(3):236-42.
11. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *Journal of clinical epidemiology* 1992;45(6):613-19.
12. Bilimoria KY, Ko CY, Tomlinson JS, et al. Wait times for cancer surgery in the United States: trends and predictors of delays. *Annals of surgery* 2011;253(4):779-85.
13. Evans SM, Earnest A, Bower W, et al. Timeliness of lung cancer care in Victoria: a retrospective cohort study. *Medical Journal of Australia* 2016;204(2):75-75.
14. Gomez DR, Liao K-P, Swisher SG, et al. Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. *Radiotherapy and Oncology* 2015;115(2):257-63.
15. Liberman M, Liberman D, Sampalis JS, et al. Delays to surgery in non-small-cell lung cancer. *Canadian journal of surgery* 2006;49(1):31.
16. Pita-Fernández S, Montero-Martinez C, Pértega-Díaz S, et al. Relationship between



- 1  
2  
3 delayed diagnosis and the degree of invasion and survival in lung cancer. *Journal of*  
4 *clinical epidemiology* 2003;56(9):820-25.
- 5  
6 17. Porta M, Gallen M, Malats N, et al. Influence of " diagnostic delay" upon cancer survival:  
7 an analysis of five tumour sites. *Journal of Epidemiology & Community Health*  
8 1991;45(3):225-30.
- 9  
10 18. Koyi H, Hillerdal G, Brandén E. Patient's and doctors' delays in the diagnosis of chest  
11 tumors. *Lung cancer* 2002;35(1):53-57.
- 12  
13 19. Billing J, Wells F. Delays in the diagnosis and surgical treatment of lung cancer. *Thorax*  
14 1996;51(9):903-06.
- 15  
16 20. Mor V, Masterson-Allen S, Goldberg R, et al. Pre-diagnostic symptom recognition and  
17 help seeking among cancer patients. *Journal of community health* 1990;15(4):253-  
18 66.
- 19  
20 21. Christensen E, Harvald T, Jendresen M, et al. The impact of delayed diagnosis of lung  
21 cancer on the stage at the time of operation. *European Journal of Cardio-Thoracic*  
22 *Surgery* 1997;12(6):880-84.
- 23  
24 22. Annakkaya AN, Arbak P, Balbay O, et al. Effect of symptom-to-treatment interval on  
25 prognosis in lung cancer. *Tumori Journal* 2007;93(1):61-67.
- 26  
27 23. Annakkaya AN, Arbak P, Balbay O, et al. Effect of symptom-to-treatment interval on  
28 prognosis in lung cancer. *Tumori* 2007;93(1):61.
- 29  
30 24. Myrdal G, Lambe M, Hillerdal G, et al. Effect of delays on prognosis in patients with non-  
31 small cell lung cancer. *Thorax* 2004;59(1):45-49.
- 32  
33 25. Robinson E, Mohilever J, Zidan J, et al. Delay in diagnosis of cancer. Possible effects on  
34 the stage of disease and survival. *Cancer* 1984;54(7):1454-60.
- 35  
36 26. Salomaa E-R, Sallinen S, Hiekkanen H, et al. Delays in the diagnosis and treatment of lung  
37 cancer. *Chest Journal* 2005;128(4):2282-88.
- 38  
39 27. Alexander M, Blum R, Burbury K, et al. Timely initiation of chemotherapy: a systematic  
40 literature review of six priority cancers—results and recommendations for clinical  
41 practice. *Internal medicine journal* 2017;47(1):16-34.
- 42  
43 28. Vinod SK, Chandra A, Berthelsen A, et al. Does timeliness of care in Non-Small Cell Lung  
44 Cancer impact on survival? *Lung Cancer* 2017;112:16-24.
- 45  
46 29. Diaconescu R, Lafond C, Whittom R. Treatment delays in non-small cell lung cancer and  
47 their prognostic implications. *Journal of Thoracic Oncology* 2011;6(7):1254-59.
- 48  
49 30. Mackintosh JA, Marshall HM, Yang IA, et al. A retrospective study of volume doubling  
50 time in surgically resected non-small cell lung cancer. *Respirology* 2014;19(5):755-62.
- 51  
52 31. Everitt S, Herschtal A, Callahan J, et al. High rates of tumor growth and disease  
53 progression detected on serial pretreatment fluorodeoxyglucose-positron emission  
54 tomography/computed tomography scans in radical radiotherapy candidates with  
55 nonsmall cell lung cancer. *Cancer* 2010;116(21):5030-37.
- 56  
57  
58  
59  
60

- 1  
2  
3  
4 32. Tsai W-C, Kung P-T, Wang S-T, et al. Beneficial impact of multidisciplinary team  
5 management on the survival in different stages of oral cavity cancer patients: results  
6 of a nationwide cohort study in Taiwan. *Oral oncology* 2015;51(2):105-11.  
7  
8 33. Boxer MM, Vinod SK, Shafiq J, et al. Do multidisciplinary team meetings make a  
9 difference in the management of lung cancer? *Cancer* 2011;117(22):5112-20.  
10  
11 34. Birchall M, Bailey D, King P. South West Cancer Intelligence Service Head and Neck  
12 Tumour Panel. Effect of process standards on survival of patients with head and neck  
13 cancer in the south and west of England. *Br J Cancer* 2004;91(8):1477-81.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




Figure 1

67x67mm (300 x 300 DPI)

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
<b>Introduction</b>			<b>5-6</b>
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any pre-specified hypotheses	6
<b>Methods</b>			<b>6-10</b>
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7,9
Bias	9	Describe any efforts to address potential sources of bias	6-7
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	10
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10-19
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10-19
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			20-26
Key results	18	Summarise key results with reference to study objectives	20
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	23
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	26
Generalisability	21	Discuss the generalisability (external validity) of the study results	26-27
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	27

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Effect of time interval from diagnosis to treatment for non-small cell lung cancer on survival: A national cohort study in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034351.R2
Article Type:	Original research
Date Submitted by the Author:	11-Feb-2020
Complete List of Authors:	Tsai, Chang-Hung; China Medical University, Department of Public Health; Miaoli General Hospital Ministry of Health and Welfare Kung, Pei-Tseng ; Asia University, Department of Healthcare Administration; China Medical University, Department of Medical Research, China Medical University Hospital Kuo, Wei-Yin; China Medical University, Department of Health Services Administration Tsai, Wen-Chen; China Medical University, Department of Health Services Administration
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Epidemiology, Health services research, Public health, Evidence based practice
Keywords:	lung cancer, non-small cell lung cancer, delay treatment, timeliness of treatment, survival

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Effect of time interval from diagnosis to treatment for non-small cell lung cancer on**  
5  
6  
7 **survival: A national cohort study in Taiwan**  
8  
9

10 **Running head:** Treatment delay and survival for non-small cell lung cancer  
11  
12

13  
14 Chang-Hung Tsai<sup>a,b,c</sup>, Pei-Tseng Kung<sup>d,e,#</sup>, Wei-Yin Kuo<sup>b</sup>, Wen-Chen Tsai<sup>b,#,\*</sup>  
15  
16

17  
18 <sup>a</sup> Miao-Li General Hospital, Ministry of Health and Welfare, Taiwan, R.O.C  
19  
20

21  
22 <sup>b</sup> Department of Health Services Administration, China Medical University, Taichung,  
23  
24 Taiwan, R.O.C.  
25  
26

27  
28 <sup>c</sup> Department of Public Health, China Medical University, Taichung, Taiwan, R.O.C.  
29  
30

31  
32 <sup>d</sup> Department of Healthcare Administration, Asia University, Taichung, Taiwan, R.O.C  
33  
34

35  
36 <sup>e</sup> Department of Medical Research, China Medical University Hospital, China Medical  
37  
38 University, Taichung, Taiwan, R.O.C.  
39  
40  
41

42  
43 <sup>#</sup> Authors had equal contributions to this work.  
44  
45  
46

47  
48 **\*Corresponding Author:** Professor Wen-Chen Tsai, Dr.PH.  
49  
50

51  
52 Address: No. 91 Hsueh-Shih Road, Taichung, Taiwan 40402, R.O.C.  
53  
54

55  
56 Tel: +886-422073070; Fax: +886-422028895  
57  
58  
59  
60



1  
2  
3  
4 E-mail: wtsai@mail.cmu.edu.tw  
5  
6  
7

8 **Words:** 3346  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Abstract

**OBJECTIVES.** This study aimed to determine if treatment delay after non-small cell lung cancer (NSCLC) diagnosis impacts patient survival rate.

**STUDY DESIGN.** This study is a natural experiment in Taiwan. A retrospective cohort investigation was conducted from 2004 to 2010, which included 42,962 patients with newly diagnosed NSCLC.

**METHODS.** We identified 42,962 patients with newly diagnosed NSCLC in the Taiwan Cancer Registry from 2004 to 2010. We calculated the time interval between diagnosis and treatment initiation. All patients were followed from the index date to death, or the end of 2012. Cox proportional hazard models were used to examine the relationship between mortality and time interval.

**RESULTS.** We included 42,962 patients (15,799 men and 27,163 women) with newly diagnosed NSCLC. The mortality rate exhibited a significantly positive correlation to time interval from cancer diagnosis to treatment initiation. The adjusted hazard ratios ranged from 1.04 to 1.08 in all subgroups time interval more than 7 days compared with the counterpart subgroup of the interval from cancer diagnosis to treatment  $\leq 7$  days. The trend was also noted regardless of the patients with lung cancer in stage I, stage II, and stage III.

**CONCLUSIONS.** There is a major association between time to treat and mortality of

1  
2  
3  
4 patients with NSCLC, especially in stages I and II. We suggest patients with NSCLC should  
5  
6  
7 receive treatment as early as possible since the diagnosis was confirmed.  
8  
9  
10  
11  
12

### 13 **Strengths and limitations of this study**

14  
15

- 16 ● It consisted of nationwide patients with non-small cell lung cancer.
- 17
- 18 ● We collected nationwide data from 42,962 non-small cell lung cancer patients, which is the  
19 largest nationwide study to date.  
20  
21  
22
- 23 ● There were very few studies investigating treatment delay effects on the reduction of  
24 survival rate of lung cancer patients.  
25  
26
- 27 ● Our lung cancer stages (stages I, II, III, and IV) were based on pathological confirmation.  
28  
29
- 30 ● The information on individual lifestyle and health behaviors is not available.  
31  
32  
33  
34  
35  
36

37 **Keywords:** lung cancer; non-small cell lung cancer; delay treatment; timeliness of treatment;  
38  
39 survival  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Lung cancer is among the most common causes of cancer death, particularly in industrialized countries.<sup>1</sup> In addition, the incidence of lung cancer has been gradually increasing over the last 50 years,<sup>2</sup> becoming a worldwide public health issue.<sup>3</sup> Lung cancer can be classified into small cell lung cancer and non-small cell lung cancer, of which the latter accounts for 80% of all lung cancer cases.<sup>4</sup> Despite recent improvements in treatment, the prognosis for lung cancer patients is still poor. Regardless of whether a patient has non-small cell lung cancer or small cell lung cancer, the 5-year survival rate is only 17.4%.<sup>2 5-7</sup> Most lung cancers are in the late stage (stages IIIB or IV) when diagnosed, which is likely to be a result of the long interval between the onset of symptoms and diagnosis.<sup>8</sup> There are often large differences in the length of the interval from the first appearance of symptoms to confirmation of diagnosis and treatment initiation in these patients.<sup>4</sup> Although there were many relevant studies on whether differences in the time delay between diagnosis to treatment initiation affects the prognosis of lung cancer patients, no definitive conclusion has been reached.<sup>4</sup> An increasing number of relevant studies have also highlighted the importance of this topic.

In Taiwan, 99.68% of the populace is covered by National Healthcare Insurance (NHI) program. Under this system, lung cancer is classified as a catastrophic illness and is exempt from treatment-related fees, thereby that patients are not affected by economic factor. According to 2016 statistics from the Taiwan Ministry of Health and Welfare, cancer has

1  
2  
3  
4 consistently been the top cause of death. Among various types of cancer, lung cancer ranks  
5  
6  
7 first in the cause of death, with a mortality rate of 39.9 per 100,000 people. Therefore, it is  
8  
9  
10 important for public health providers to improve lung cancer prognoses and increase survival  
11  
12  
13 rates. The Taiwan Cancer Registry (TCR), a population-based cancer registry, was founded in  
14  
15  
16 1979. The registry is organized by the Ministry of Health and Welfare. The Taiwan Cancer  
17  
18  
19 Registry Database (TCRD) records data of all types of cancer diagnosed and treatments in  
20  
21  
22 patients in Taiwan. The completeness (97%) and data quality of the Cancer Registry Database  
23  
24  
25 has achieved at an excellent level.<sup>9</sup> The accuracy of NHIRD has been validated in previous  
26  
27  
28 studies.<sup>10</sup> This study aims to utilize national large-scale statistical data to investigate whether  
29  
30  
31 the interval between lung cancer diagnosis and treatment affects survival rate; concurrently,  
32  
33  
34 we also aim to examine the impact of other relevant factors on survival. This will provide a  
35  
36  
37 reference for future treatment for lung cancer patients of improving their survival.  
38  
39

## 40 **METHODS**

### 41 **Data sources and participants**

42  
43  
44 We included 55,014 newly diagnosed non-small cell lung cancer patients from 2004 to  
45  
46  
47 2010. The newly diagnosed non-small cell lung cancer patients were defined as ICD-O-3 with  
48  
49  
50 C339 to C349 without any cancers before. Then we excluded those lung cancer patients with  
51  
52  
53 C339 to C349 without any cancers before. Then we excluded those lung cancer patients with  
54  
55  
56 unknown stage for 3,993 patients. We also excluded lung cancer patients in situ (70 patients),  
57  
58  
59 with multiple cancer (1,298 patients), palliative treatment at the beginning (1,934 patients),  
60

1  
2  
3  
4 mortality before lung cancer diagnosed (64 patients), personal characteristics data missing (109  
5  
6  
7 patients), and hospital data missing (4,584 patients). In our study, patients with multiple cancers  
8  
9  
10 may affect survival due to other cancer effect. In Taiwan, palliative treatment is coded as  
11  
12 special code in NHIRD. Non-small cell lung cancer patients with palliative treatment at  
13  
14 beginning may be due to patients refusing further treatment or not receiving aggressive  
15  
16 treatment. We excluded them for informal treatment. Otherwise, we also excluded those  
17  
18 patients with data missing for accuracy. Finally, we had 42,962 people.  
19  
20  
21  
22  
23  
24

25 The data for this study was obtained from the Taiwan Cancer Registry, which was used  
26  
27 to acquire study participants. We also linked this data to the National Health Insurance  
28  
29 Database and the Cause of Death File from 2002 to 2012 that was provided by the Ministry of  
30  
31 Health and Welfare. The accuracy of Taiwan Cancer Registry and NHIRD has achieved at an  
32  
33 excellent level.  
34  
35  
36  
37  
38  
39

#### 40 **Patient and public involvement**

41  
42  
43 No patients were involved in the planning, conception and design of this study, as this  
44  
45 study was based on the National Health Insurance Research Database, published by the  
46  
47 Ministry of Health and Welfare, Taiwan.  
48  
49  
50  
51

#### 52 **Variable descriptions**

53  
54  
55 In this study, with regards to the variables used, the general characteristics of lung cancer  
56  
57 patients included sex and age. Age was defined as the age at which the patient had a  
58  
59  
60

1  
2  
3  
4 confirmatory diagnosis by pathology. The financial status of the patient was based on their  
5  
6  
7 monthly salary. The degree of urbanization at the patient's place of residence was used to  
8  
9  
10 represent environmental factors. The level of urbanization was based on 7 levels of  
11  
12  
13 classification from highly urbanized developed cities (level 1) to remote areas (level 7). The  
14  
15  
16 health status of the patient included data on whether the patient had other catastrophic illnesses  
17  
18  
19 besides cancer, their Charlson Comorbidity Index (CCI), and the stage of non-small cell lung  
20  
21  
22 cancer. The definition of catastrophic illness was based on the 30 types of catastrophic illnesses  
23  
24  
25 or injuries as defined by the National Health Insurance Administration, which include stroke,  
26  
27  
28 chronic kidney failure, systemic lupus erythematosus, type I diabetes and severe mental illness.  
29  
30  
31 The degree of comorbidity was classified into three levels based on the CCI<sup>11</sup>. Tumor staging  
32  
33  
34 was based on the guidelines of the American Joint Committee on Cancer (6<sup>th</sup> edition for tumors  
35  
36  
37 diagnosed from 2004-2009, 7<sup>th</sup> edition for tumors diagnosed in 2010), which includes stages I,  
38  
39  
40 II, III, and IV. Hospital attributes include the level of hospital (medical centers, regional  
41  
42  
43 hospitals, district hospitals, and others), hospital ownership (public or private institutions), and  
44  
45  
46 the volume of hospital services (low, medium, high) in treatment of non-small cell lung cancer  
47  
48  
49 patients. The volume of hospital services was divided into low, medium, and high on the basis  
50  
51  
52 of quartiles: service volumes of <25%, 25-75% and >75% were defined as low, medium and  
53  
54  
55 high, respectively. Patients were considered to be enrolled in multidisciplinary team (MDT)  
56  
57  
58 care if they received MDT treatment after pathological diagnosis of non-small cell lung cancer;  
59  
60

1  
2  
3  
4 the definition of MDT is based on patients who were declared MDT treatment fees in the NHI  
5  
6  
7 database (47079B). The interval between diagnosis of non-small cell lung cancer and treatment  
8  
9  
10 initiation was defined as the period between pathological sectioning and diagnosis of non-small  
11  
12  
13 cell lung cancer after biopsy to the time when the patient underwent their first treatment  
14  
15  
16 (including surgery, radiotherapy, or chemotherapy). The operating definition of relevant  
17  
18  
19 treatments is based on the relevant treatment code that was declared in the NHI database, which  
20  
21  
22 was checked against the treatment registration information in the Taiwan Cancer Information  
23  
24  
25 Database.

### 26 27 28 **Main outcome measurements**

29  
30  
31 The main outcome examined in this study was the survival rate of lung cancer patients.  
32  
33  
34 Confirmation of death was based on patient data from the NHI database and this was compared  
35  
36  
37 with the Taiwan Cause of Death archives for confirmation.  
38  
39

### 40 **Statistical analysis**

41  
42  
43 We employed descriptive statistics to show general characteristics, financial status,  
44  
45  
46 environmental factors, health status of patients, hospital attributes, enrolment in MDT and the  
47  
48  
49 distribution status of the interval from diagnosis confirmation to treatment initiation in lung  
50  
51  
52 cancer patients who had a confirmatory diagnosis by pathology from 2004 to 2010. Following  
53  
54  
55 this, bivariate analysis was performed using the log-rank test to investigate whether there were  
56  
57  
58 significant differences between survival status by the end of 2012 and the interval from  
59  
60



1  
2  
3  
4 diagnosis to treatment initiation. We then used univariate Cox proportional hazards regression  
5  
6  
7 to analyze relevant prognostic factors that affect the survival of lung cancer patients. The  
8  
9  
10 adjusted Cox proportional hazards model was used to investigate the relative risk of survival  
11  
12  
13 of lung cancer patients with different cancer stages with different intervals from diagnosis  
14  
15  
16 confirmation to treatment initiation, after controlling for related variables. Independent  
17  
18  
19 variables included patient characteristics, financial status, environmental factors, health status,  
20  
21  
22 hospital attributes, enrolment in MDT, and grouping of time to treatment initiation. The  
23  
24  
25 dependent variable was survival. Lastly, after controlling for relevant variables, the adjusted  
26  
27  
28 Cox proportional hazards model was used to generate survival curves for lung cancer patients  
29  
30  
31 of various stages and with different interval periods.  
32  
33

34 All statistical analyses were performed using SAS software, version 9.2 (SAS Institute  
35  
36  
37 Inc., Cary, NC). A P value  $<0.05$  was regarded as statistically significant and all tests were  
38  
39  
40 two-sided.  
41  
42

## 43 **RESULTS**

### 44 **Descriptive statistics of lung cancer patient characteristics for different treatment** 45 **intervals** 46 47 48 49

50 In all lung cancer patients, the mean 5-year survival rate was 17.61%. As the interval from  
51  
52  
53 diagnosis to treatment initiation increased, the 5-year survival rate decreased from 26.12% to  
54  
55  
56 6.02% (Table 1). We also included time to treatment with 0 day (TTT=0) cases in the  $<7$  days  
57  
58  
59 group in our study. There were 7,363 cases with TTT=0 accounting for 17.14% of all patients  
60

1  
2  
3  
4 in our study. We had 3,258 females accounting for 44.25% in this subgroup. The age of  
5  
6  
7 diagnosed in most patients was from 65-74 years old accounting for 28.28% with mean age of  
8  
9  
10 64.67 years old. The treatment of most patients with TTT=0 was surgery combining with  
11  
12  
13 radiotherapy and chemotherapy. The 5-year survival rate was 34.9% in this group with TTT=0.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1. Bivariate analysis of lung cancer patient characteristics for different treatment intervals

Variables	Total		Interval from cancer diagnosis to treatment								P value <sup>a</sup>
			≤ 7 days		8~14 days		15~60 days		≥ 61 days		
	N	%	N	%	N	%	N	%	N	%	
<b>Total number</b>	42,962	100.00	15,769	36.70	9,296	21.64	12,510	29.12	5,387	12.54	-
<b>Five-year survival rate</b>	42,962	17.61	15,769	26.12	9,296	15.96	12,510	12.99	5,387	6.02	<0.001
<b>Gender</b>											<0.001
Female	15,799	36.77	6,154	38.95	3,235	20.48	4,419	27.97	1,991	12.60	
Male	27,163	63.23	9,615	35.40	6,061	22.31	8,091	29.79	3,396	12.50	
<b>Age</b>											<0.001
≤ 44	2,106	4.90	889	42.21	455	21.60	568	26.97	194	9.21	
45~54	5,686	13.23	2,375	41.77	1,263	22.21	1,549	27.24	499	8.78	
55~64	9,155	21.31	3,634	39.69	2,033	22.21	2,658	29.03	830	9.07	
65~74	12,659	29.47	4,548	35.93	2,801	22.13	3,819	30.17	1,491	11.78	
≥ 75	13,356	31.09	4,323	32.37	2,744	20.55	3,916	29.32	2,373	17.77	
<b>Mean age (m, sd)</b>	66.76	12.44	65.52	12.55	66.45	12.22	67.04	12.15	70.25	12.46	<0.001
<b>Monthly salary</b>											<0.001
Low-income	461	1.07	137	29.72	101	21.91	154	33.41	69	14.97	
≤ 17280	1,475	3.43	542	36.75	311	21.08	447	30.31	175	11.86	
17281~22800	22,935	53.38	8,074	35.20	5,079	22.15	6,751	29.44	3,031	13.22	
22801~28800	8,069	18.78	2,961	36.70	1,690	20.94	2,376	29.45	1,042	12.91	
28801~36300	2,676	6.23	1,011	37.78	588	21.97	782	29.22	295	11.02	
36301~45800	3,280	7.63	1,333	40.64	689	21.01	923	28.14	335	10.21	
≥ 45801	4,066	9.46	1,711	42.08	838	20.61	1,077	26.49	440	10.82	

Table 1. Bivariate analysis of lung cancer patient characteristics for different treatment intervals (continued)

Variables	Total		Interval from cancer diagnosis to treatment								P value <sup>a</sup>
			≤ 7 days		8~14 days		15~60 days		≥ 61 days		
	N	%	N	%	N	%	N	%	N	%	
<b>Urbanization</b>											0.186
Level 1	11,759	27.37	4,335	36.87	2,494	21.21	3,404	28.95	1,526	12.98	
Level 2	12,117	28.20	4,506	37.19	2,615	21.58	3,527	29.11	1,469	12.12	
Level 3	6,523	15.18	2,334	35.78	1,424	21.83	1,946	29.83	819	12.56	
Level 4	6,795	15.82	2,518	37.06	1,506	22.16	1,974	29.05	797	11.73	
Level 5	1,524	3.55	523	34.32	338	22.18	439	28.81	224	14.70	
Level 6	2,217	5.16	807	36.40	490	22.10	627	28.28	293	13.22	
Level 7	2,027	4.72	746	36.80	429	21.16	593	29.26	259	12.78	
<b>CCI score</b>											<0.001
≤ 3	20,388	47.46	7,475	36.66	4,576	22.44	6,186	30.34	2,151	10.55	
4~6	7,587	17.66	2,761	36.39	1,646	21.70	2,218	29.23	962	12.68	
≥ 7	14,987	34.88	5,533	36.92	3,074	20.51	4,106	27.40	2,274	15.17	
<b>Other catastrophic illness</b>											<0.001
No	41,474	96.54	15,300	36.89	8,984	21.66	12,076	29.12	5,114	12.33	
Yes	1,488	3.46	469	31.52	312	20.97	434	29.17	273	18.35	
<b>Cancer stage</b>											<0.001
Stage I	5,681	13.22	3,226	56.79	910	16.02	1,269	22.34	276	4.86	
Stage II	1,526	3.55	589	38.60	338	22.15	462	30.28	137	8.98	
Stage III	11,696	27.22	4,030	34.46	2,843	24.31	3,500	29.92	1,323	11.31	
Stage IV	24,059	56.00	7,924	32.94	5,205	21.63	7,279	30.25	3,651	15.18	

Table 1. Bivariate analysis of lung cancer patient characteristics for different treatment intervals (continued)

Variables	Total		Interval from cancer diagnosis to treatment								P value <sup>a</sup>
			≤ 7 days		8~14 days		15~60 days		≥ 61 days		
	N	%	N	%	N	%	N	%	N	%	
<b>MDT care</b>											<0.001
No	37,716	87.79	13,669	36.24	8,012	21.24	10,974	29.10	5,061	13.42	
Yes	5,246	12.21	2,100	40.03	1,284	24.48	1,536	29.28	326	6.21	
<b>Hospital level</b>											<0.001
Medical centers	29,228	68.03	11,075	37.89	6,452	22.07	8,427	28.83	3,274	11.20	
Regional hospitals	12,601	29.33	4,395	34.88	2,655	21.07	3,787	30.05	1,764	14.00	
District hospitals	1,014	2.36	261	25.74	178	17.55	279	27.51	296	29.19	
Others	119	0.28	38	31.93	11	9.24	17	14.29	53	44.54	
<b>Hospital ownership</b>											<0.001
Public	16,770	39.03	6,619	39.47	3,776	22.52	4,558	27.18	1,817	10.83	
Private	26,192	60.97	9,150	34.93	5,520	21.08	7,952	30.36	3,570	13.63	
<b>Hospital services volume</b>											<0.001
Low	10,807	25.15	3,905	36.13	2,177	20.14	2,935	27.16	1,790	16.56	
Middle	21,043	48.98	7,519	35.73	4,652	22.11	6,486	30.82	2,386	11.34	
High	11,112	25.86	4,345	39.10	2,467	22.20	3,089	27.80	1,211	10.90	

<sup>a</sup> Log-rank test

### Five-year survival rate of patients for different treatment intervals

At the same time, we found that in stage I patients, the 5-year survival rate decreased by 9.07% due to delayed treatment (patients with intervals >7 days). In stage

II patients, if patients started treatment earlier (interval  $\leq 7$  days), their 5-year survival rate increased by 9.01%. Early treatment (interval  $\leq 7$  days) was found to have a smaller effect on 5-year survival rate in stage III and stage IV patients, with an increase in 5-year survival rate of 1.91% and 0.49% (Table 2).

Table 2. Five-year survival rate of patients for different treatment intervals

Variables	Stage I		Stage II		Stage III		Stage IV		P value <sup>a</sup>
	N	%	N	%	N	%	N	%	
<b>Total number</b>	5,681	61.61	1,526	34.41	11,696	12.95	24,059	5.11	
<b>Interval from cancer diagnosis to treatment</b>									<0.001
$\leq 7$ days	3,226	70.68	589	43.42	4,030	14.86	7,924	5.60	
8~14 days	910	60.58	338	33.74	2,843	12.11	5,205	4.58	
15~60 days	1,269	49.07	462	29.81	3,500	13.81	7,279	5.43	
$\geq 61$ days	276	21.10	137	14.56	1,323	6.83	3,651	4.12	

<sup>a</sup> Log-rank test

## **The effect of different treatment intervals on mortality risk in patients with lung cancer**

Table 3 shows that when the group with interval from cancer diagnosis to treatment  $\leq 7$  days was used as a reference, the adjusted HR for mortality in other groups (8-14 days, 15-60 days, and  $\geq 61$  days) was significantly increased with increasing interval time (HR: 1.04-1.08). Among patients at various cancer stages, using stage I patients as a control group, the adjusted HRs for mortality for cancer patients at various stages was significantly higher (HR: 2.06-5.89) and the more advanced the cancer stages, the higher the adjusted HR for mortality. Patients who underwent MDT care had a significantly lower adjusted HR for mortality compared with patients who did not (HR: 0.91, 95% CI: 0.88-0.94).

Table 3. Relative risk of death in patients for different treatment intervals

Variables	Unadjusted		Adjusted			
	HR	P value	HR	95% CI	P value <sup>a</sup>	
<b>Interval from cancer diagnosis to treatment</b>						
≤ 7 days (ref.)						
8~14 days	<b>1.26</b>	<0.001	<b>1.04</b>	1.01	1.07	0.004
15~60 days	<b>1.30</b>	<0.001	<b>1.06</b>	1.04	1.09	<0.001
≥ 61 days	<b>1.66</b>	<0.001	<b>1.08</b>	1.04	1.11	<0.001
<b>Gender</b>						
Female (ref.)						
Male	<b>1.54</b>	<0.001	<b>1.50</b>	1.47	1.53	<0.001
<b>Age</b>						
≤ 44 (ref.)						
45~54	<b>0.97</b>	0.357	<b>0.97</b>	0.92	1.03	0.351
55~64	<b>1.02</b>	0.478	<b>1.03</b>	0.97	1.09	0.331
65~74	<b>1.63</b>	<0.001	<b>1.27</b>	1.21	1.34	<0.001
≥ 75	<b>1.93</b>	<0.001	<b>1.79</b>	1.69	1.88	<0.001
<b>Monthly salary</b>						
Low-income (ref.)						
≤ 17280	<b>0.72</b>	<0.001	<b>0.89</b>	0.80	1.00	0.049
17281~22800	<b>0.81</b>	<0.001	<b>0.86</b>	0.78	0.95	0.002
22801~28800	<b>0.74</b>	<0.001	<b>0.83</b>	0.75	0.91	<0.001
28801~36300	<b>0.60</b>	<0.001	<b>0.79</b>	0.71	0.87	<0.001
36301~45800	<b>0.59</b>	<0.001	<b>0.78</b>	0.70	0.87	<0.001



Variables	Unadjusted		Adjusted			
	HR	P value	HR	95% CI	P value <sup>a</sup>	
≥ 45801	<b>0.56</b>	<0.001	<b>0.73</b>	0.66	0.81	<0.001
<b>Urbanization level</b>						
Level 1 (ref.)						
Level 2	<b>1.07</b>	<0.001	<b>0.99</b>	0.96	1.02	0.523
Level 3	<b>1.20</b>	<0.001	<b>1.04</b>	1.00	1.07	0.036
Level 4	<b>1.21</b>	<0.001	<b>1.01</b>	0.98	1.05	0.596
Level 5	<b>1.33</b>	<0.001	<b>1.01</b>	0.95	1.08	0.671
Level 6	<b>1.39</b>	<0.001	<b>1.09</b>	1.04	1.15	0.001
Level 7	<b>1.25</b>	<0.001	<b>1.02</b>	0.96	1.07	0.570
<b>CCI score</b>						
≤ 3 (ref.)						
4~6	<b>1.35</b>	<0.001	<b>1.18</b>	1.14	1.21	<0.001
≥ 7	<b>1.80</b>	<0.001	<b>1.28</b>	1.25	1.31	<0.001
<b>Other catastrophic illness</b>						
No (ref.)						
Yes	<b>1.25</b>	<0.001	<b>1.26</b>	1.19	1.33	<0.001
<b>Cancer stage</b>						
Stage I (ref.)						
Stage II	<b>2.29</b>	<0.001	<b>2.06</b>	1.91	2.23	<0.001
Stage III	<b>4.48</b>	<0.001	<b>3.94</b>	3.75	4.13	<0.001
Stage IV	<b>6.51</b>	<0.001	<b>5.89</b>	5.62	6.17	<0.001
<b>MDT care</b>						
No (ref.)						

Variables	Unadjusted		Adjusted			
	HR	P value	HR	95% CI	P value <sup>a</sup>	
Yes	<b>0.95</b>	0.001	<b>0.91</b>	0.88	0.94	<0.001
<b>Hospital level</b>						
Medical centers (ref.)						
Regional hospitals	<b>1.28</b>	<0.001	<b>0.99</b>	0.96	1.02	0.347
District hospitals	<b>2.06</b>	<0.001	<b>1.25</b>	1.17	1.34	<0.001
Others	<b>1.17</b>	0.137	<b>0.90</b>	0.73	1.10	0.286
<b>Hospital ownership</b>						
Public (ref.)						
Private	<b>1.27</b>	<0.001	<b>1.13</b>	1.10	1.16	<0.001
<b>Hospital services volume</b>						
Low (ref.)						
Middle	<b>0.72</b>	<0.001	<b>0.83</b>	0.81	0.85	<0.001
High	<b>0.59</b>	<0.001	<b>0.71</b>	0.68	0.74	<0.001

<sup>a</sup> Cox proportional hazards regression

### The effect of different treatment intervals on mortality risk in patients with lung cancer at different cancer stages

Table 4 shows that in stage I lung cancer patients, with patients with intervals of  $\leq 7$  days as the reference group, as the interval increased, the relative risk of death also significantly increased (HR: 1.45-2.41). This was also true for stage II (HR: 1.21-1.58) and the intervals more than 60 days of stage III lung cancer patients (HR: 1.13, 95% CI: 1.06-1.21). In stage IV patients, using patients with an interval  $\leq 7$  days as a

1  
2  
3  
4 reference group, the relative risk of death was without significantly difference. Figure

5  
6  
7 1 shows adjusted survival curve in lung cancer patients with different cancer stages.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 4. Relative risk of death in patients for different treatment intervals and at different cancer stages

Variables	Stage I <sup>a</sup>			Stage II <sup>a</sup>			Stage III <sup>a</sup>			Stage IV <sup>a</sup>		
	HR	95% CI	P value <sup>b</sup>	HR	95% CI	P value <sup>b</sup>	HR	95% CI	P value <sup>b</sup>	HR	95% CI	P value <sup>b</sup>
<b>Interval from cancer diagnosis to treatment</b>												
≤ 7 days (ref.)												
8~14 days	<b>1.45</b>	1.28 1.64	<0.001	<b>1.21</b>	1.01 1.45	0.039	<b>1.04</b>	0.98 1.09	0.177	<b>0.99</b>	0.95 1.03	0.561
15~60 days	<b>1.66</b>	1.49 1.84	<0.001	<b>1.44</b>	1.22 1.69	<0.001	<b>1.02</b>	0.97 1.07	0.560	<b>1.01</b>	0.98 1.04	0.572
≥ 61 days	<b>2.41</b>	2.06 2.83	<0.001	<b>1.58</b>	1.26 1.97	<0.001	<b>1.13</b>	1.06 1.21	<0.001	<b>0.98</b>	0.94 1.02	0.249

a. Patient age, gender, monthly salary, level of urbanization of place of residence, CCI score, other illness, MDT care, hospital level, hospital ownership, and hospital services volume were all controlled for using various models.

<sup>b</sup> adjusted Cox proportional hazards model

## DISCUSSION

We found that the mortality rate exhibited significantly positive correlation to time interval from cancer diagnosis to treatment initiation in all stage NSCLC patients. The ratio of male to female in our study is similar to that in previous studies.<sup>12 13</sup> The delays between diagnosis and treatment can be categorized into three stages: namely, patient delay, diagnosis delay, and treatment delay.<sup>2</sup> Of all studies which investigated treatment delays in lung cancer patients, the study with the largest number of patients included 54,338 patients, but was limited to non-metastatic lung cancer patients.<sup>12</sup> In addition, the study only focused on patients who underwent surgical excision and did not analyze the treatment delay status and associated factors for all lung cancer patients. Another study collected data from 28,732 patients to investigate whether treatment delay affects survival rate.<sup>14</sup> The researchers found that if the interval from diagnosis to treatment was within 35 days, then there is improved survival for patients with localized disease, reduced survival for those with distant disease, but didn't have significant effect on patients with regional disease.<sup>14</sup> However, in that study, the diagnosis to treatment interval was divided into just two groups (<35 days and >35 days), which makes it more difficult to show the correlation between different treatment delay groups and patient survival rates. In addition, in that study, the authors did not investigate whether different treatment delay periods affect survival rate for different cancer stages as they only

1  
2  
3  
4 classified cancers as localized, regional, or distant. To the best of our knowledge, the  
5  
6  
7 current study is the first large-scale nationwide study that examines whether treatment  
8  
9  
10 delay in non-small cell lung cancer affects patient survival rate. In addition, we also  
11  
12  
13 investigated the correlation between lung cancer treatment delay and survival rate for  
14  
15  
16 different cancer stages (stages I, II, III and IV).  
17

18  
19 Previous studies have observed that if patients are older, have more comorbidities,  
20  
21  
22 or have stage I cancer, they are more likely to delay treatment (interval from diagnosis  
23  
24  
25 to treatment >30 days).<sup>12</sup> Similar findings were observed in our study: for patients aged  
26  
27  
28  $\geq 55$  years, the greater the age the greater the proportion with treatment delay (interval  
29  
30  
31  $\geq 61$  days) (Table 1). Patients with high CCI scores also demonstrated significantly  
32  
33  
34 increased proportions in treatment delay (interval  $\geq 61$  days) (Table 1). CCI is a general  
35  
36  
37 score to evaluate patients' comorbidity and does not focus on lung cancer patients. The  
38  
39  
40 lung function testing such as forced expiratory volume in one second (FEV1) and  
41  
42  
43 diffusing capacity of the lung for carbon monoxide (DLCO) is more accurate for  
44  
45  
46 evaluating their severity but is not available in our study. It is a fact that patients with  
47  
48  
49 poorer lung function require additional testing to determine candidacy for surgery. This  
50  
51  
52 testing, including six minute walk test, quantitative perfusion scans, cardiopulmonary  
53  
54  
55 exercise testing and consultation with pulmonary medicine takes time and is not  
56  
57  
58 available in our study. However, during analysis of the correlation between treatment  
59  
60

1  
2  
3  
4 delay and lung cancer stage, we found that the proportion of stage I patients with  
5  
6  
7 treatment delay was significantly lower than patients with other stages of lung cancer.  
8  
9

10 A previous study has observed that in non-small cell lung cancer patients, treatment  
11  
12  
13 delay is not associated with cancer stage.<sup>15, 16-20</sup> In contrast, treatment delay had more  
14  
15  
16 serious effects in stage III and IV patients.<sup>21</sup> However, in our study, we found that the  
17  
18  
19 proportion of stage I patients with treatment delay (interval from diagnosis to treatment  
20  
21  
22  $\geq 61$  days) was significantly lower (4.86%,  $p < 0.001$ ), when compared with patients at  
23  
24  
25 other stages.  
26  
27

28 Previous studies have mentioned that in non-small cell lung cancer patients, our  
29  
30  
31 understanding of the effects of diagnosis and treatment delay on the prognosis of  
32  
33  
34 patients is limited, although an increasing number of recent studies are emphasizing the  
35  
36  
37 importance of this topic.<sup>4</sup> Some studies have found that in patients with a symptom-to-  
38  
39  
40 treatment interval (STI) of  $> 60$  days, the survival rate was significantly higher than that  
41  
42  
43 of patients with a STI of  $< 60$  days.<sup>22</sup> However, if patients were further divided on the  
44  
45  
46 basis of the type of lung cancer, this difference was only significant in NSCLC  
47  
48  
49 patients.<sup>22</sup> However, the number of patients included in this study was only 103 (96  
50  
51  
52 men).<sup>23</sup> Two other studies, with 378 and 410 patients each, found that delaying  
53  
54  
55 diagnosis and treatment did not affect patient survival rates.<sup>16 17</sup> Another study of 466  
56  
57  
58 non-small cell lung cancer patients found that patients with shorter STIs had lower  
59  
60

1  
2  
3  
4 survival rates.<sup>24</sup> One study with 189 lung cancer patients found that treatment delay  
5  
6  
7 resulted in poorer prognosis for patients,<sup>25</sup> whilst another study with 132 patients found  
8  
9  
10 that longer specialist treatment delay does not result in poorer prognosis.<sup>26</sup> An  
11  
12  
13 aforementioned article also observed that most previous studies in different countries  
14  
15  
16 were monocentric studies and that it is difficult to decide which study is most reliable  
17  
18  
19 with regards to whether treatment delay affects patient survival rates.<sup>4</sup>  
20  
21

22 Most studies show no relationship between time-to-chemotherapy (TTC) and their  
23  
24 survival rate.<sup>27</sup> However, it should be noted that in these review articles, the number of  
25  
26 cases collected is generally very low, with the highest number of patients only 10,583.<sup>27</sup>  
27  
28  
29 Another study showed time intervals from diagnosis to treatment were not associated  
30  
31 with survival outcomes in NSCLC.<sup>28</sup> In this previous study, they discussed NSCLC  
32  
33 patients with different treatment such as surgery, radiotherapy, systemic therapy and  
34  
35 palliative care which were not discussed in our study. They also suggested that delays  
36  
37 to treatment might impact on other outcomes other than survival. However, there were  
38  
39 only 1,729 patients in this previous study.<sup>28</sup> In summary, the majority of previous  
40  
41 studies into whether treatment delay affects survival rate in non-small cell lung cancer  
42  
43 patients lack large-scale nationwide statistical data. This can easily lead to bias and  
44  
45 produce divergent conclusions. In this study, we collected nationwide data from 42,962  
46  
47 non-small cell lung cancer patients, which, to the best of our knowledge, is the largest  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 nationwide study to date. In addition, we also investigated the correlation between lung  
5  
6  
7 cancer treatment delay and survival rate in different cancer stages (stages I, II, III and  
8  
9  
10 IV).

11  
12  
13 In addition, detailed examination of the literature found that a decreased treatment  
14  
15  
16 delay increases the risk of death in patients; the explanation provided for this is that a  
17  
18  
19 shorter treatment delay may mean that the patients have more obvious or more severe  
20  
21  
22 symptoms.<sup>24</sup> Therefore, there is a need to correct the result with cancer stage and  
23  
24  
25 severity.<sup>24</sup> A previous study has also suggested that a shorter treatment delay may  
26  
27  
28 reflect a requirement for more urgent treatment due to severity of symptoms, resulting  
29  
30  
31 in a poor prognosis.<sup>29</sup> Therefore, in this paper, we also considered the effects of cancer  
32  
33  
34 stage on treatment delay and patient prognosis. In another paper, it was also mentioned  
35  
36  
37 that the definition of treatment delay should be more standardized and accurate.<sup>4</sup>  
38  
39  
40 Another paper mentioned that it is not easy to accurately calculate the time of treatment  
41  
42  
43 initiation.<sup>24</sup> In addition, the calculation of patient delay (from symptom to doctor) is  
44  
45  
46 also prone to errors. Therefore, in this study, our definition of treatment delay was made  
47  
48  
49 according to the cancer registration archives and NHI database, from pathological  
50  
51  
52 diagnosis confirmation until treatment initiation.

53  
54  
55 For cancer patients in general, current medical guidelines all recommend early  
56  
57  
58 diagnosis and treatment to improve patient prognosis. However, early diagnosis is  
59  
60

1  
2  
3  
4 difficult due to multiple factors, such as non-apparent symptoms and patient delay.  
5  
6  
7 However, in this study, we found that if the interval from confirmation of pathological  
8  
9  
10 diagnosis to treatment initiation in non-small cell lung cancer patients is shortened to 7  
11  
12  
13 days, this can effectively improve their 5-year survival rate (improvements of 0.49-  
14  
15  
16 9.07% were observed, according to the different stages of lung cancer). We also found  
17  
18  
19 that this improvement in 5-year survival rate was particularly marked for non-small cell  
20  
21  
22 lung cancer patients at early stages (stage I and II), at 10.28-10.34%. However, in late  
23  
24  
25 stage (stage III and stage IV) patients, the 5-year survival rate was only increased by  
26  
27  
28 1.91% and 0.49%. It is extremely ambitious for lung cancer treatment to commence  
29  
30  
31 within 7 days of diagnosis considering the staging exam taking time. This group in the  
32  
33  
34 study (< 7 days to treatment) may be skewed towards those whose cancer was  
35  
36  
37 diagnosed at the time of surgery. A previous study showed that NSCLC growth rate  
38  
39  
40 appeared to be highly variable and related to histological subtype which was not  
41  
42  
43 discussed in our study.<sup>30</sup> Doubling times can be quite variable in different stages of  
44  
45  
46 NSCLC. Another study showed that rapid tumor progression was noted in patients with  
47  
48  
49 untreated, predominantly stage III NSCLC.<sup>31</sup> In our study, table 4 shows stage III non-  
50  
51  
52 small cell lung cancer patients with the interval from diagnosis to treatment initiation  
53  
54  
55 more than 60 days had significantly higher relative risk of death than patients with an  
56  
57  
58 interval  $\leq 7$  days (HR: 1.13, 95% CI: 1.06-1.21). This may be due to rapid tumor  
59  
60

1  
2  
3  
4 progression characteristics of stage III NSCLC. However, the delay treatment effect is  
5  
6  
7 not significant in stage IV NSCLC patients, which may be associated with poor  
8  
9  
10 outcome and low survival rate in late stage of NSCLC. Therefore, we recommended  
11  
12  
13 that in future policies, treatment recommendations should be formulated so that patients  
14  
15  
16 can start treatment within 7 days after pathological diagnosis confirmation of non-small  
17  
18  
19 cell lung cancer to increase their 5-year survival rate. This is particularly important for  
20  
21  
22 early stage (stage I and II) non-small cell lung cancer patients, where improvement  
23  
24  
25 effects are more significant.  
26  
27

28 In this study, we also found that the effect of the interval from diagnosis to  
29  
30  
31 treatment initiation and patient survival rate decreased with more advanced cancer  
32  
33  
34 stages. Therefore, in patients who have stage I (HR: 1.45-2.41) or stage II (HR: 1.21-  
35  
36  
37 1.58) cancer, the longer the interval from diagnosis to treatment initiation, the higher  
38  
39  
40 the risk of death in patients. However, in stage III patients, compared with patients with  
41  
42  
43 an interval from diagnosis to treatment initiation  $\leq 7$  days, only when the interval from  
44  
45  
46 diagnosis to treatment initiation was  $\geq 61$  days was the risk of death increased. However,  
47  
48  
49 the magnitude of the increased risk of death is lower than in stage I and II patients (HR:  
50  
51  
52 1.03-1.06). Therefore, this study found that timely treatment of stage I and II lung  
53  
54  
55 cancer patients has greater benefits. Therefore, we recommend that we should shorten  
56  
57  
58 the interval from diagnosis to treatment initiation especially in stage I and II lung cancer  
59  
60

1  
2  
3  
4 patients, thus decreasing the risk of death and improving prognosis. However, due to  
5  
6  
7 data limitation, we used crude survival instead of disease free survival.  
8  
9

10 In recent studies, it was found that patients with oral cancers who underwent MDT  
11  
12 treatment had significantly higher survival rates, and that the proportion of patients who  
13  
14 underwent treatment was higher than those who did not joining MDT.<sup>32</sup> Previous  
15  
16 studies have shown that the use of MDT care in cancer treatment can improve patient  
17  
18 prognosis.<sup>33</sup> This is particularly the case in head and neck cancers, where MDT care is  
19  
20 not only cost-effective but can also improve survival rates.<sup>34</sup> Previous studies have  
21  
22 shown that in lung cancer patients MDT care can significantly improve the patient's  
23  
24 acceptance of treatment, but does not significantly improve patient survival rates.<sup>33</sup> In  
25  
26 this study, we found that patients who underwent MDT care had a significantly lower  
27  
28 adjusted HR for mortality compared with patients who did not (HR: 0.91, 95% CI: 0.88-  
29  
30 0.94).  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 In summary, this study recommends that the interval from diagnosis to treatment  
44  
45 initiation should be minimized during treatment of lung cancer patients at various  
46  
47 cancer stages, particularly in stage I and II patients. In addition, in stage III and stage  
48  
49 IV patients, we recommend the addition of MDT care to decrease the risk of death and  
50  
51 improve prognosis.  
52  
53  
54  
55  
56

## 57 **Limitations**

58  
59  
60

1  
2  
3  
4 A secondary random database derived from the National Health Insurance  
5  
6  
7 Research Database was employed for this study. The information on individual lifestyle,  
8  
9  
10 health behaviors, which may also affect the result, is not available. The lung function  
11  
12  
13 testing such as forced expiratory volume in one second (FEV1) and diffusing capacity  
14  
15  
16 of the lung for carbon monoxide (DLCO) is not available in our database, and disease  
17  
18  
19 free survival is also not available in our study.  
20  
21  
22  
23  
24

## 25 **Conclusions**

26  
27  
28 In this study, we collected nationwide data from 42,962 non-small cell lung cancer  
29  
30  
31 patients, which, to the best of our knowledge, is the largest nationwide study to date. In  
32  
33  
34 addition, we also investigated the correlation between lung cancer treatment delay and  
35  
36  
37 survival rate in different cancer stages (stages I, II, III and stage IV) with pathological  
38  
39  
40 confirmation. NSCLC patients with timeliness treatment in stage I and II have better  
41  
42  
43 survival rate than others.  
44  
45  
46  
47

## 48 **Acknowledgements**

49  
50  
51 We are grateful to the Science Center of the Ministry of Health and Welfare for  
52  
53  
54 providing us with access to the National Health Insurance Research Database, Cancer  
55  
56  
57 Registry Files, and Cause of Death File. We are also grateful to Health Data Science  
58  
59  
60

Center, China Medical University Hospital for providing administrative, technical and funding support.

### **Funding source**

This study was supported by the grants (CMU107-ASIA-18; MOST 104-2410-H-039-002) from China Medical University, Asia University, and the Ministry of Science and Technology, Taiwan.

### **Competing interests**

The authors declare that they have no competing interests.

### **Author's contribution**

Conceptualization: Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai

Methodology: Chang-Hung Tsai, Pei-Tseng Kung, Wei-Yin Kuo, Wen-Chen Tsai

Software: Wen-Chen Tsai

Validation: Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai

Formal analysis: Chang-Hung Tsai, Wei-Yin Kuo

Data curation: Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai

Resources: Pei-Tseng Kung, Wen-Chen Tsai

Writing (original draft preparation): Chang-Hung Tsai, Wen-Chen Tsai

Writing (review and editing): Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai

Supervision: Wen-Chen Tsai

1  
2  
3  
4 Project administration: Chang-Hung Tsai, Wei-Yin Kuo, Pei-Tseng Kung  
5  
6

7 Funding acquisition: Pei-Tseng Kung, Wen-Chen Tsai  
8  
9

### 10 **Patient consent form**

11  
12

13 As this study used anonymized secondary data retrieved from the Taiwan's National  
14  
15  
16 Health Insurance Research Database, the requirement for informed consent was  
17  
18  
19 waived by the ethics committee.  
20  
21  
22

### 23 **Data sharing**

24  
25  
26

27 This study used the National Health Insurance Research Database published by the  
28  
29  
30 Ministry of Health, Taiwan. Due to legal restrictions imposed by the Taiwan  
31  
32  
33 government related to the Personal Information Protection Act, the database cannot be  
34  
35  
36 made publicly available. All researchers can apply for using the databases for  
37  
38  
39 conducting their studies. Requests for data can be sent as a formal proposal to the  
40  
41  
42 Science Center of the Ministry of Health and Welfare  
43  
44  
45 (<http://www.mohw.gov.tw/EN/Ministry/Index.aspx>). Any raw data are not allowed to  
46  
47  
48 be brought out from the Science Center. Only the analytic outputs in format of table  
49  
50  
51 or figure can be printed out. The restrictions prohibited the authors from making the  
52  
53  
54 minimal data set publicly available.  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Figure Legend

Figure 1. Adjusted survival curve in lung cancer patients with different cancer stages

For peer review only



## References

1. Ferlay J. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10. <http://globocan.iarc.fr> 2010
2. Jensen AR, Mainz J, Overgaard J. Impact of delay on diagnosis and treatment of primary lung cancer. *Acta Oncologica* 2002;41(2):147-52.
3. Valdés S, García E, Pérez H, et al. Length of diagnostic delay in patients with non-small-cell lung cancer. *MEDICC review* 2010;12(1)
4. Vinas F, Ben Hassen I, Jabot L, et al. Delays for diagnosis and treatment of lung cancers: a systematic review. *The clinical respiratory journal* 2016;10(3):267-71.
5. Storm H, Dickman P, Engeland A, et al. Do morphology and stage explain the inferior lung cancer survival in Denmark? *European Respiratory Journal* 1999;13(2):430-35.
6. Teppo L, Dickman PW, Hakulinen T, et al. Cancer patient survival-patterns, comparisons, trends: A population-based cancer registry study in Finland. *Acta oncologica* 1999;38(3):283-94.
7. Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. *Journal of the National Comprehensive Cancer Network* 2016;14(3):255-64.
8. Chandra S, Mohan A, Guleria R, et al. Delays during the diagnostic evaluation and treatment of lung cancer. *Asian Pac J Cancer Prev* 2009;10(3):453-6.
9. Chiang C-J, You S-L, Chen C-J, et al. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. *Japanese journal of clinical oncology* 2015;45(3):291-96.
10. Cheng CL, Kao YHY, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. *Pharmacoepidemiology and drug safety* 2011;20(3):236-42.
11. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *Journal of clinical epidemiology* 1992;45(6):613-19.
12. Bilimoria KY, Ko CY, Tomlinson JS, et al. Wait times for cancer surgery in the United States: trends and predictors of delays. *Annals of surgery* 2011;253(4):779-85.
13. Evans SM, Earnest A, Bower W, et al. Timeliness of lung cancer care in Victoria: a retrospective cohort study. *Medical Journal of Australia* 2016;204(2):75-75.
14. Gomez DR, Liao K-P, Swisher SG, et al. Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. *Radiotherapy and Oncology* 2015;115(2):257-63.
15. Liberman M, Liberman D, Sampalis JS, et al. Delays to surgery in non-small-cell lung cancer. *Canadian journal of surgery* 2006;49(1):31.

16. Pita-Fernández S, Montero-Martinez C, Pérttega-Diaz S, et al. Relationship between delayed diagnosis and the degree of invasion and survival in lung cancer. *Journal of clinical epidemiology* 2003;56(9):820-25.
17. Porta M, Gallen M, Malats N, et al. Influence of " diagnostic delay" upon cancer survival: an analysis of five tumour sites. *Journal of Epidemiology & Community Health* 1991;45(3):225-30.
18. Koyi H, Hillerdal G, Brandén E. Patient's and doctors' delays in the diagnosis of chest tumors. *Lung cancer* 2002;35(1):53-57.
19. Billing J, Wells F. Delays in the diagnosis and surgical treatment of lung cancer. *Thorax* 1996;51(9):903-06.
20. Mor V, Masterson-Allen S, Goldberg R, et al. Pre-diagnostic symptom recognition and help seeking among cancer patients. *Journal of community health* 1990;15(4):253-66.
21. Christensen E, Harvald T, Jendresen M, et al. The impact of delayed diagnosis of lung cancer on the stage at the time of operation. *European Journal of Cardio-Thoracic Surgery* 1997;12(6):880-84.
22. Annakkaya AN, Arbak P, Balbay O, et al. Effect of symptom-to-treatment interval on prognosis in lung cancer. *Tumori Journal* 2007;93(1):61-67.
23. Annakkaya AN, Arbak P, Balbay O, et al. Effect of symptom-to-treatment interval on prognosis in lung cancer. *Tumori* 2007;93(1):61.
24. Myrdal G, Lambe M, Hillerdal G, et al. Effect of delays on prognosis in patients with non-small cell lung cancer. *Thorax* 2004;59(1):45-49.
25. Robinson E, Mohilever J, Zidan J, et al. Delay in diagnosis of cancer. Possible effects on the stage of disease and survival. *Cancer* 1984;54(7):1454-60.
26. Salomaa E-R, Sallinen S, Hiekkanen H, et al. Delays in the diagnosis and treatment of lung cancer. *Chest Journal* 2005;128(4):2282-88.
27. Alexander M, Blum R, Burbury K, et al. Timely initiation of chemotherapy: a systematic literature review of six priority cancers—results and recommendations for clinical practice. *Internal medicine journal* 2017;47(1):16-34.
28. Vinod SK, Chandra A, Berthelsen A, et al. Does timeliness of care in Non-Small Cell Lung Cancer impact on survival? *Lung Cancer* 2017;112:16-24.
29. Diaconescu R, Lafond C, Whittom R. Treatment delays in non-small cell lung cancer and their prognostic implications. *Journal of Thoracic Oncology* 2011;6(7):1254-59.
30. Mackintosh JA, Marshall HM, Yang IA, et al. A retrospective study of volume doubling time in surgically resected non-small cell lung cancer. *Respirology* 2014;19(5):755-62.
31. Everitt S, Herschtal A, Callahan J, et al. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with

- 1  
2  
3 nonsmall cell lung cancer. *Cancer* 2010;116(21):5030-37.  
4  
5 32. Tsai W-C, Kung P-T, Wang S-T, et al. Beneficial impact of multidisciplinary team  
6 management on the survival in different stages of oral cavity cancer patients: results  
7 of a nationwide cohort study in Taiwan. *Oral oncology* 2015;51(2):105-11.  
8  
9 33. Boxer MM, Vinod SK, Shafiq J, et al. Do multidisciplinary team meetings make a  
10 difference in the management of lung cancer? *Cancer* 2011;117(22):5112-20.  
11  
12 34. Birchall M, Bailey D, King P. South West Cancer Intelligence Service Head and Neck  
13 Tumour Panel. Effect of process standards on survival of patients with head and neck  
14 cancer in the south and west of England. *Br J Cancer* 2004;91(8):1477-81.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




Figure 1

67x67mm (600 x 600 DPI)

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
<b>Introduction</b>			<b>5-6</b>
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any pre-specified hypotheses	6
<b>Methods</b>			<b>6-10</b>
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7,9
Bias	9	Describe any efforts to address potential sources of bias	6-7
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	10
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10-19
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10-19
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			20-26
Key results	18	Summarise key results with reference to study objectives	20
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	23
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	26
Generalisability	21	Discuss the generalisability (external validity) of the study results	26-27
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	27

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Effect of time interval from diagnosis to treatment for non-small cell lung cancer on survival: A national cohort study in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034351.R3
Article Type:	Original research
Date Submitted by the Author:	22-Feb-2020
Complete List of Authors:	Tsai, Chang-Hung; China Medical University, Department of Public Health; Miaoli General Hospital Ministry of Health and Welfare Kung, Pei-Tseng ; Asia University, Department of Healthcare Administration; China Medical University, Department of Medical Research, China Medical University Hospital Kuo, Wei-Yin; China Medical University, Department of Health Services Administration Tsai, Wen-Chen; China Medical University, Department of Health Services Administration
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Epidemiology, Health services research, Public health, Evidence based practice
Keywords:	lung cancer, non-small cell lung cancer, delay treatment, timeliness of treatment, survival

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



1  
2  
3  
4 **Effect of time interval from diagnosis to treatment for non-small cell lung cancer on**  
5  
6  
7 **survival: A national cohort study in Taiwan**  
8  
9

10 **Running head:** Treatment delay and survival for non-small cell lung cancer  
11  
12

13  
14 Chang-Hung Tsai<sup>a,b,c</sup>, Pei-Tseng Kung<sup>d,e,#</sup>, Wei-Yin Kuo<sup>b</sup>, Wen-Chen Tsai<sup>b,#,\*</sup>  
15  
16

17  
18 <sup>a</sup> Miao-Li General Hospital, Ministry of Health and Welfare, Taiwan, R.O.C  
19  
20

21  
22 <sup>b</sup> Department of Health Services Administration, China Medical University, Taichung,  
23  
24 Taiwan, R.O.C.  
25  
26

27  
28 <sup>c</sup> Department of Public Health, China Medical University, Taichung, Taiwan, R.O.C.  
29  
30

31  
32 <sup>d</sup> Department of Healthcare Administration, Asia University, Taichung, Taiwan, R.O.C  
33  
34

35  
36 <sup>e</sup> Department of Medical Research, China Medical University Hospital, China Medical  
37  
38 University, Taichung, Taiwan, R.O.C.  
39  
40  
41

42  
43 <sup>#</sup> Authors had equal contributions to this work.  
44  
45  
46

47  
48 **\*Corresponding Author:** Professor Wen-Chen Tsai, Dr.PH.  
49  
50

51  
52 Address: No. 91 Hsueh-Shih Road, Taichung, Taiwan 40402, R.O.C.  
53  
54

55  
56 Tel: +886-422073070; Fax: +886-422028895  
57  
58  
59  
60

1  
2  
3  
4 E-mail: wtsai@mail.cmu.edu.tw  
5  
6  
7

8 **Words:** 3346  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Abstract

**OBJECTIVES.** This study aimed to determine if treatment delay after non-small cell lung cancer (NSCLC) diagnosis impacts patient survival rate.

**STUDY DESIGN.** This study is a natural experiment in Taiwan. A retrospective cohort investigation was conducted from 2004 to 2010, which included 42,962 patients with newly diagnosed NSCLC.

**METHODS.** We identified 42,962 patients with newly diagnosed NSCLC in the Taiwan Cancer Registry from 2004 to 2010. We calculated the time interval between diagnosis and treatment initiation. All patients were followed from the index date to death, or the end of 2012. Cox proportional hazard models were used to examine the relationship between mortality and time interval.

**RESULTS.** We included 42,962 patients (15,799 men and 27,163 women) with newly diagnosed NSCLC. The mortality rate exhibited a significantly positive correlation to time interval from cancer diagnosis to treatment initiation. The adjusted hazard ratios ranged from 1.04 to 1.08 in all subgroups time interval more than 7 days compared with the counterpart subgroup of the interval from cancer diagnosis to treatment  $\leq 7$  days. The trend was also noted regardless of the patients with lung cancer in stage I, stage II, and stage III.

**CONCLUSIONS.** There is a major association between time to treat and mortality of patients with NSCLC, especially in stages I and II. We suggest that efforts should be made to

1  
2  
3  
4 minimize the interval from diagnosis to treatment while further study is ongoing to determine  
5  
6  
7 causation.  
8  
9  
10  
11  
12

### 13 **Strengths and limitations of this study**

14  
15

- 16 ● It consisted of nationwide patients with non-small cell lung cancer.
- 17
- 18 ● We collected nationwide data from 42,962 non-small cell lung cancer patients, which is the
- 19
- 20 largest nationwide study to date.
- 21
- 22
- 23
- 24 ● There were very few studies investigating treatment delay effects on the reduction of
- 25 survival rate of lung cancer patients.
- 26
- 27
- 28 ● Our lung cancer stages (stages I, II, III, and IV) were based on pathological confirmation.
- 29
- 30
- 31 ● Information on patients' quantitative lung function and need for provocative cardiac testing
- 32
- 33 are not available and may be significant factors determining the time to treat interval.
- 34
- 35
- 36
- 37
- 38
- 39

40 **Keywords:** lung cancer; non-small cell lung cancer; delay treatment; timeliness of treatment;  
41  
42 survival  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Lung cancer is among the most common causes of cancer death, particularly in industrialized countries.<sup>1</sup> In addition, the incidence of lung cancer has been gradually increasing over the last 50 years,<sup>2</sup> becoming a worldwide public health issue.<sup>3</sup> Lung cancer can be classified into small cell lung cancer and non-small cell lung cancer, of which the latter accounts for 80% of all lung cancer cases.<sup>4</sup> Despite recent improvements in treatment, the prognosis for lung cancer patients is still poor. Regardless of whether a patient has non-small cell lung cancer or small cell lung cancer, the 5-year survival rate is only 17.4%.<sup>2 5-7</sup> Most lung cancers are in the late stage (stages IIIB or IV) when diagnosed, which is likely to be a result of the long interval between the onset of symptoms and diagnosis.<sup>8</sup> There are often large differences in the length of the interval from the first appearance of symptoms to confirmation of diagnosis and treatment initiation in these patients.<sup>4</sup> Although there were many relevant studies on whether differences in the time delay between diagnosis to treatment initiation affects the prognosis of lung cancer patients, no definitive conclusion has been reached.<sup>4</sup> An increasing number of relevant studies have also highlighted the importance of this topic.

In Taiwan, 99.68% of the populace is covered by National Healthcare Insurance (NHI) program. Under this system, lung cancer is classified as a catastrophic illness and is exempt from treatment-related fees, thereby that patients are not affected by economic factor. According to 2016 statistics from the Taiwan Ministry of Health and Welfare, cancer has

1  
2  
3  
4 consistently been the top cause of death. Among various types of cancer, lung cancer ranks  
5  
6  
7 first in the cause of death, with a mortality rate of 39.9 per 100,000 people. Therefore, it is  
8  
9  
10 important for public health providers to improve lung cancer prognoses and increase survival  
11  
12  
13 rates. The Taiwan Cancer Registry (TCR), a population-based cancer registry, was founded in  
14  
15  
16 1979. The registry is organized by the Ministry of Health and Welfare. The Taiwan Cancer  
17  
18  
19 Registry Database (TCRD) records data of all types of cancer diagnosed and treatments in  
20  
21  
22 patients in Taiwan. The completeness (97%) and data quality of the Cancer Registry Database  
23  
24  
25 has achieved at an excellent level.<sup>9</sup> The accuracy of NHIRD has been validated in previous  
26  
27  
28 studies.<sup>10</sup> This study aims to utilize national large-scale statistical data to investigate whether  
29  
30  
31 the interval between lung cancer diagnosis and treatment affects survival rate; concurrently,  
32  
33  
34 we also aim to examine the impact of other relevant factors on survival. This will provide a  
35  
36  
37 reference for future treatment for lung cancer patients of improving their survival.  
38  
39

## 40 **METHODS**

### 41 42 43 **Data sources and participants**

44  
45  
46 We included 55,014 newly diagnosed non-small cell lung cancer patients from 2004 to  
47  
48  
49 2010. The newly diagnosed non-small cell lung cancer patients were defined as ICD-O-3 with  
50  
51  
52 C339 to C349 without any cancers before. Then we excluded those lung cancer patients with  
53  
54  
55 unknown stage for 3,993 patients. We also excluded lung cancer patients in situ (70 patients),  
56  
57  
58 with multiple cancer (1,298 patients), palliative treatment at the beginning (1,934 patients),  
59  
60

1  
2  
3  
4 mortality before lung cancer diagnosed (64 patients), personal characteristics data missing (109  
5  
6  
7 patients), and hospital data missing (4,584 patients). In our study, patients with multiple cancers  
8  
9  
10 may affect survival due to other cancer effect. In Taiwan, palliative treatment is coded as  
11  
12 special code in NHIRD. Non-small cell lung cancer patients with palliative treatment at  
13  
14 beginning may be due to patients refusing further treatment or not receiving aggressive  
15  
16 treatment. We excluded them for informal treatment. Otherwise, we also excluded those  
17  
18 patients with data missing for accuracy. Finally, we had 42,962 people.  
19  
20  
21  
22  
23  
24

25 The data for this study was obtained from the Taiwan Cancer Registry, which was used  
26  
27 to acquire study participants. We also linked this data to the National Health Insurance  
28  
29 Database and the Cause of Death File from 2002 to 2012 that was provided by the Ministry of  
30  
31 Health and Welfare. The accuracy of Taiwan Cancer Registry and NHIRD has achieved at an  
32  
33 excellent level.  
34  
35  
36  
37  
38  
39

#### 40 **Patient and public involvement**

41  
42  
43 No patients were involved in the planning, conception and design of this study, as this  
44  
45 study was based on the National Health Insurance Research Database, published by the  
46  
47 Ministry of Health and Welfare, Taiwan.  
48  
49  
50

#### 51 **Variable descriptions**

52  
53  
54  
55 In this study, with regards to the variables used, the general characteristics of lung cancer  
56  
57 patients included sex and age. Age was defined as the age at which the patient had a  
58  
59  
60

1  
2  
3  
4 confirmatory diagnosis by pathology. The financial status of the patient was based on their  
5  
6  
7 monthly salary. The degree of urbanization at the patient's place of residence was used to  
8  
9  
10 represent environmental factors. The level of urbanization was based on 7 levels of  
11  
12  
13 classification from highly urbanized developed cities (level 1) to remote areas (level 7). The  
14  
15  
16 health status of the patient included data on whether the patient had other catastrophic illnesses  
17  
18  
19 besides cancer, their Charlson Comorbidity Index (CCI), and the stage of non-small cell lung  
20  
21  
22 cancer. The definition of catastrophic illness was based on the 30 types of catastrophic illnesses  
23  
24  
25 or injuries as defined by the National Health Insurance Administration, which include stroke,  
26  
27  
28 chronic kidney failure, systemic lupus erythematosus, type I diabetes and severe mental illness.  
29  
30  
31 The degree of comorbidity was classified into three levels based on the CCI<sup>11</sup>. Tumor staging  
32  
33  
34 was based on the guidelines of the American Joint Committee on Cancer (6<sup>th</sup> edition for tumors  
35  
36  
37 diagnosed from 2004-2009, 7<sup>th</sup> edition for tumors diagnosed in 2010), which includes stages I,  
38  
39  
40 II, III, and IV. Hospital attributes include the level of hospital (medical centers, regional  
41  
42  
43 hospitals, district hospitals, and others), hospital ownership (public or private institutions), and  
44  
45  
46 the volume of hospital services (low, medium, high) in treatment of non-small cell lung cancer  
47  
48  
49 patients. The volume of hospital services was divided into low, medium, and high on the basis  
50  
51  
52 of quartiles: service volumes of <25%, 25-75% and >75% were defined as low, medium and  
53  
54  
55 high, respectively. Patients were considered to be enrolled in multidisciplinary team (MDT)  
56  
57  
58 care if they received MDT treatment after pathological diagnosis of non-small cell lung cancer;  
59  
60



1  
2  
3  
4 the definition of MDT is based on patients who were declared MDT treatment fees in the NHI  
5  
6  
7 database (47079B). The interval between diagnosis of non-small cell lung cancer and treatment  
8  
9  
10 initiation was defined as the period between pathological sectioning and diagnosis of non-small  
11  
12  
13 cell lung cancer after biopsy to the time when the patient underwent their first treatment  
14  
15  
16 (including surgery, radiotherapy, or chemotherapy). The operating definition of relevant  
17  
18  
19 treatments is based on the relevant treatment code that was declared in the NHI database, which  
20  
21  
22 was checked against the treatment registration information in the Taiwan Cancer Information  
23  
24  
25 Database.

### 26 27 28 **Main outcome measurements**

29  
30  
31 The main outcome examined in this study was the survival rate of lung cancer patients.  
32  
33  
34 Confirmation of death was based on patient data from the NHI database and this was compared  
35  
36  
37 with the Taiwan Cause of Death archives for confirmation.  
38  
39

### 40 **Statistical analysis**

41  
42  
43 We employed descriptive statistics to show general characteristics, financial status,  
44  
45  
46 environmental factors, health status of patients, hospital attributes, enrolment in MDT and the  
47  
48  
49 distribution status of the interval from diagnosis confirmation to treatment initiation in lung  
50  
51  
52 cancer patients who had a confirmatory diagnosis by pathology from 2004 to 2010. Following  
53  
54  
55 this, bivariate analysis was performed using the log-rank test to investigate whether there were  
56  
57  
58 significant differences between survival status by the end of 2012 and the interval from  
59  
60

1  
2  
3  
4 diagnosis to treatment initiation. We then used univariate Cox proportional hazards regression  
5  
6  
7 to analyze relevant prognostic factors that affect the survival of lung cancer patients. The  
8  
9  
10 adjusted Cox proportional hazards model was used to investigate the relative risk of survival  
11  
12  
13 of lung cancer patients with different cancer stages with different intervals from diagnosis  
14  
15  
16 confirmation to treatment initiation, after controlling for related variables. Independent  
17  
18  
19 variables included patient characteristics, financial status, environmental factors, health status,  
20  
21  
22 hospital attributes, enrolment in MDT, and grouping of time to treatment initiation. The  
23  
24  
25 dependent variable was survival. Lastly, after controlling for relevant variables, the adjusted  
26  
27  
28 Cox proportional hazards model was used to generate survival curves for lung cancer patients  
29  
30  
31 of various stages and with different interval periods.  
32  
33

34 All statistical analyses were performed using SAS software, version 9.2 (SAS Institute  
35  
36  
37 Inc., Cary, NC). A P value  $<0.05$  was regarded as statistically significant and all tests were  
38  
39  
40 two-sided.  
41  
42

## 43 **RESULTS**

### 44 **Descriptive statistics of lung cancer patient characteristics for different treatment** 45 **intervals** 46 47 48 49

50 In all lung cancer patients, the mean 5-year survival rate was 17.61%. As the interval from  
51  
52  
53 diagnosis to treatment initiation increased, the 5-year survival rate decreased from 26.12% to  
54  
55  
56 6.02% (Table 1). We also included time to treatment with 0 day (TTT=0) cases in the  $<7$  days  
57  
58  
59 group in our study. There were 7,363 cases with TTT=0 accounting for 17.14% of all patients  
60

1  
2  
3  
4 in our study. We had 3,258 females accounting for 44.25% in this subgroup. The age of  
5  
6  
7 diagnosed in most patients was from 65-74 years old accounting for 28.28% with mean age of  
8  
9  
10 64.67 years old. The treatment of most patients with TTT=0 was surgery combining with  
11  
12  
13 radiotherapy and chemotherapy. The 5-year survival rate was 34.9% in this group with TTT=0.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1. Bivariate analysis of lung cancer patient characteristics for different treatment intervals

Variables	Total		Interval from cancer diagnosis to treatment								P value <sup>a</sup>
			≤ 7 days		8~14 days		15~60 days		≥ 61 days		
	N	%	N	%	N	%	N	%	N	%	
<b>Total number</b>	42,962	100.00	15,769	36.70	9,296	21.64	12,510	29.12	5,387	12.54	-
<b>Five-year survival rate</b>	42,962	17.61	15,769	26.12	9,296	15.96	12,510	12.99	5,387	6.02	<0.001
<b>Gender</b>											<0.001
Female	15,799	36.77	6,154	38.95	3,235	20.48	4,419	27.97	1,991	12.60	
Male	27,163	63.23	9,615	35.40	6,061	22.31	8,091	29.79	3,396	12.50	
<b>Age</b>											<0.001
≤ 44	2,106	4.90	889	42.21	455	21.60	568	26.97	194	9.21	
45~54	5,686	13.23	2,375	41.77	1,263	22.21	1,549	27.24	499	8.78	
55~64	9,155	21.31	3,634	39.69	2,033	22.21	2,658	29.03	830	9.07	
65~74	12,659	29.47	4,548	35.93	2,801	22.13	3,819	30.17	1,491	11.78	
≥ 75	13,356	31.09	4,323	32.37	2,744	20.55	3,916	29.32	2,373	17.77	
<b>Mean age (m, sd)</b>	66.76	12.44	65.52	12.55	66.45	12.22	67.04	12.15	70.25	12.46	<0.001
<b>Monthly salary</b>											<0.001
Low-income	461	1.07	137	29.72	101	21.91	154	33.41	69	14.97	
≤ 17280	1,475	3.43	542	36.75	311	21.08	447	30.31	175	11.86	
17281~22800	22,935	53.38	8,074	35.20	5,079	22.15	6,751	29.44	3,031	13.22	
22801~28800	8,069	18.78	2,961	36.70	1,690	20.94	2,376	29.45	1,042	12.91	
28801~36300	2,676	6.23	1,011	37.78	588	21.97	782	29.22	295	11.02	
36301~45800	3,280	7.63	1,333	40.64	689	21.01	923	28.14	335	10.21	
≥ 45801	4,066	9.46	1,711	42.08	838	20.61	1,077	26.49	440	10.82	

Table 1. Bivariate analysis of lung cancer patient characteristics for different treatment intervals (continued)

Variables	Total		Interval from cancer diagnosis to treatment								P value <sup>a</sup>
			≤ 7 days		8~14 days		15~60 days		≥ 61 days		
	N	%	N	%	N	%	N	%	N	%	
<b>Urbanization</b>											0.186
Level 1	11,759	27.37	4,335	36.87	2,494	21.21	3,404	28.95	1,526	12.98	
Level 2	12,117	28.20	4,506	37.19	2,615	21.58	3,527	29.11	1,469	12.12	
Level 3	6,523	15.18	2,334	35.78	1,424	21.83	1,946	29.83	819	12.56	
Level 4	6,795	15.82	2,518	37.06	1,506	22.16	1,974	29.05	797	11.73	
Level 5	1,524	3.55	523	34.32	338	22.18	439	28.81	224	14.70	
Level 6	2,217	5.16	807	36.40	490	22.10	627	28.28	293	13.22	
Level 7	2,027	4.72	746	36.80	429	21.16	593	29.26	259	12.78	
<b>CCI score</b>											<0.001
≤ 3	20,388	47.46	7,475	36.66	4,576	22.44	6,186	30.34	2,151	10.55	
4~6	7,587	17.66	2,761	36.39	1,646	21.70	2,218	29.23	962	12.68	
≥ 7	14,987	34.88	5,533	36.92	3,074	20.51	4,106	27.40	2,274	15.17	
<b>Other catastrophic illness</b>											<0.001
No	41,474	96.54	15,300	36.89	8,984	21.66	12,076	29.12	5,114	12.33	
Yes	1,488	3.46	469	31.52	312	20.97	434	29.17	273	18.35	
<b>Cancer stage</b>											<0.001
Stage I	5,681	13.22	3,226	56.79	910	16.02	1,269	22.34	276	4.86	
Stage II	1,526	3.55	589	38.60	338	22.15	462	30.28	137	8.98	
Stage III	11,696	27.22	4,030	34.46	2,843	24.31	3,500	29.92	1,323	11.31	
Stage IV	24,059	56.00	7,924	32.94	5,205	21.63	7,279	30.25	3,651	15.18	

Table 1. Bivariate analysis of lung cancer patient characteristics for different treatment intervals (continued)

Variables	Total		Interval from cancer diagnosis to treatment								P value <sup>a</sup>
			≤ 7 days		8~14 days		15~60 days		≥ 61 days		
	N	%	N	%	N	%	N	%	N	%	
<b>MDT care</b>											<0.001
No	37,716	87.79	13,669	36.24	8,012	21.24	10,974	29.10	5,061	13.42	
Yes	5,246	12.21	2,100	40.03	1,284	24.48	1,536	29.28	326	6.21	
<b>Hospital level</b>											<0.001
Medical centers	29,228	68.03	11,075	37.89	6,452	22.07	8,427	28.83	3,274	11.20	
Regional hospitals	12,601	29.33	4,395	34.88	2,655	21.07	3,787	30.05	1,764	14.00	
District hospitals	1,014	2.36	261	25.74	178	17.55	279	27.51	296	29.19	
Others	119	0.28	38	31.93	11	9.24	17	14.29	53	44.54	
<b>Hospital ownership</b>											<0.001
Public	16,770	39.03	6,619	39.47	3,776	22.52	4,558	27.18	1,817	10.83	
Private	26,192	60.97	9,150	34.93	5,520	21.08	7,952	30.36	3,570	13.63	
<b>Hospital services volume</b>											<0.001
Low	10,807	25.15	3,905	36.13	2,177	20.14	2,935	27.16	1,790	16.56	
Middle	21,043	48.98	7,519	35.73	4,652	22.11	6,486	30.82	2,386	11.34	
High	11,112	25.86	4,345	39.10	2,467	22.20	3,089	27.80	1,211	10.90	

<sup>a</sup> Log-rank test

### Five-year survival rate of patients for different treatment intervals

At the same time, we found that in stage I patients, the 5-year survival rate decreased by 9.07% due to delayed treatment (patients with intervals >7 days). In stage

II patients, if patients started treatment earlier (interval  $\leq 7$  days), their 5-year survival rate increased by 9.01%. Early treatment (interval  $\leq 7$  days) was found to have a smaller effect on 5-year survival rate in stage III and stage IV patients, with an increase in 5-year survival rate of 1.91% and 0.49% (Table 2).

Table 2. Five-year survival rate of patients for different treatment intervals

Variables	Stage I		Stage II		Stage III		Stage IV		P value <sup>a</sup>
	N	%	N	%	N	%	N	%	
<b>Total number</b>	5,681	61.61	1,526	34.41	11,696	12.95	24,059	5.11	
<b>Interval from cancer diagnosis to treatment</b>									<0.001
$\leq 7$ days	3,226	70.68	589	43.42	4,030	14.86	7,924	5.60	
8~14 days	910	60.58	338	33.74	2,843	12.11	5,205	4.58	
15~60 days	1,269	49.07	462	29.81	3,500	13.81	7,279	5.43	
$\geq 61$ days	276	21.10	137	14.56	1,323	6.83	3,651	4.12	

<sup>a</sup> Log-rank test

## **The effect of different treatment intervals on mortality risk in patients with lung cancer**

Table 3 shows that when the group with interval from cancer diagnosis to treatment  $\leq 7$  days was used as a reference, the adjusted HR for mortality in other groups (8-14 days, 15-60 days, and  $\geq 61$  days) was significantly increased with increasing interval time (HR: 1.04-1.08). Among patients at various cancer stages, using stage I patients as a control group, the adjusted HRs for mortality for cancer patients at various stages was significantly higher (HR: 2.06-5.89) and the more advanced the cancer stages, the higher the adjusted HR for mortality. Patients who underwent MDT care had a significantly lower adjusted HR for mortality compared with patients who did not (HR: 0.91, 95% CI: 0.88-0.94).



Table 3. Relative risk of death in patients for different treatment intervals

Variables	Unadjusted		Adjusted			
	HR	P value	HR	95% CI	P value <sup>a</sup>	
<b>Interval from cancer diagnosis to treatment</b>						
≤ 7 days (ref.)						
8~14 days	<b>1.26</b>	<0.001	<b>1.04</b>	1.01	1.07	0.004
15~60 days	<b>1.30</b>	<0.001	<b>1.06</b>	1.04	1.09	<0.001
≥ 61 days	<b>1.66</b>	<0.001	<b>1.08</b>	1.04	1.11	<0.001
<b>Gender</b>						
Female (ref.)						
Male	<b>1.54</b>	<0.001	<b>1.50</b>	1.47	1.53	<0.001
<b>Age</b>						
≤ 44 (ref.)						
45~54	<b>0.97</b>	0.357	<b>0.97</b>	0.92	1.03	0.351
55~64	<b>1.02</b>	0.478	<b>1.03</b>	0.97	1.09	0.331
65~74	<b>1.63</b>	<0.001	<b>1.27</b>	1.21	1.34	<0.001
≥ 75	<b>1.93</b>	<0.001	<b>1.79</b>	1.69	1.88	<0.001
<b>Monthly salary</b>						
Low-income (ref.)						
≤ 17280	<b>0.72</b>	<0.001	<b>0.89</b>	0.80	1.00	0.049
17281~22800	<b>0.81</b>	<0.001	<b>0.86</b>	0.78	0.95	0.002
22801~28800	<b>0.74</b>	<0.001	<b>0.83</b>	0.75	0.91	<0.001
28801~36300	<b>0.60</b>	<0.001	<b>0.79</b>	0.71	0.87	<0.001
36301~45800	<b>0.59</b>	<0.001	<b>0.78</b>	0.70	0.87	<0.001

Variables	Unadjusted		Adjusted			
	HR	P value	HR	95% CI	P value <sup>a</sup>	
≥ 45801	<b>0.56</b>	<0.001	<b>0.73</b>	0.66	0.81	<0.001
<b>Urbanization level</b>						
Level 1 (ref.)						
Level 2	<b>1.07</b>	<0.001	<b>0.99</b>	0.96	1.02	0.523
Level 3	<b>1.20</b>	<0.001	<b>1.04</b>	1.00	1.07	0.036
Level 4	<b>1.21</b>	<0.001	<b>1.01</b>	0.98	1.05	0.596
Level 5	<b>1.33</b>	<0.001	<b>1.01</b>	0.95	1.08	0.671
Level 6	<b>1.39</b>	<0.001	<b>1.09</b>	1.04	1.15	0.001
Level 7	<b>1.25</b>	<0.001	<b>1.02</b>	0.96	1.07	0.570
<b>CCI score</b>						
≤ 3 (ref.)						
4~6	<b>1.35</b>	<0.001	<b>1.18</b>	1.14	1.21	<0.001
≥ 7	<b>1.80</b>	<0.001	<b>1.28</b>	1.25	1.31	<0.001
<b>Other catastrophic illness</b>						
No (ref.)						
Yes	<b>1.25</b>	<0.001	<b>1.26</b>	1.19	1.33	<0.001
<b>Cancer stage</b>						
Stage I (ref.)						
Stage II	<b>2.29</b>	<0.001	<b>2.06</b>	1.91	2.23	<0.001
Stage III	<b>4.48</b>	<0.001	<b>3.94</b>	3.75	4.13	<0.001
Stage IV	<b>6.51</b>	<0.001	<b>5.89</b>	5.62	6.17	<0.001
<b>MDT care</b>						
No (ref.)						

Variables	Unadjusted		Adjusted			
	HR	P value	HR	95% CI	P value <sup>a</sup>	
Yes	<b>0.95</b>	0.001	<b>0.91</b>	0.88	0.94	<0.001
<b>Hospital level</b>						
Medical centers (ref.)						
Regional hospitals	<b>1.28</b>	<0.001	<b>0.99</b>	0.96	1.02	0.347
District hospitals	<b>2.06</b>	<0.001	<b>1.25</b>	1.17	1.34	<0.001
Others	<b>1.17</b>	0.137	<b>0.90</b>	0.73	1.10	0.286
<b>Hospital ownership</b>						
Public (ref.)						
Private	<b>1.27</b>	<0.001	<b>1.13</b>	1.10	1.16	<0.001
<b>Hospital services volume</b>						
Low (ref.)						
Middle	<b>0.72</b>	<0.001	<b>0.83</b>	0.81	0.85	<0.001
High	<b>0.59</b>	<0.001	<b>0.71</b>	0.68	0.74	<0.001

<sup>a</sup> Cox proportional hazards regression

### The effect of different treatment intervals on mortality risk in patients with lung cancer at different cancer stages

Table 4 shows that in stage I lung cancer patients, with patients with intervals of  $\leq 7$  days as the reference group, as the interval increased, the relative risk of death also significantly increased (HR: 1.45-2.41). This was also true for stage II (HR: 1.21-1.58) and the intervals more than 60 days of stage III lung cancer patients (HR: 1.13, 95% CI: 1.06-1.21). In stage IV patients, using patients with an interval  $\leq 7$  days as a

1  
2  
3  
4 reference group, the relative risk of death was without significantly difference. Figure

5  
6  
7 1 shows adjusted survival curve in lung cancer patients with different cancer stages.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 4. Relative risk of death in patients for different treatment intervals and at different cancer stages

Variables	Stage I <sup>a</sup>			Stage II <sup>a</sup>			Stage III <sup>a</sup>			Stage IV <sup>a</sup>		
	HR	95% CI	P value <sup>b</sup>	HR	95% CI	P value <sup>b</sup>	HR	95% CI	P value <sup>b</sup>	HR	95% CI	P value <sup>b</sup>
<b>Interval from cancer diagnosis to treatment</b>												
≤ 7 days (ref.)												
8~14 days	<b>1.45</b>	1.28 1.64	<0.001	<b>1.21</b>	1.01 1.45	0.039	<b>1.04</b>	0.98 1.09	0.177	<b>0.99</b>	0.95 1.03	0.561
15~60 days	<b>1.66</b>	1.49 1.84	<0.001	<b>1.44</b>	1.22 1.69	<0.001	<b>1.02</b>	0.97 1.07	0.560	<b>1.01</b>	0.98 1.04	0.572
≥ 61 days	<b>2.41</b>	2.06 2.83	<0.001	<b>1.58</b>	1.26 1.97	<0.001	<b>1.13</b>	1.06 1.21	<0.001	<b>0.98</b>	0.94 1.02	0.249

a. Patient age, gender, monthly salary, level of urbanization of place of residence, CCI score, other illness, MDT care, hospital level, hospital ownership, and hospital services volume were all controlled for using various models.

<sup>b</sup> adjusted Cox proportional hazards model

## DISCUSSION

We found that the mortality rate exhibited significantly positive correlation to time interval from cancer diagnosis to treatment initiation in all stage NSCLC patients. The ratio of male to female in our study is similar to that in previous studies.<sup>12 13</sup> The delays between diagnosis and treatment can be categorized into three stages: namely, patient delay, diagnosis delay, and treatment delay.<sup>2</sup> Of all studies which investigated treatment delays in lung cancer patients, the study with the largest number of patients included 54,338 patients, but was limited to non-metastatic lung cancer patients.<sup>12</sup> In addition, the study only focused on patients who underwent surgical excision and did not analyze the treatment delay status and associated factors for all lung cancer patients. Another study collected data from 28,732 patients to investigate whether treatment delay affects survival rate.<sup>14</sup> The researchers found that if the interval from diagnosis to treatment was within 35 days, then there is improved survival for patients with localized disease, reduced survival for those with distant disease, but didn't have significant effect on patients with regional disease.<sup>14</sup> However, in that study, the diagnosis to treatment interval was divided into just two groups (<35 days and >35 days), which makes it more difficult to show the correlation between different treatment delay groups and patient survival rates. In addition, in that study, the authors did not investigate whether different treatment delay periods affect survival rate for different cancer stages as they only

1  
2  
3  
4 classified cancers as localized, regional, or distant. To the best of our knowledge, the  
5  
6  
7 current study is the first large-scale nationwide study that examines whether treatment  
8  
9  
10 delay in non-small cell lung cancer affects patient survival rate. In addition, we also  
11  
12  
13 investigated the correlation between lung cancer treatment delay and survival rate for  
14  
15  
16 different cancer stages (stages I, II, III and IV).  
17

18  
19 Previous studies have observed that if patients are older, have more comorbidities,  
20  
21  
22 or have stage I cancer, they are more likely to delay treatment (interval from diagnosis  
23  
24  
25 to treatment >30 days).<sup>12</sup> Similar findings were observed in our study: for patients aged  
26  
27  
28  $\geq 55$  years, the greater the age the greater the proportion with treatment delay (interval  
29  
30  
31  $\geq 61$  days) (Table 1). Patients with high CCI scores also demonstrated significantly  
32  
33  
34 increased proportions in treatment delay (interval  $\geq 61$  days) (Table 1). CCI is a general  
35  
36  
37 score to evaluate patients' comorbidity and does not focus on lung cancer patients. The  
38  
39  
40 lung function testing such as forced expiratory volume in one second (FEV1) and  
41  
42  
43 diffusing capacity of the lung for carbon monoxide (DLCO) is more accurate for  
44  
45  
46 evaluating their severity but is not available in our study. It is a fact that patients with  
47  
48  
49 poorer lung function require additional testing to determine candidacy for surgery. This  
50  
51  
52 testing, including six minute walk test, quantitative perfusion scans, cardiopulmonary  
53  
54  
55 exercise testing and consultation with pulmonary medicine takes time and is not  
56  
57  
58 available in our study. However, during analysis of the correlation between treatment  
59  
60

1  
2  
3  
4 delay and lung cancer stage, we found that the proportion of stage I patients with  
5  
6  
7 treatment delay was significantly lower than patients with other stages of lung cancer.  
8  
9

10 A previous study has observed that in non-small cell lung cancer patients, treatment  
11  
12 delay is not associated with cancer stage.<sup>15, 16-20</sup> In contrast, treatment delay had more  
13  
14 serious effects in stage III and IV patients.<sup>21</sup> However, in our study, we found that the  
15  
16 proportion of stage I patients with treatment delay (interval from diagnosis to treatment  
17  
18  $\geq 61$  days) was significantly lower (4.86%,  $p < 0.001$ ), when compared with patients at  
19  
20 other stages.  
21  
22  
23  
24  
25  
26  
27

28 Previous studies have mentioned that in non-small cell lung cancer patients, our  
29  
30 understanding of the effects of diagnosis and treatment delay on the prognosis of  
31  
32 patients is limited, although an increasing number of recent studies are emphasizing the  
33  
34 importance of this topic.<sup>4</sup> Some studies have found that in patients with a symptom-to-  
35  
36 treatment interval (STI) of  $> 60$  days, the survival rate was significantly higher than that  
37  
38 of patients with a STI of  $< 60$  days.<sup>22</sup> However, if patients were further divided on the  
39  
40 basis of the type of lung cancer, this difference was only significant in NSCLC  
41  
42 patients.<sup>22</sup> However, the number of patients included in this study was only 103 (96  
43  
44 men).<sup>23</sup> Two other studies, with 378 and 410 patients each, found that delaying  
45  
46 diagnosis and treatment did not affect patient survival rates.<sup>16 17</sup> Another study of 466  
47  
48 non-small cell lung cancer patients found that patients with shorter STIs had lower  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 survival rates.<sup>24</sup> One study with 189 lung cancer patients found that treatment delay  
5  
6  
7 resulted in poorer prognosis for patients,<sup>25</sup> whilst another study with 132 patients found  
8  
9  
10 that longer specialist treatment delay does not result in poorer prognosis.<sup>26</sup> An  
11  
12  
13 aforementioned article also observed that most previous studies in different countries  
14  
15  
16 were monocentric studies and that it is difficult to decide which study is most reliable  
17  
18  
19 with regards to whether treatment delay affects patient survival rates.<sup>4</sup>  
20  
21

22 Most studies show no relationship between time-to-chemotherapy (TTC) and their  
23  
24 survival rate.<sup>27</sup> However, it should be noted that in these review articles, the number of  
25  
26 cases collected is generally very low, with the highest number of patients only 10,583.<sup>27</sup>  
27  
28  
29 Another study showed time intervals from diagnosis to treatment were not associated  
30  
31 with survival outcomes in NSCLC.<sup>28</sup> In this previous study, they discussed NSCLC  
32  
33 patients with different treatment such as surgery, radiotherapy, systemic therapy and  
34  
35 palliative care which were not discussed in our study. They also suggested that delays  
36  
37 to treatment might impact on other outcomes other than survival. However, there were  
38  
39 only 1,729 patients in this previous study.<sup>28</sup> In summary, the majority of previous  
40  
41 studies into whether treatment delay affects survival rate in non-small cell lung cancer  
42  
43 patients lack large-scale nationwide statistical data. This can easily lead to bias and  
44  
45 produce divergent conclusions. In this study, we collected nationwide data from 42,962  
46  
47 non-small cell lung cancer patients, which, to the best of our knowledge, is the largest  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 nationwide study to date. In addition, we also investigated the correlation between lung  
5  
6  
7 cancer treatment delay and survival rate in different cancer stages (stages I, II, III and  
8  
9  
10 IV).

11  
12  
13 In addition, detailed examination of the literature found that a decreased treatment  
14  
15  
16 delay increases the risk of death in patients; the explanation provided for this is that a  
17  
18  
19 shorter treatment delay may mean that the patients have more obvious or more severe  
20  
21  
22 symptoms.<sup>24</sup> Therefore, there is a need to correct the result with cancer stage and  
23  
24  
25 severity.<sup>24</sup> A previous study has also suggested that a shorter treatment delay may  
26  
27  
28 reflect a requirement for more urgent treatment due to severity of symptoms, resulting  
29  
30  
31 in a poor prognosis.<sup>29</sup> Therefore, in this paper, we also considered the effects of cancer  
32  
33  
34 stage on treatment delay and patient prognosis. In another paper, it was also mentioned  
35  
36  
37 that the definition of treatment delay should be more standardized and accurate.<sup>4</sup>  
38  
39  
40 Another paper mentioned that it is not easy to accurately calculate the time of treatment  
41  
42  
43 initiation.<sup>24</sup> In addition, the calculation of patient delay (from symptom to doctor) is  
44  
45  
46 also prone to errors. Therefore, in this study, our definition of treatment delay was made  
47  
48  
49 according to the cancer registration archives and NHI database, from pathological  
50  
51  
52 diagnosis confirmation until treatment initiation.

53  
54  
55 For cancer patients in general, current medical guidelines all recommend early  
56  
57  
58 diagnosis and treatment to improve patient prognosis. However, early diagnosis is  
59  
60

1  
2  
3  
4 difficult due to multiple factors, such as non-apparent symptoms and patient delay.  
5  
6  
7 However, in this study, we found that if the interval from confirmation of pathological  
8  
9  
10 diagnosis to treatment initiation in non-small cell lung cancer patients is shortened to 7  
11  
12  
13 days, this can effectively improve their 5-year survival rate (improvements of 0.49-  
14  
15  
16 9.07% were observed, according to the different stages of lung cancer). We also found  
17  
18  
19 that this improvement in 5-year survival rate was particularly marked for non-small cell  
20  
21  
22 lung cancer patients at early stages (stage I and II), at 10.28-10.34%. However, in late  
23  
24  
25 stage (stage III and stage IV) patients, the 5-year survival rate was only increased by  
26  
27  
28 1.91% and 0.49%. It is extremely ambitious for lung cancer treatment to commence  
29  
30  
31 within 7 days of diagnosis considering the staging exam taking time. This group in the  
32  
33  
34 study (< 7 days to treatment) may be skewed towards those whose cancer was  
35  
36  
37 diagnosed at the time of surgery. A previous study showed that NSCLC growth rate  
38  
39  
40 appeared to be highly variable and related to histological subtype which was not  
41  
42  
43 discussed in our study.<sup>30</sup> Doubling times can be quite variable in different stages of  
44  
45  
46 NSCLC. Another study showed that rapid tumor progression was noted in patients with  
47  
48  
49 untreated, predominantly stage III NSCLC.<sup>31</sup> In our study, table 4 shows stage III non-  
50  
51  
52 small cell lung cancer patients with the interval from diagnosis to treatment initiation  
53  
54  
55 more than 60 days had significantly higher relative risk of death than patients with an  
56  
57  
58 interval  $\leq 7$  days (HR: 1.13, 95% CI: 1.06-1.21). This may be due to rapid tumor  
59  
60

1  
2  
3  
4 progression characteristics of stage III NSCLC. However, the delay treatment effect is  
5  
6  
7 not significant in stage IV NSCLC patients, which may be associated with poor  
8  
9  
10 outcome and low survival rate in late stage of NSCLC. Therefore, we recommended  
11  
12  
13 that in future policies, treatment recommendations should be formulated so that patients  
14  
15  
16 can start treatment within 7 days after pathological diagnosis confirmation of non-small  
17  
18  
19 cell lung cancer to increase their 5-year survival rate. This is particularly important for  
20  
21  
22 early stage (stage I and II) non-small cell lung cancer patients, where improvement  
23  
24  
25 effects are more significant.  
26  
27

28 In this study, we also found that the effect of the interval from diagnosis to  
29  
30  
31 treatment initiation and patient survival rate decreased with more advanced cancer  
32  
33  
34 stages. Therefore, in patients who have stage I (HR: 1.45-2.41) or stage II (HR: 1.21-  
35  
36  
37 1.58) cancer, the longer the interval from diagnosis to treatment initiation, the higher  
38  
39  
40 the risk of death in patients. However, in stage III patients, compared with patients with  
41  
42  
43 an interval from diagnosis to treatment initiation  $\leq 7$  days, only when the interval from  
44  
45  
46 diagnosis to treatment initiation was  $\geq 61$  days was the risk of death increased. However,  
47  
48  
49 the magnitude of the increased risk of death is lower than in stage I and II patients (HR:  
50  
51  
52 1.03-1.06). Therefore, this study found that timely treatment of stage I and II lung  
53  
54  
55 cancer patients has greater benefits. Therefore, we recommend that we should shorten  
56  
57  
58 the interval from diagnosis to treatment initiation especially in stage I and II lung cancer  
59  
60

1  
2  
3  
4 patients, thus decreasing the risk of death and improving prognosis. However, due to  
5  
6  
7 data limitation, we used crude survival instead of disease free survival.  
8  
9

10 In recent studies, it was found that patients with oral cancers who underwent MDT  
11  
12 treatment had significantly higher survival rates, and that the proportion of patients who  
13  
14 underwent treatment was higher than those who did not joining MDT.<sup>32</sup> Previous  
15  
16 studies have shown that the use of MDT care in cancer treatment can improve patient  
17  
18 prognosis.<sup>33</sup> This is particularly the case in head and neck cancers, where MDT care is  
19  
20 not only cost-effective but can also improve survival rates.<sup>34</sup> Previous studies have  
21  
22 shown that in lung cancer patients MDT care can significantly improve the patient's  
23  
24 acceptance of treatment, but does not significantly improve patient survival rates.<sup>33</sup> In  
25  
26 this study, we found that patients who underwent MDT care had a significantly lower  
27  
28 adjusted HR for mortality compared with patients who did not (HR: 0.91, 95% CI: 0.88-  
29  
30 0.94).  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 In summary, this study identifies an association between time to treat and survival  
44  
45 in NSCLC. Although causation is not definitive, efforts to diminish time to treat in the  
46  
47 lung cancer patient would seem prudent while awaiting further study on the issue. In  
48  
49 addition, in stage III and stage IV patients, we recommend the addition of MDT care to  
50  
51 decrease the risk of death and improve prognosis.  
52  
53  
54  
55  
56  
57

## 58 **Limitations**

59  
60

1  
2  
3  
4 A secondary random database derived from the National Health Insurance  
5  
6  
7 Research Database was employed for this study. The information on individual lifestyle,  
8  
9  
10 health behaviors, which may also affect the result, is not available. The lung function  
11  
12  
13 testing such as forced expiratory volume in one second (FEV1) and diffusing capacity  
14  
15  
16 of the lung for carbon monoxide (DLCO) is not available in our database, and disease  
17  
18  
19 free survival is also not available in our study.  
20  
21  
22  
23  
24

## 25 **Conclusions**

26  
27  
28 In this study, we collected nationwide data from 42,962 non-small cell lung cancer  
29  
30  
31 patients, which, to the best of our knowledge, is the largest nationwide study to date. In  
32  
33  
34 addition, we also investigated the correlation between lung cancer treatment delay and  
35  
36  
37 survival rate in different cancer stages (stages I, II, III and stage IV) with pathological  
38  
39  
40 confirmation. Treatment timeliness is associated with better survival rates in patients  
41  
42  
43 with NSCLC, particularly stage I and II.  
44  
45  
46  
47

## 48 **Acknowledgements**

49  
50  
51 We are grateful to the Science Center of the Ministry of Health and Welfare for  
52  
53  
54 providing us with access to the National Health Insurance Research Database, Cancer  
55  
56  
57 Registry Files, and Cause of Death File. We are also grateful to Health Data Science  
58  
59  
60

Center, China Medical University Hospital for providing administrative, technical and funding support.

### **Funding source**

This study was supported by the grants (CMU107-ASIA-18; MOST 104-2410-H-039-002) from China Medical University, Asia University, and the Ministry of Science and Technology, Taiwan.

### **Competing interests**

The authors declare that they have no competing interests.

### **Author's contribution**

Conceptualization: Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai

Methodology: Chang-Hung Tsai, Pei-Tseng Kung, Wei-Yin Kuo, Wen-Chen Tsai

Software: Wen-Chen Tsai

Validation: Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai

Formal analysis: Chang-Hung Tsai, Wei-Yin Kuo

Data curation: Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai

Resources: Pei-Tseng Kung, Wen-Chen Tsai

Writing (original draft preparation): Chang-Hung Tsai, Wen-Chen Tsai

Writing (review and editing): Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai

Supervision: Wen-Chen Tsai

1  
2  
3  
4 Project administration: Chang-Hung Tsai, Wei-Yin Kuo, Pei-Tseng Kung  
5  
6

7 Funding acquisition: Pei-Tseng Kung, Wen-Chen Tsai  
8  
9

### 10 **Patient consent form**

11  
12

13 As this study used anonymized secondary data retrieved from the Taiwan's National  
14  
15  
16 Health Insurance Research Database, the requirement for informed consent was  
17  
18  
19 waived by the ethics committee.  
20  
21  
22

### 23 **Data sharing**

24  
25  
26

27 This study used the National Health Insurance Research Database published by the  
28  
29  
30 Ministry of Health, Taiwan. Due to legal restrictions imposed by the Taiwan  
31  
32  
33 government related to the Personal Information Protection Act, the database cannot be  
34  
35  
36 made publicly available. All researchers can apply for using the databases for  
37  
38  
39 conducting their studies. Requests for data can be sent as a formal proposal to the  
40  
41  
42 Science Center of the Ministry of Health and Welfare  
43  
44  
45 (<http://www.mohw.gov.tw/EN/Ministry/Index.aspx>). Any raw data are not allowed to  
46  
47  
48 be brought out from the Science Center. Only the analytic outputs in format of table  
49  
50  
51 or figure can be printed out. The restrictions prohibited the authors from making the  
52  
53  
54 minimal data set publicly available.  
55  
56  
57  
58  
59  
60



1  
2  
3 **Figure Legend**  
4

5  
6 Figure 1. Adjusted survival curve in lung cancer patients with different cancer stages  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## References

1. Ferlay J. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10. <http://globocan.iarc.fr> 2010
2. Jensen AR, Mainz J, Overgaard J. Impact of delay on diagnosis and treatment of primary lung cancer. *Acta Oncologica* 2002;41(2):147-52.
3. Valdés S, García E, Pérez H, et al. Length of diagnostic delay in patients with non-small-cell lung cancer. *MEDICC review* 2010;12(1)
4. Vinas F, Ben Hassen I, Jabot L, et al. Delays for diagnosis and treatment of lung cancers: a systematic review. *The clinical respiratory journal* 2016;10(3):267-71.
5. Storm H, Dickman P, Engeland A, et al. Do morphology and stage explain the inferior lung cancer survival in Denmark? *European Respiratory Journal* 1999;13(2):430-35.
6. Teppo L, Dickman PW, Hakulinen T, et al. Cancer patient survival-patterns, comparisons, trends: A population-based cancer registry study in Finland. *Acta oncologica* 1999;38(3):283-94.
7. Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. *Journal of the National Comprehensive Cancer Network* 2016;14(3):255-64.
8. Chandra S, Mohan A, Guleria R, et al. Delays during the diagnostic evaluation and treatment of lung cancer. *Asian Pac J Cancer Prev* 2009;10(3):453-6.
9. Chiang C-J, You S-L, Chen C-J, et al. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. *Japanese journal of clinical oncology* 2015;45(3):291-96.
10. Cheng CL, Kao YHY, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. *Pharmacoepidemiology and drug safety* 2011;20(3):236-42.
11. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *Journal of clinical epidemiology* 1992;45(6):613-19.
12. Bilimoria KY, Ko CY, Tomlinson JS, et al. Wait times for cancer surgery in the United States: trends and predictors of delays. *Annals of surgery* 2011;253(4):779-85.
13. Evans SM, Earnest A, Bower W, et al. Timeliness of lung cancer care in Victoria: a retrospective cohort study. *Medical Journal of Australia* 2016;204(2):75-75.
14. Gomez DR, Liao K-P, Swisher SG, et al. Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. *Radiotherapy and Oncology* 2015;115(2):257-63.
15. Liberman M, Liberman D, Sampalis JS, et al. Delays to surgery in non-small-cell lung cancer. *Canadian journal of surgery* 2006;49(1):31.

16. Pita-Fernández S, Montero-Martinez C, Pérttega-Diaz S, et al. Relationship between delayed diagnosis and the degree of invasion and survival in lung cancer. *Journal of clinical epidemiology* 2003;56(9):820-25.
17. Porta M, Gallen M, Malats N, et al. Influence of " diagnostic delay" upon cancer survival: an analysis of five tumour sites. *Journal of Epidemiology & Community Health* 1991;45(3):225-30.
18. Koyi H, Hillerdal G, Brandén E. Patient's and doctors' delays in the diagnosis of chest tumors. *Lung cancer* 2002;35(1):53-57.
19. Billing J, Wells F. Delays in the diagnosis and surgical treatment of lung cancer. *Thorax* 1996;51(9):903-06.
20. Mor V, Masterson-Allen S, Goldberg R, et al. Pre-diagnostic symptom recognition and help seeking among cancer patients. *Journal of community health* 1990;15(4):253-66.
21. Christensen E, Harvald T, Jendresen M, et al. The impact of delayed diagnosis of lung cancer on the stage at the time of operation. *European Journal of Cardio-Thoracic Surgery* 1997;12(6):880-84.
22. Annakkaya AN, Arbak P, Balbay O, et al. Effect of symptom-to-treatment interval on prognosis in lung cancer. *Tumori Journal* 2007;93(1):61-67.
23. Annakkaya AN, Arbak P, Balbay O, et al. Effect of symptom-to-treatment interval on prognosis in lung cancer. *Tumori* 2007;93(1):61.
24. Myrdal G, Lambe M, Hillerdal G, et al. Effect of delays on prognosis in patients with non-small cell lung cancer. *Thorax* 2004;59(1):45-49.
25. Robinson E, Mohilever J, Zidan J, et al. Delay in diagnosis of cancer. Possible effects on the stage of disease and survival. *Cancer* 1984;54(7):1454-60.
26. Salomaa E-R, Sallinen S, Hiekkanen H, et al. Delays in the diagnosis and treatment of lung cancer. *Chest Journal* 2005;128(4):2282-88.
27. Alexander M, Blum R, Burbury K, et al. Timely initiation of chemotherapy: a systematic literature review of six priority cancers—results and recommendations for clinical practice. *Internal medicine journal* 2017;47(1):16-34.
28. Vinod SK, Chandra A, Berthelsen A, et al. Does timeliness of care in Non-Small Cell Lung Cancer impact on survival? *Lung Cancer* 2017;112:16-24.
29. Diaconescu R, Lafond C, Whittom R. Treatment delays in non-small cell lung cancer and their prognostic implications. *Journal of Thoracic Oncology* 2011;6(7):1254-59.
30. Mackintosh JA, Marshall HM, Yang IA, et al. A retrospective study of volume doubling time in surgically resected non-small cell lung cancer. *Respirology* 2014;19(5):755-62.
31. Everitt S, Herschtal A, Callahan J, et al. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with

- 1  
2  
3 nonsmall cell lung cancer. *Cancer* 2010;116(21):5030-37.  
4  
5 32. Tsai W-C, Kung P-T, Wang S-T, et al. Beneficial impact of multidisciplinary team  
6 management on the survival in different stages of oral cavity cancer patients: results  
7 of a nationwide cohort study in Taiwan. *Oral oncology* 2015;51(2):105-11.  
8  
9 33. Boxer MM, Vinod SK, Shafiq J, et al. Do multidisciplinary team meetings make a  
10 difference in the management of lung cancer? *Cancer* 2011;117(22):5112-20.  
11  
12 34. Birchall M, Bailey D, King P. South West Cancer Intelligence Service Head and Neck  
13 Tumour Panel. Effect of process standards on survival of patients with head and neck  
14 cancer in the south and west of England. *Br J Cancer* 2004;91(8):1477-81.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




Figure 1

67x67mm (600 x 600 DPI)

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
<b>Introduction</b>			<b>5-6</b>
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any pre-specified hypotheses	6
<b>Methods</b>			<b>6-10</b>
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7,9
Bias	9	Describe any efforts to address potential sources of bias	6-7
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	10
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10-19
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10-19
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			20-26
Key results	18	Summarise key results with reference to study objectives	20
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	23
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	26
Generalisability	21	Discuss the generalisability (external validity) of the study results	26-27
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	27

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Effect of time interval from diagnosis to treatment for non-small cell lung cancer on survival: A national cohort study in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034351.R4
Article Type:	Original research
Date Submitted by the Author:	07-Mar-2020
Complete List of Authors:	Tsai, Chang-Hung; China Medical University, Department of Public Health; Miaoli General Hospital Ministry of Health and Welfare Kung, Pei-Tseng ; Asia University, Department of Healthcare Administration; China Medical University, Department of Medical Research, China Medical University Hospital Kuo, Wei-Yin; China Medical University, Department of Health Services Administration Tsai, Wen-Chen; China Medical University, Department of Health Services Administration
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Epidemiology, Health services research, Public health, Evidence based practice
Keywords:	lung cancer, non-small cell lung cancer, delay treatment, timeliness of treatment, survival

SCHOLARONE™  
Manuscripts





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Effect of time interval from diagnosis to treatment for non-small cell lung cancer on**  
5  
6  
7 **survival: A national cohort study in Taiwan**  
8  
9

10 **Running head:** Treatment delay and survival for non-small cell lung cancer  
11  
12

13  
14 Chang-Hung Tsai<sup>a,b,c</sup>, Pei-Tseng Kung<sup>d,e,#</sup>, Wei-Yin Kuo<sup>b</sup>, Wen-Chen Tsai<sup>b,#,\*</sup>  
15  
16

17  
18 <sup>a</sup> Miao-Li General Hospital, Ministry of Health and Welfare, Taiwan, R.O.C  
19  
20

21  
22 <sup>b</sup> Department of Health Services Administration, China Medical University, Taichung,  
23  
24 Taiwan, R.O.C.  
25  
26

27  
28 <sup>c</sup> Department of Public Health, China Medical University, Taichung, Taiwan, R.O.C.  
29  
30

31  
32 <sup>d</sup> Department of Healthcare Administration, Asia University, Taichung, Taiwan, R.O.C  
33  
34

35  
36 <sup>e</sup> Department of Medical Research, China Medical University Hospital, China Medical  
37  
38 University, Taichung, Taiwan, R.O.C.  
39  
40  
41

42  
43 <sup>#</sup> Authors had equal contributions to this work.  
44  
45  
46

47  
48 **\*Corresponding Author:** Professor Wen-Chen Tsai, Dr.PH.  
49  
50

51  
52 Address: No. 91 Hsueh-Shih Road, Taichung, Taiwan 40402, R.O.C.  
53  
54

55  
56 Tel: +886-422073070; Fax: +886-422028895  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

E-mail: [wtsai@mail.cmu.edu.tw](mailto:wtsai@mail.cmu.edu.tw)

**Words:** 3346

For peer review only

## Abstract

**OBJECTIVES.** This study aimed to determine if treatment delay after non-small cell lung cancer (NSCLC) diagnosis impacts patient survival rate.

**STUDY DESIGN.** This study is a natural experiment in Taiwan. A retrospective cohort investigation was conducted from 2004 to 2010, which included 42,962 patients with newly diagnosed NSCLC.

**METHODS.** We identified 42,962 patients with newly diagnosed NSCLC in the Taiwan Cancer Registry from 2004 to 2010. We calculated the time interval between diagnosis and treatment initiation. All patients were followed from the index date to death, or the end of 2012. Cox proportional hazard models were used to examine the relationship between mortality and time interval.

**RESULTS.** We included 42,962 patients (15,799 men and 27,163 women) with newly diagnosed NSCLC. The mortality rate exhibited a significantly positive correlation to time interval from cancer diagnosis to treatment initiation. The adjusted hazard ratios ranged from 1.04 to 1.08 in all subgroups time interval more than 7 days compared with the counterpart subgroup of the interval from cancer diagnosis to treatment  $\leq 7$  days. The trend was also noted regardless of the patients with lung cancer in stage I, stage II, and stage III.

**CONCLUSIONS.** There is a major association between time to treat and mortality of patients with NSCLC, especially in stages I and II. We suggest that efforts should be made to

1  
2  
3  
4 minimize the interval from diagnosis to treatment while further study is ongoing to determine  
5  
6  
7 causation.  
8  
9

### 10 11 12 13 **Strengths and limitations of this study** 14

- 15  
16 ● It consisted of nationwide patients with non-small cell lung cancer.  
17
- 18  
19 ● We collected nationwide data from 42,962 non-small cell lung cancer patients, which is  
20  
21 the largest nationwide study to date.  
22  
23
- 24  
25 ● There were very few studies investigating treatment delay effects on the reduction of  
26  
27 survival rate of lung cancer patients.  
28
- 29  
30 ● Our lung cancer stages (stages I, II, III, and IV) were based on pathological confirmation.  
31
- 32  
33 ● Information on patients' quantitative lung function and need for provocative cardiac  
34  
35 testing are not available and may be significant factors determining the time to treat  
36  
37 interval.  
38  
39  
40  
41  
42

43 **Keywords:** lung cancer; non-small cell lung cancer; delay treatment; timeliness of treatment;  
44  
45 survival  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Lung cancer is among the most common causes of cancer death, particularly in industrialized countries.<sup>1</sup> In addition, the incidence of lung cancer has been gradually increasing over the last 50 years,<sup>2</sup> becoming a worldwide public health issue.<sup>3</sup> Lung cancer can be classified into small cell lung cancer and non-small cell lung cancer, of which the latter accounts for 80% of all lung cancer cases.<sup>4</sup> Despite recent improvements in treatment, the prognosis for lung cancer patients is still poor. Regardless of whether a patient has non-small cell lung cancer or small cell lung cancer, the 5-year survival rate is only 17.4%.<sup>2</sup> Most lung cancers are in the late stage (stages IIIB or IV) when diagnosed, which is likely to be a result of the long interval between the onset of symptoms and diagnosis.<sup>8</sup> There are often large differences in the length of the interval from the first appearance of symptoms to confirmation of diagnosis and treatment initiation in these patients.<sup>4</sup> Although there were many relevant studies on whether differences in the time delay between diagnosis to treatment initiation affects the prognosis of lung cancer patients, no definitive conclusion has been reached.<sup>4</sup> An increasing number of relevant studies have also highlighted the importance of this topic.

In Taiwan, 99.68% of the populace is covered by National Healthcare Insurance (NHI) program. Under this system, lung cancer is classified as a catastrophic illness and is exempt from treatment-related fees, thereby that patients are not affected by economic factor.

1  
2  
3  
4 According to 2016 statistics from the Taiwan Ministry of Health and Welfare, cancer has  
5  
6  
7 consistently been the top cause of death. Among various types of cancer, lung cancer ranks  
8  
9  
10 first in the cause of death, with a mortality rate of 39.9 per 100,000 people. Therefore, it is  
11  
12  
13 important for public health providers to improve lung cancer prognoses and increase survival  
14  
15  
16 rates. The Taiwan Cancer Registry (TCR), a population-based cancer registry, was founded  
17  
18  
19 in 1979. The registry is organized by the Ministry of Health and Welfare. The Taiwan Cancer  
20  
21  
22 Registry Database (TCRD) records data of all types of cancer diagnosed and treatments in  
23  
24  
25 patients in Taiwan. The completeness (97%) and data quality of the Cancer Registry  
26  
27  
28 Database has achieved at an excellent level.<sup>9</sup> The accuracy of NHIRD has been validated in  
29  
30  
31 previous studies.<sup>10</sup> This study aims to utilize national large-scale statistical data to investigate  
32  
33  
34 whether the interval between lung cancer diagnosis and treatment affects survival rate;  
35  
36  
37 concurrently, we also aim to examine the impact of other relevant factors on survival. This  
38  
39  
40 will provide a reference for future treatment for lung cancer patients of improving their  
41  
42  
43 survival.

## 44 45 46 **METHODS**

### 47 48 49 **Data sources and participants**

50  
51  
52 We included 55,014 newly diagnosed non-small cell lung cancer patients from 2004 to  
53  
54  
55 2010. The newly diagnosed non-small cell lung cancer patients were defined as ICD-O-3  
56  
57  
58 with C339 to C349 without any cancers before. Then we excluded those lung cancer patients  
59  
60

1  
2  
3  
4 with unknown stage for 3,993 patients. We also excluded lung cancer patients in situ (70  
5  
6  
7 patients), with multiple cancer (1,298 patients), palliative treatment at the beginning (1,934  
8  
9  
10 patients), mortality before lung cancer diagnosed (64 patients), personal characteristics data  
11  
12  
13 missing (109 patients), and hospital data missing (4,584 patients). In our study, patients with  
14  
15  
16 multiple cancers may affect survival due to other cancer effect. In Taiwan, palliative  
17  
18  
19 treatment is coded as special code in NHIRD. Non-small cell lung cancer patients with  
20  
21  
22 palliative treatment at beginning may be due to patients refusing further treatment or not  
23  
24  
25 receiving aggressive treatment. We excluded them for informal treatment. Otherwise, we also  
26  
27  
28 excluded those patients with data missing for accuracy. Finally, we had 42,962 people.  
29  
30

31 The data for this study was obtained from the Taiwan Cancer Registry, which was used  
32  
33  
34 to acquire study participants. We also linked this data to the National Health Insurance  
35  
36  
37 Database and the Cause of Death File from 2002 to 2012 that was provided by the Ministry  
38  
39  
40 of Health and Welfare. The accuracy of Taiwan Cancer Registry and NHIRD has achieved at  
41  
42  
43 an excellent level.  
44  
45

#### 46 **Patient and public involvement**

47  
48  
49 No patients were involved in the planning, conception and design of this study, as this  
50  
51  
52 study was based on the National Health Insurance Research Database, published by the  
53  
54  
55 Ministry of Health and Welfare, Taiwan.  
56  
57

#### 58 **Variable descriptions**



1  
2  
3  
4 In this study, with regards to the variables used, the general characteristics of lung  
5  
6  
7 cancer patients included sex and age. Age was defined as the age at which the patient had a  
8  
9  
10 confirmatory diagnosis by pathology. The financial status of the patient was based on their  
11  
12  
13 monthly salary. The degree of urbanization at the patient's place of residence was used to  
14  
15  
16 represent environmental factors. The level of urbanization was based on 7 levels of  
17  
18  
19 classification from highly urbanized developed cities (level 1) to remote areas (level 7). The  
20  
21  
22 health status of the patient included data on whether the patient had other catastrophic  
23  
24  
25 illnesses besides cancer, their Charlson Comorbidity Index (CCI), and the stage of non-small  
26  
27  
28 cell lung cancer. The definition of catastrophic illness was based on the 30 types of  
29  
30  
31 catastrophic illnesses or injuries as defined by the National Health Insurance Administration,  
32  
33  
34 which include stroke, chronic kidney failure, systemic lupus erythematosus, type I diabetes  
35  
36  
37 and severe mental illness. The degree of comorbidity was classified into three levels based on  
38  
39  
40 the CCI <sup>11</sup>. Tumor staging was based on the guidelines of the American Joint Committee on  
41  
42  
43 Cancer (6<sup>th</sup> edition for tumors diagnosed from 2004-2009, 7<sup>th</sup> edition for tumors diagnosed in  
44  
45  
46 2010), which includes stages I, II, III, and IV. Hospital attributes include the level of hospital  
47  
48  
49 (medical centers, regional hospitals, district hospitals, and others), hospital ownership (public  
50  
51  
52 or private institutions), and the volume of hospital services (low, medium, high) in treatment  
53  
54  
55 of non-small cell lung cancer patients. The volume of hospital services was divided into low,  
56  
57  
58 medium, and high on the basis of quartiles: service volumes of <25%, 25-75% and >75%  
59  
60

1  
2  
3  
4 were defined as low, medium and high, respectively. Patients were considered to be enrolled  
5  
6  
7 in multidisciplinary team (MDT) care if they received MDT treatment after pathological  
8  
9  
10 diagnosis of non-small cell lung cancer; the definition of MDT is based on patients who were  
11  
12  
13 declared MDT treatment fees in the NHI database (47079B). The interval between diagnosis  
14  
15  
16 of non-small cell lung cancer and treatment initiation was defined as the period between  
17  
18  
19 pathological sectioning and diagnosis of non-small cell lung cancer after biopsy to the time  
20  
21  
22 when the patient underwent their first treatment (including surgery, radiotherapy, or  
23  
24  
25 chemotherapy). The operating definition of relevant treatments is based on the relevant  
26  
27  
28 treatment code that was declared in the NHI database, which was checked against the  
29  
30  
31 treatment registration information in the Taiwan Cancer Information Database.  
32  
33

### 34 **Main outcome measurements**

35  
36  
37 The main outcome examined in this study was the survival rate of lung cancer patients.  
38  
39  
40 Confirmation of death was based on patient data from the NHI database and this was  
41  
42  
43 compared with the Taiwan Cause of Death archives for confirmation.  
44  
45

### 46 **Statistical analysis**

47  
48  
49 We employed descriptive statistics to show general characteristics, financial status,  
50  
51  
52 environmental factors, health status of patients, hospital attributes, enrolment in MDT and the  
53  
54  
55 distribution status of the interval from diagnosis confirmation to treatment initiation in lung  
56  
57  
58 cancer patients who had a confirmatory diagnosis by pathology from 2004 to 2010.  
59  
60

1  
2  
3  
4 Following this, bivariate analysis was performed using the log-rank test to investigate  
5  
6 whether there were significant differences between survival status by the end of 2012 and the  
7  
8 interval from diagnosis to treatment initiation. We then used univariate Cox proportional  
9  
10 hazards regression to analyze relevant prognostic factors that affect the survival of lung  
11  
12 cancer patients. The adjusted Cox proportional hazards model was used to investigate the  
13  
14 relative risk of survival of lung cancer patients with different cancer stages with different  
15  
16 intervals from diagnosis confirmation to treatment initiation, after controlling for related  
17  
18 variables. Independent variables included patient characteristics, financial status,  
19  
20 environmental factors, health status, hospital attributes, enrolment in MDT, and grouping of  
21  
22 time to treatment initiation. The dependent variable was survival. Lastly, after controlling for  
23  
24 relevant variables, the adjusted Cox proportional hazards model was used to generate survival  
25  
26 curves for lung cancer patients of various stages and with different interval periods.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 All statistical analyses were performed using SAS software, version 9.2 (SAS Institute  
41  
42 Inc., Cary, NC). A P value  $<0.05$  was regarded as statistically significant and all tests were  
43  
44 two-sided.  
45  
46  
47  
48

## 49 **RESULTS**

### 50 **Descriptive statistics of lung cancer patient characteristics for different treatment** 51 **intervals** 52 53 54 55

56 In all lung cancer patients, the mean 5-year survival rate was 17.61%. As the interval  
57  
58 from diagnosis to treatment initiation increased, the 5-year survival rate decreased from  
59  
60

1  
2  
3  
4 26.12% to 6.02% (Table 1). We also included time to treatment with 0 day (TTT=0) cases in  
5  
6  
7 the <7 days group in our study. There were 7,363 cases with TTT=0 accounting for 17.14%  
8  
9  
10 of all patients in our study. We had 3,258 females accounting for 44.25% in this subgroup.  
11  
12  
13 The age of diagnosed in most patients was from 65-74 years old accounting for 28.28% with  
14  
15  
16 mean age of 64.67 years old. The treatment of most patients with TTT=0 was surgery  
17  
18  
19 combining with radiotherapy and chemotherapy. The 5-year survival rate was 34.9% in this  
20  
21  
22 group with TTT=0.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Bivariate analysis of lung cancer patient characteristics for different treatment intervals

Variables	Total		Interval from cancer diagnosis to treatment								P value <sup>a</sup>
			≤ 7 days		8~14 days		15~60 days		≥ 61 days		
	N	%	N	%	N	%	N	%	N	%	
<b>Total number</b>	42,962	100.00	15,769	36.70	9,296	21.64	12,510	29.12	5,387	12.54	-
<b>Five-year survival rate</b>	42,962	17.61	15,769	26.12	9,296	15.96	12,510	12.99	5,387	6.02	<0.001
<b>Gender</b>											<0.001
Female	15,799	36.77	6,154	38.95	3,235	20.48	4,419	27.97	1,991	12.60	
Male	27,163	63.23	9,615	35.40	6,061	22.31	8,091	29.79	3,396	12.50	
<b>Age</b>											<0.001
≤ 44	2,106	4.90	889	42.21	455	21.60	568	26.97	194	9.21	
45~54	5,686	13.23	2,375	41.77	1,263	22.21	1,549	27.24	499	8.78	
55~64	9,155	21.31	3,634	39.69	2,033	22.21	2,658	29.03	830	9.07	
65~74	12,659	29.47	4,548	35.93	2,801	22.13	3,819	30.17	1,491	11.78	
≥ 75	13,356	31.09	4,323	32.37	2,744	20.55	3,916	29.32	2,373	17.77	
<b>Mean age (m, sd)</b>	66.76	12.44	65.52	12.55	66.45	12.22	67.04	12.15	70.25	12.46	<0.001
<b>Monthly salary</b>											<0.001
Low-income	461	1.07	137	29.72	101	21.91	154	33.41	69	14.97	
≤ 17280	1,475	3.43	542	36.75	311	21.08	447	30.31	175	11.86	
17281~22800	22,935	53.38	8,074	35.20	5,079	22.15	6,751	29.44	3,031	13.22	
22801~28800	8,069	18.78	2,961	36.70	1,690	20.94	2,376	29.45	1,042	12.91	
28801~36300	2,676	6.23	1,011	37.78	588	21.97	782	29.22	295	11.02	
36301~45800	3,280	7.63	1,333	40.64	689	21.01	923	28.14	335	10.21	
≥ 45801	4,066	9.46	1,711	42.08	838	20.61	1,077	26.49	440	10.82	

Table 1. Bivariate analysis of lung cancer patient characteristics for different treatment intervals (continued)

Variables	Total		Interval from cancer diagnosis to treatment								P value <sup>a</sup>
			≤ 7 days		8~14 days		15~60 days		≥ 61 days		
	N	%	N	%	N	%	N	%	N	%	
<b>Urbanization</b>											0.186
Level 1	11,759	27.37	4,335	36.87	2,494	21.21	3,404	28.95	1,526	12.98	
Level 2	12,117	28.20	4,506	37.19	2,615	21.58	3,527	29.11	1,469	12.12	
Level 3	6,523	15.18	2,334	35.78	1,424	21.83	1,946	29.83	819	12.56	
Level 4	6,795	15.82	2,518	37.06	1,506	22.16	1,974	29.05	797	11.73	
Level 5	1,524	3.55	523	34.32	338	22.18	439	28.81	224	14.70	
Level 6	2,217	5.16	807	36.40	490	22.10	627	28.28	293	13.22	
Level 7	2,027	4.72	746	36.80	429	21.16	593	29.26	259	12.78	
<b>CCI score</b>											<0.001
≤ 3	20,388	47.46	7,475	36.66	4,576	22.44	6,186	30.34	2,151	10.55	
4~6	7,587	17.66	2,761	36.39	1,646	21.70	2,218	29.23	962	12.68	
≥ 7	14,987	34.88	5,533	36.92	3,074	20.51	4,106	27.40	2,274	15.17	
<b>Other catastrophic illness</b>											<0.001
No	41,474	96.54	15,300	36.89	8,984	21.66	12,076	29.12	5,114	12.33	
Yes	1,488	3.46	469	31.52	312	20.97	434	29.17	273	18.35	
<b>Cancer stage</b>											<0.001
Stage I	5,681	13.22	3,226	56.79	910	16.02	1,269	22.34	276	4.86	
Stage II	1,526	3.55	589	38.60	338	22.15	462	30.28	137	8.98	
Stage III	11,696	27.22	4,030	34.46	2,843	24.31	3,500	29.92	1,323	11.31	
Stage IV	24,059	56.00	7,924	32.94	5,205	21.63	7,279	30.25	3,651	15.18	

Table 1. Bivariate analysis of lung cancer patient characteristics for different treatment intervals (continued)

Variables	Total		Interval from cancer diagnosis to treatment								P value <sup>a</sup>
			≤ 7 days		8~14 days		15~60 days		≥ 61 days		
	N	%	N	%	N	%	N	%	N	%	
<b>MDT care</b>											<0.001
No	37,716	87.79	13,669	36.24	8,012	21.24	10,974	29.10	5,061	13.42	
Yes	5,246	12.21	2,100	40.03	1,284	24.48	1,536	29.28	326	6.21	
<b>Hospital level</b>											<0.001
Medical centers	29,228	68.03	11,075	37.89	6,452	22.07	8,427	28.83	3,274	11.20	
Regional hospitals	12,601	29.33	4,395	34.88	2,655	21.07	3,787	30.05	1,764	14.00	
District hospitals	1,014	2.36	261	25.74	178	17.55	279	27.51	296	29.19	
Others	119	0.28	38	31.93	11	9.24	17	14.29	53	44.54	
<b>Hospital ownership</b>											<0.001
Public	16,770	39.03	6,619	39.47	3,776	22.52	4,558	27.18	1,817	10.83	
Private	26,192	60.97	9,150	34.93	5,520	21.08	7,952	30.36	3,570	13.63	
<b>Hospital services volume</b>											<0.001
Low	10,807	25.15	3,905	36.13	2,177	20.14	2,935	27.16	1,790	16.56	
Middle	21,043	48.98	7,519	35.73	4,652	22.11	6,486	30.82	2,386	11.34	
High	11,112	25.86	4,345	39.10	2,467	22.20	3,089	27.80	1,211	10.90	

<sup>a</sup> Log-rank test

### Five-year survival rate of patients for different treatment intervals

At the same time, we found that in stage I patients, the 5-year survival rate decreased by 9.07% due to delayed treatment (patients with intervals >7 days). In

stage II patients, if patients started treatment earlier (interval  $\leq 7$  days), their 5-year survival rate increased by 9.01%. Early treatment (interval  $\leq 7$  days) was found to have a smaller effect on 5-year survival rate in stage III and stage IV patients, with an increase in 5-year survival rate of 1.91% and 0.49% (Table 2).

Table 2. Five-year survival rate of patients for different treatment intervals

Variables	Stage I		Stage II		Stage III		Stage IV		P value <sup>a</sup>
	N	%	N	%	N	%	N	%	
<b>Total number</b>	5,681	61.61	1,526	34.41	11,696	12.95	24,059	5.11	
<b>Interval from cancer diagnosis to treatment</b>									<0.001
$\leq 7$ days	3,226	70.68	589	43.42	4,030	14.86	7,924	5.60	
8~14 days	910	60.58	338	33.74	2,843	12.11	5,205	4.58	
15~60 days	1,269	49.07	462	29.81	3,500	13.81	7,279	5.43	
$\geq 61$ days	276	21.10	137	14.56	1,323	6.83	3,651	4.12	

<sup>a</sup> Log-rank test



## **The effect of different treatment intervals on mortality risk in patients with lung cancer**

Table 3 shows that when the group with interval from cancer diagnosis to treatment  $\leq 7$  days was used as a reference, the adjusted HR for mortality in other groups (8-14 days, 15-60 days, and  $\geq 61$  days) was significantly increased with increasing interval time (HR: 1.04-1.08). Among patients at various cancer stages, using stage I patients as a control group, the adjusted HRs for mortality for cancer patients at various stages was significantly higher (HR: 2.06-5.89) and the more advanced the cancer stages, the higher the adjusted HR for mortality. Patients who underwent MDT care had a significantly lower adjusted HR for mortality compared with patients who did not (HR: 0.91, 95% CI: 0.88-0.94).

Table 3. Relative risk of death in patients for different treatment intervals

Variables	Unadjusted		Adjusted			
	HR	P value	HR	95% CI	P value <sup>a</sup>	
<b>Interval from cancer diagnosis to treatment</b>						
≤ 7 days (ref.)						
8~14 days	<b>1.26</b>	<0.001	<b>1.04</b>	1.01	1.07	0.004
15~60 days	<b>1.30</b>	<0.001	<b>1.06</b>	1.04	1.09	<0.001
≥ 61 days	<b>1.66</b>	<0.001	<b>1.08</b>	1.04	1.11	<0.001
<b>Gender</b>						
Female (ref.)						
Male	<b>1.54</b>	<0.001	<b>1.50</b>	1.47	1.53	<0.001
<b>Age</b>						
≤ 44 (ref.)						
45~54	<b>0.97</b>	0.357	<b>0.97</b>	0.92	1.03	0.351
55~64	<b>1.02</b>	0.478	<b>1.03</b>	0.97	1.09	0.331
65~74	<b>1.63</b>	<0.001	<b>1.27</b>	1.21	1.34	<0.001
≥ 75	<b>1.93</b>	<0.001	<b>1.79</b>	1.69	1.88	<0.001
<b>Monthly salary</b>						
Low-income (ref.)						
≤ 17280	<b>0.72</b>	<0.001	<b>0.89</b>	0.80	1.00	0.049
17281~22800	<b>0.81</b>	<0.001	<b>0.86</b>	0.78	0.95	0.002
22801~28800	<b>0.74</b>	<0.001	<b>0.83</b>	0.75	0.91	<0.001
28801~36300	<b>0.60</b>	<0.001	<b>0.79</b>	0.71	0.87	<0.001
36301~45800	<b>0.59</b>	<0.001	<b>0.78</b>	0.70	0.87	<0.001

Variables	Unadjusted		Adjusted			
	HR	P value	HR	95% CI	P value <sup>a</sup>	
≥ 45801	<b>0.56</b>	<0.001	<b>0.73</b>	0.66	0.81	<0.001
<b>Urbanization level</b>						
Level 1 (ref.)						
Level 2	<b>1.07</b>	<0.001	<b>0.99</b>	0.96	1.02	0.523
Level 3	<b>1.20</b>	<0.001	<b>1.04</b>	1.00	1.07	0.036
Level 4	<b>1.21</b>	<0.001	<b>1.01</b>	0.98	1.05	0.596
Level 5	<b>1.33</b>	<0.001	<b>1.01</b>	0.95	1.08	0.671
Level 6	<b>1.39</b>	<0.001	<b>1.09</b>	1.04	1.15	0.001
Level 7	<b>1.25</b>	<0.001	<b>1.02</b>	0.96	1.07	0.570
<b>CCI score</b>						
≤ 3 (ref.)						
4~6	<b>1.35</b>	<0.001	<b>1.18</b>	1.14	1.21	<0.001
≥ 7	<b>1.80</b>	<0.001	<b>1.28</b>	1.25	1.31	<0.001
<b>Other catastrophic illness</b>						
No (ref.)						
Yes	<b>1.25</b>	<0.001	<b>1.26</b>	1.19	1.33	<0.001
<b>Cancer stage</b>						
Stage I (ref.)						
Stage II	<b>2.29</b>	<0.001	<b>2.06</b>	1.91	2.23	<0.001
Stage III	<b>4.48</b>	<0.001	<b>3.94</b>	3.75	4.13	<0.001
Stage IV	<b>6.51</b>	<0.001	<b>5.89</b>	5.62	6.17	<0.001
<b>MDT care</b>						
No (ref.)						

Variables	Unadjusted		Adjusted			
	HR	P value	HR	95% CI	P value <sup>a</sup>	
Yes	<b>0.95</b>	0.001	<b>0.91</b>	0.88	0.94	<0.001
<b>Hospital level</b>						
Medical centers (ref.)						
Regional hospitals	<b>1.28</b>	<0.001	<b>0.99</b>	0.96	1.02	0.347
District hospitals	<b>2.06</b>	<0.001	<b>1.25</b>	1.17	1.34	<0.001
Others	<b>1.17</b>	0.137	<b>0.90</b>	0.73	1.10	0.286
<b>Hospital ownership</b>						
Public (ref.)						
Private	<b>1.27</b>	<0.001	<b>1.13</b>	1.10	1.16	<0.001
<b>Hospital services volume</b>						
Low (ref.)						
Middle	<b>0.72</b>	<0.001	<b>0.83</b>	0.81	0.85	<0.001
High	<b>0.59</b>	<0.001	<b>0.71</b>	0.68	0.74	<0.001

<sup>a</sup> Cox proportional hazards regression

### The effect of different treatment intervals on mortality risk in patients with lung cancer at different cancer stages

Table 4 shows that in stage I lung cancer patients, with patients with intervals of  $\leq 7$  days as the reference group, as the interval increased, the relative risk of death also significantly increased (HR: 1.45-2.41). This was also true for stage II (HR: 1.21-1.58) and the intervals more than 60 days of stage III lung cancer patients (HR: 1.13, 95% CI: 1.06-1.21). In stage IV patients, using patients with an interval  $\leq 7$  days

1  
2  
3  
4 as a reference group, the relative risk of death was without significantly difference.  
5  
6

7 Figure 1 shows adjusted survival curve in lung cancer patients with different cancer  
8  
9  
10 stages.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 4. Relative risk of death in patients for different treatment intervals and at different cancer stages

Variables	Stage I <sup>a</sup>			Stage II <sup>a</sup>			Stage III <sup>a</sup>			Stage IV <sup>a</sup>		
	HR	95% CI	P value <sup>b</sup>	HR	95% CI	P value <sup>b</sup>	HR	95% CI	P value <sup>b</sup>	HR	95% CI	P value <sup>b</sup>
<b>Interval from cancer diagnosis to treatment</b>												
≤ 7 days (ref.)												
8~14 days	<b>1.45</b>	1.28 1.64	<0.001	<b>1.21</b>	1.01 1.45	0.039	<b>1.04</b>	0.98 1.09	0.177	<b>0.99</b>	0.95 1.03	0.561
15~60 days	<b>1.66</b>	1.49 1.84	<0.001	<b>1.44</b>	1.22 1.69	<0.001	<b>1.02</b>	0.97 1.07	0.560	<b>1.01</b>	0.98 1.04	0.572
≥ 61 days	<b>2.41</b>	2.06 2.83	<0.001	<b>1.58</b>	1.26 1.97	<0.001	<b>1.13</b>	1.06 1.21	<0.001	<b>0.98</b>	0.94 1.02	0.249

a. Patient age, gender, monthly salary, level of urbanization of place of residence, CCI score, other illness, MDT care, hospital level, hospital ownership, and hospital services volume were all controlled for using various models.

<sup>b</sup> adjusted Cox proportional hazards model

## DISCUSSION

We found that the mortality rate exhibited significantly positive correlation to time interval from cancer diagnosis to treatment initiation in all stage NSCLC patients. The ratio of male to female in our study is similar to that in previous studies.<sup>12 13</sup> The delays between diagnosis and treatment can be categorized into three stages: namely, patient delay, diagnosis delay, and treatment delay.<sup>2</sup> Of all studies which investigated treatment delays in lung cancer patients, the study with the largest number of patients included 54,338 patients, but was limited to non-metastatic lung cancer patients.<sup>12</sup> In addition, the study only focused on patients who underwent surgical excision and did not analyze the treatment delay status and associated factors for all lung cancer patients. Another study collected data from 28,732 patients to investigate whether treatment delay affects survival rate.<sup>14</sup> The researchers found that if the interval from diagnosis to treatment was within 35 days, then there is improved survival for patients with localized disease, reduced survival for those with distant disease, but didn't have significant effect on patients with regional disease.<sup>14</sup> However, in that study, the diagnosis to treatment interval was divided into just two groups (<35 days and >35 days), which makes it more difficult to show the correlation between different treatment delay groups and patient survival rates. In addition, in that study, the authors did not investigate whether different treatment

1  
2  
3  
4 delay periods affect survival rate for different cancer stages as they only classified  
5  
6  
7 cancers as localized, regional, or distant. To the best of our knowledge, the current  
8  
9  
10 study is the first large-scale nationwide study that examines whether treatment delay  
11  
12  
13 in non-small cell lung cancer affects patient survival rate. In addition, we also  
14  
15  
16 investigated the correlation between lung cancer treatment delay and survival rate for  
17  
18  
19 different cancer stages (stages I, II, III and IV).  
20

21  
22 Previous studies have observed that if patients are older, have more  
23  
24 comorbidities, or have stage I cancer, they are more likely to delay treatment (interval  
25  
26 from diagnosis to treatment >30 days).<sup>12</sup> Similar findings were observed in our study:  
27  
28 for patients aged  $\geq 55$  years, the greater the age the greater the proportion with  
29  
30 treatment delay (interval  $\geq 61$  days) (Table 1). Patients with high CCI scores also  
31  
32 demonstrated significantly increased proportions in treatment delay (interval  $\geq 61$   
33  
34 days) (Table 1). CCI is a general score to evaluate patients' comorbidity and does not  
35  
36 focus on lung cancer patients. The lung function testing such as forced expiratory  
37  
38 volume in one second (FEV1) and diffusing capacity of the lung for carbon monoxide  
39  
40 (DLCO) is more accurate for evaluating their severity but is not available in our  
41  
42 study. It is a fact that patients with poorer lung function require additional testing to  
43  
44 determine candidacy for surgery. This testing, including six minute walk test,  
45  
46 quantitative perfusion scans, cardiopulmonary exercise testing and consultation with  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 pulmonary medicine takes time and is not available in our study. However, during  
5  
6  
7 analysis of the correlation between treatment delay and lung cancer stage, we found  
8  
9  
10 that the proportion of stage I patients with treatment delay was significantly lower  
11  
12  
13 than patients with other stages of lung cancer. A previous study has observed that in  
14  
15  
16 non-small cell lung cancer patients, treatment delay is not associated with cancer  
17  
18  
19 stage.<sup>15, 16-20</sup> In contrast, treatment delay had more serious effects in stage III and IV  
20  
21  
22 patients.<sup>21</sup> However, in our study, we found that the proportion of stage I patients with  
23  
24  
25 treatment delay (interval from diagnosis to treatment  $\geq 61$  days) was significantly  
26  
27  
28 lower (4.86%,  $p < 0.001$ ), when compared with patients at other stages.

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Previous studies have mentioned that in non-small cell lung cancer patients, our understanding of the effects of diagnosis and treatment delay on the prognosis of patients is limited, although an increasing number of recent studies are emphasizing the importance of this topic.<sup>4</sup> Some studies have found that in patients with a symptom-to-treatment interval (STI) of  $>60$  days, the survival rate was significantly higher than that of patients with a STI of  $<60$  days.<sup>22</sup> However, if patients were further divided on the basis of the type of lung cancer, this difference was only significant in NSCLC patients.<sup>22</sup> However, the number of patients included in this study was only 103 (96 men).<sup>23</sup> Two other studies, with 378 and 410 patients each, found that delaying diagnosis and treatment did not affect patient survival rates.<sup>16 17</sup>

1  
2  
3  
4 Another study of 466 non-small cell lung cancer patients found that patients with  
5  
6 shorter STIs had lower survival rates.<sup>24</sup> One study with 189 lung cancer patients found  
7  
8 that treatment delay resulted in poorer prognosis for patients,<sup>25</sup> whilst another study  
9  
10 with 132 patients found that longer specialist treatment delay does not result in poorer  
11  
12 prognosis.<sup>26</sup> An aforementioned article also observed that most previous studies in  
13  
14 different countries were monocentric studies and that it is difficult to decide which  
15  
16 study is most reliable with regards to whether treatment delay affects patient survival  
17  
18 rates.<sup>4</sup>  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 Most studies show no relationship between time-to-chemotherapy (TTC) and  
29  
30 their survival rate.<sup>27</sup> However, it should be noted that in these review articles, the  
31  
32 number of cases collected is generally very low, with the highest number of patients  
33  
34 only 10,583.<sup>27</sup> Another study showed time intervals from diagnosis to treatment were  
35  
36 not associated with survival outcomes in NSCLC.<sup>28</sup> In this previous study, they  
37  
38 discussed NSCLC patients with different treatment such as surgery, radiotherapy,  
39  
40 systemic therapy and palliative care which were not discussed in our study. They also  
41  
42 suggested that delays to treatment might impact on other outcomes other than  
43  
44 survival. However, there were only 1,729 patients in this previous study.<sup>28</sup> In  
45  
46 summary, the majority of previous studies into whether treatment delay affects  
47  
48 survival rate in non-small cell lung cancer patients lack large-scale nationwide  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 statistical data. This can easily lead to bias and produce divergent conclusions. In this  
5  
6  
7 study, we collected nationwide data from 42,962 non-small cell lung cancer patients,  
8  
9  
10 which, to the best of our knowledge, is the largest nationwide study to date. In  
11  
12  
13 addition, we also investigated the correlation between lung cancer treatment delay and  
14  
15  
16 survival rate in different cancer stages (stages I, II, III and IV).  
17

18  
19 In addition, detailed examination of the literature found that a decreased  
20  
21  
22 treatment delay increases the risk of death in patients; the explanation provided for  
23  
24  
25 this is that a shorter treatment delay may mean that the patients have more obvious or  
26  
27  
28 more severe symptoms.<sup>24</sup> Therefore, there is a need to correct the result with cancer  
29  
30  
31 stage and severity.<sup>24</sup> A previous study has also suggested that a shorter treatment  
32  
33  
34 delay may reflect a requirement for more urgent treatment due to severity of  
35  
36  
37 symptoms, resulting in a poor prognosis.<sup>29</sup> Therefore, in this paper, we also  
38  
39  
40 considered the effects of cancer stage on treatment delay and patient prognosis. In  
41  
42  
43 another paper, it was also mentioned that the definition of treatment delay should be  
44  
45  
46 more standardized and accurate.<sup>4</sup> Another paper mentioned that it is not easy to  
47  
48  
49 accurately calculate the time of treatment initiation.<sup>24</sup> In addition, the calculation of  
50  
51  
52 patient delay (from symptom to doctor) is also prone to errors. Therefore, in this  
53  
54  
55 study, our definition of treatment delay was made according to the cancer registration  
56  
57  
58 archives and NHI database, from pathological diagnosis confirmation until treatment  
59  
60

1  
2  
3  
4 initiation.

5  
6  
7 For cancer patients in general, current medical guidelines all recommend early  
8  
9  
10 diagnosis and treatment to improve patient prognosis. However, early diagnosis is  
11  
12  
13 difficult due to multiple factors, such as non-apparent symptoms and patient delay.  
14  
15  
16 However, in this study, we found that if the interval from confirmation of pathological  
17  
18  
19 diagnosis to treatment initiation in non-small cell lung cancer patients is shortened to  
20  
21  
22 7 days, this is associated with an improvement in 5 year life expectancy  
23  
24  
25 (improvements of 0.49-9.07% were observed, according to the different stages of lung  
26  
27  
28 cancer). We also found that this improvement in 5-year survival rate was particularly  
29  
30  
31 marked for non-small cell lung cancer patients at early stages (stage I and II), at  
32  
33  
34 10.28-10.34%. However, in late stage (stage III and stage IV) patients, the 5-year  
35  
36  
37 survival rate was only increased by 1.91% and 0.49%. It is extremely ambitious for  
38  
39  
40 lung cancer treatment to commence within 7 days of diagnosis considering the staging  
41  
42  
43 exam taking time. This group in the study (< 7 days to treatment) may be skewed  
44  
45  
46 towards those whose cancer was diagnosed at the time of surgery. A previous study  
47  
48  
49 showed that NSCLC growth rate appeared to be highly variable and related to  
50  
51  
52 histological subtype which was not discussed in our study.<sup>30</sup> Doubling times can be  
53  
54  
55 quite variable in different stages of NSCLC. Another study showed that rapid tumor  
56  
57  
58 progression was noted in patients with untreated, predominantly stage III NSCLC.<sup>31</sup>  
59  
60

1  
2  
3  
4 In our study, table 4 shows stage III non-small cell lung cancer patients with the  
5  
6 interval from diagnosis to treatment initiation more than 60 days had significantly  
7  
8 higher relative risk of death than patients with an interval  $\leq 7$  days (HR: 1.13, 95% CI:  
9  
10 1.06-1.21). This may be due to rapid tumor progression characteristics of stage III  
11  
12 NSCLC. However, the delay treatment effect is not significant in stage IV NSCLC  
13  
14 patients, which may be associated with poor outcome and low survival rate in late  
15  
16 stage of NSCLC. Therefore, we recommended that in future policies, treatment  
17  
18 recommendations should be formulated so that patients can start treatment within 7  
19  
20 days after pathological diagnosis confirmation of non-small cell lung cancer to  
21  
22 increase their 5-year survival rate. This is particularly important for early stage (stage  
23  
24 I and II) non-small cell lung cancer patients, where improvement effects are more  
25  
26 significant.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 In this study, we also found that the effect of the interval from diagnosis to  
41  
42 treatment initiation and patient survival rate decreased with more advanced cancer  
43  
44 stages. Therefore, in patients who have stage I (HR: 1.45-2.41) or stage II (HR:  
45  
46 1.21-1.58) cancer, the longer the interval from diagnosis to treatment initiation, the  
47  
48 higher the risk of death in patients. However, in stage III patients, compared with  
49  
50 patients with an interval from diagnosis to treatment initiation  $\leq 7$  days, only when the  
51  
52 interval from diagnosis to treatment initiation was  $\geq 61$  days was the risk of death  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 increased. However, the magnitude of the increased risk of death is lower than in  
5  
6  
7 stage I and II patients (HR: 1.03-1.06). It appears the association between time to  
8  
9  
10 treatment and outcome is stronger with lower stage disease. This may have  
11  
12  
13 implications on resource allocation specifically addressing the TTT phenomenon.  
14  
15  
16 Further study, however, is necessary to better understand causation.

17  
18  
19 In recent studies, it was found that patients with oral cancers who underwent  
20  
21  
22 MDT treatment had significantly higher survival rates, and that the proportion of  
23  
24  
25 patients who underwent treatment was higher than those who did not joining MDT.<sup>32</sup>  
26  
27  
28 Previous studies have shown that the use of MDT care in cancer treatment can  
29  
30  
31 improve patient prognosis.<sup>33</sup> This is particularly the case in head and neck cancers,  
32  
33  
34 where MDT care is not only cost-effective but can also improve survival rates.<sup>34</sup>  
35  
36  
37 Previous studies have shown that in lung cancer patients MDT care can significantly  
38  
39  
40 improve the patient's acceptance of treatment, but does not significantly improve  
41  
42  
43 patient survival rates.<sup>33</sup> In this study, we found that patients who underwent MDT  
44  
45  
46 care had a significantly lower adjusted HR for mortality compared with patients who  
47  
48  
49 did not (HR: 0.91, 95% CI: 0.88-0.94).

50  
51  
52 In summary, this study identifies an association between time to treat and  
53  
54  
55 survival in NSCLC. Although causation is not definitive, efforts to diminish time to  
56  
57  
58 treat in the lung cancer patient would seem prudent while awaiting further study on  
59  
60

1  
2  
3  
4 the issue. In addition, in patients with NSCLC, we recommend the addition of MDT  
5  
6  
7 care to decrease the risk of death and improve prognosis.  
8  
9

### 10 **Limitations**

11  
12  
13 A secondary random database derived from the National Health Insurance  
14  
15  
16 Research Database was employed for this study. The information on individual  
17  
18  
19 lifestyle, health behaviors, which may also affect the result, is not available. The lung  
20  
21  
22 function testing such as forced expiratory volume in one second (FEV1) and diffusing  
23  
24  
25 capacity of the lung for carbon monoxide (DLCO) is not available in our database,  
26  
27  
28 and disease free survival is also not available in our study.  
29  
30  
31  
32  
33

### 34 **Conclusions**

35  
36  
37  
38 In this study, we collected nationwide data from 42,962 non-small cell lung  
39  
40  
41 cancer patients, which, to the best of our knowledge, is the largest nationwide study to  
42  
43  
44 date. In addition, we also investigated the correlation between lung cancer treatment  
45  
46  
47 delay and survival rate in different cancer stages (stages I, II, III and stage IV) with  
48  
49  
50 pathological confirmation. Treatment timeliness is associated with better survival  
51  
52  
53 rates in patients with NSCLC, particularly stage I and II.  
54  
55  
56

### 57 **Acknowledgements**

1  
2  
3  
4 We are grateful to the Science Center of the Ministry of Health and Welfare for  
5  
6  
7 providing us with access to the National Health Insurance Research Database, Cancer  
8  
9  
10 Registry Files, and Cause of Death File. We are also grateful to Health Data Science  
11  
12  
13 Center, China Medical University Hospital for providing administrative, technical and  
14  
15  
16 funding support.

### 17 18 19 **Funding source**

20  
21  
22 This study was supported by the grants (CMU107-ASIA-18; MOST 104-2410-H-039  
23  
24  
25 -002) from China Medical University, Asia University, and the Ministry of Science  
26  
27  
28 and Technology, Taiwan.

### 29 30 31 **Competing interests**

32  
33  
34 The authors declare that they have no competing interests.

### 35 36 37 **Author's contribution**

38  
39  
40 Conceptualization: Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai

41  
42  
43 Methodology: Chang-Hung Tsai, Pei-Tseng Kung, Wei-Yin Kuo, Wen-Chen Tsai

44  
45  
46 Software: Wen-Chen Tsai

47  
48  
49 Validation: Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai

50  
51  
52 Formal analysis: Chang-Hung Tsai, Wei-Yin Kuo

53  
54  
55 Data curation: Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai

56  
57  
58 Resources: Pei-Tseng Kung, Wen-Chen Tsai



1  
2  
3  
4 Writing (original draft preparation): Chang-Hung Tsai, Wen-Chen Tsai  
5  
6

7 Writing (review and editing): Chang-Hung Tsai, Pei-Tseng Kung, Wen-Chen Tsai  
8  
9

10 Supervision: Wen-Chen Tsai  
11  
12

13 Project administration: Chang-Hung Tsai, Wei-Yin Kuo, Pei-Tseng Kung  
14  
15

16 Funding acquisition: Pei-Tseng Kung, Wen-Chen Tsai  
17  
18

### 19 **Patient consent form** 20

21  
22 As this study used anonymized secondary data retrieved from the Taiwan's National  
23  
24 Health Insurance Research Database, the requirement for informed consent was  
25  
26  
27  
28 waived by the ethics committee.  
29  
30

### 31 **Data sharing** 32

33  
34  
35 This study used the National Health Insurance Research Database published by the  
36  
37  
38 Ministry of Health, Taiwan. Due to legal restrictions imposed by the Taiwan  
39  
40  
41 government related to the Personal Information Protection Act, the database cannot be  
42  
43  
44 made publicly available. All researchers can apply for using the databases for  
45  
46  
47 conducting their studies. Requests for data can be sent as a formal proposal to the  
48  
49  
50 Science Center of the Ministry of Health and Welfare  
51  
52  
53 (<http://www.mohw.gov.tw/EN/Ministry/Index.aspx>). Any raw data are not allowed to  
54  
55  
56 be brought out from the Science Center. Only the analytic outputs in format of table  
57  
58  
59 or figure can be printed out. The restrictions prohibited the authors from making the  
60

1  
2  
3  
4 minimal data set publicly available.  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 **Figure Legend**  
4

5 Figure 1. Adjusted survival curve in lung cancer patients with different cancer stages  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## References

1. Ferlay J. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10. <http://globocan.iarc.fr> 2010
2. Jensen AR, Mainz J, Overgaard J. Impact of delay on diagnosis and treatment of primary lung cancer. *Acta Oncologica* 2002;41(2):147-52.
3. Valdés S, García E, Pérez H, et al. Length of diagnostic delay in patients with non-small-cell lung cancer. *MEDICC review* 2010;12(1)
4. Vinas F, Ben Hassen I, Jabot L, et al. Delays for diagnosis and treatment of lung cancers: a systematic review. *The clinical respiratory journal* 2016;10(3):267-71.
5. Storm H, Dickman P, Engeland A, et al. Do morphology and stage explain the inferior lung cancer survival in Denmark? *European Respiratory Journal* 1999;13(2):430-35.
6. Teppo L, Dickman PW, Hakulinen T, et al. Cancer patient survival-patterns, comparisons, trends: A population-based cancer registry study in Finland. *Acta oncologica* 1999;38(3):283-94.
7. Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. *Journal of the National Comprehensive Cancer Network* 2016;14(3):255-64.
8. Chandra S, Mohan A, Guleria R, et al. Delays during the diagnostic evaluation and treatment of lung cancer. *Asian Pac J Cancer Prev* 2009;10(3):453-6.
9. Chiang C-J, You S-L, Chen C-J, et al. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. *Japanese journal of clinical oncology* 2015;45(3):291-96.
10. Cheng CL, Kao YHY, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. *Pharmacoepidemiology and drug safety* 2011;20(3):236-42.
11. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *Journal of clinical epidemiology* 1992;45(6):613-19.
12. Bilimoria KY, Ko CY, Tomlinson JS, et al. Wait times for cancer surgery in the United States: trends and predictors of delays. *Annals of surgery* 2011;253(4):779-85.
13. Evans SM, Earnest A, Bower W, et al. Timeliness of lung cancer care in Victoria: a retrospective cohort study. *Medical Journal of Australia* 2016;204(2):75-75.
14. Gomez DR, Liao K-P, Swisher SG, et al. Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. *Radiotherapy and Oncology* 2015;115(2):257-63.
15. Liberman M, Liberman D, Sampalis JS, et al. Delays to surgery in non-small-cell lung cancer. *Canadian journal of surgery* 2006;49(1):31.

16. Pita-Fernández S, Montero-Martinez C, Pérttega-Diaz S, et al. Relationship between delayed diagnosis and the degree of invasion and survival in lung cancer. *Journal of clinical epidemiology* 2003;56(9):820-25.
17. Porta M, Gallen M, Malats N, et al. Influence of " diagnostic delay" upon cancer survival: an analysis of five tumour sites. *Journal of Epidemiology & Community Health* 1991;45(3):225-30.
18. Koyi H, Hillerdal G, Brandén E. Patient's and doctors' delays in the diagnosis of chest tumors. *Lung cancer* 2002;35(1):53-57.
19. Billing J, Wells F. Delays in the diagnosis and surgical treatment of lung cancer. *Thorax* 1996;51(9):903-06.
20. Mor V, Masterson-Allen S, Goldberg R, et al. Pre-diagnostic symptom recognition and help seeking among cancer patients. *Journal of community health* 1990;15(4):253-66.
21. Christensen E, Harvald T, Jendresen M, et al. The impact of delayed diagnosis of lung cancer on the stage at the time of operation. *European Journal of Cardio-Thoracic Surgery* 1997;12(6):880-84.
22. Annakkaya AN, Arbak P, Balbay O, et al. Effect of symptom-to-treatment interval on prognosis in lung cancer. *Tumori Journal* 2007;93(1):61-67.
23. Annakkaya AN, Arbak P, Balbay O, et al. Effect of symptom-to-treatment interval on prognosis in lung cancer. *Tumori* 2007;93(1):61.
24. Myrdal G, Lambe M, Hillerdal G, et al. Effect of delays on prognosis in patients with non-small cell lung cancer. *Thorax* 2004;59(1):45-49.
25. Robinson E, Mohilever J, Zidan J, et al. Delay in diagnosis of cancer. Possible effects on the stage of disease and survival. *Cancer* 1984;54(7):1454-60.
26. Salomaa E-R, Sallinen S, Hiekkanen H, et al. Delays in the diagnosis and treatment of lung cancer. *Chest Journal* 2005;128(4):2282-88.
27. Alexander M, Blum R, Burbury K, et al. Timely initiation of chemotherapy: a systematic literature review of six priority cancers—results and recommendations for clinical practice. *Internal medicine journal* 2017;47(1):16-34.
28. Vinod SK, Chandra A, Berthelsen A, et al. Does timeliness of care in Non-Small Cell Lung Cancer impact on survival? *Lung Cancer* 2017;112:16-24.
29. Diaconescu R, Lafond C, Whittom R. Treatment delays in non-small cell lung cancer and their prognostic implications. *Journal of Thoracic Oncology* 2011;6(7):1254-59.
30. Mackintosh JA, Marshall HM, Yang IA, et al. A retrospective study of volume doubling time in surgically resected non-small cell lung cancer. *Respirology* 2014;19(5):755-62.
31. Everitt S, Herschtal A, Callahan J, et al. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. *Cancer* 2010;116(21):5030-37.

- 1  
2  
3  
4 32. Tsai W-C, Kung P-T, Wang S-T, et al. Beneficial impact of multidisciplinary team  
5 management on the survival in different stages of oral cavity cancer patients: results  
6 of a nationwide cohort study in Taiwan. *Oral oncology* 2015;51(2):105-11.  
7  
8 33. Boxer MM, Vinod SK, Shafiq J, et al. Do multidisciplinary team meetings make a  
9 difference in the management of lung cancer? *Cancer* 2011;117(22):5112-20.  
10  
11 34. Birchall M, Bailey D, King P. South West Cancer Intelligence Service Head and Neck  
12 Tumour Panel. Effect of process standards on survival of patients with head and neck  
13 cancer in the south and west of England. *Br J Cancer* 2004;91(8):1477-81.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1

67x67mm (600 x 600 DPI)

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
<b>Introduction</b>			<b>5-6</b>
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any pre-specified hypotheses	6
<b>Methods</b>			<b>6-10</b>
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7,9
Bias	9	Describe any efforts to address potential sources of bias	6-7
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	



		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	10
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10-19
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10-19
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			20-26
Key results	18	Summarise key results with reference to study objectives	20
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	23
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	26
Generalisability	21	Discuss the generalisability (external validity) of the study results	26-27
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	27

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).